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Abstract  
Previous prognostic signatures for melanoma based on tumour transcriptomic data 
were developed predominantly on cohorts of AJCC (American Joint Committee on 
Cancer) stages III and IV melanoma. Since 92% of melanoma patients are diagnosed 
at AJCC stages I and II, there is an urgent need for better prognostic biomarkers to 
allow patient stratification for receiving early adjuvant therapies. 
This study uses genome-wide tumour gene expression levels and clinico-
histopathological characteristics of patients from the Leeds Melanoma Cohort (LMC). 
Several unsupervised and supervised classification approaches were applied to the 
transcriptomic data, to identify biological classes of melanoma, and to develop 
prognostic classification models respectively. 
Unsupervised clustering identified six biologically distinct primary melanoma classes 
(LMC classes). Unlike previous molecular classes of melanoma, the LMC classes were 
prognostic in both the whole LMC dataset and in stage I tumours. The prognostic value 
of the LMC classes was replicated in an independent dataset, but insufficient data were 
available to replicate in an AJCC stage I subset.  
Supervised classification using the Random Forest (RF) approach provided improved 
performances when adjustments were made to deal with class imbalance, while this did 
not improve performance of the Support Vector Machine (SVM). However, RF and SVM 
had similar results overall, with RF only marginally better. Combining clinical and 
transcriptomic information in the RF further improved the performance of the prediction 
model in comparison to using clinical information alone. Finally, the agnostically derived 
LMC classes and the supervised RF model showed convergence in their association 
with outcome in some groups of patients, but not in others.  
In conclusion, this study reports six molecular classes of primary melanoma with 
prognostic value in stage I disease and overall, and a prognostic classification model 
that predicts outcome in primary melanoma.  
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Chapter 1 
Introduction 
This chapter provides an introduction to melanoma research by presenting an 
overview of melanoma formation, epidemiology and genetics. This is followed by 
different methods of classification: histopathological, genomic and transcriptomic. 
1.1 Human skin and melanoma 
Human skin, the largest organ of the human body, is not directly thought of as a 
functional organ like the heart or the liver, but is simply believed to just protect us 
from external stimuli, like extreme hot or cold temperatures [1]. However it plays a 
unique and complex role in maintaining a barrier between internal and external 
environment, and in maintaining the steady state of internal body (homeostasis) in 
terms of heat and hydration [1, 2]. 
 
Figure 1.1 Anatomy of human skin 
Adapted from [2]. 
Human skin is arranged into three layers: epidermis (outer layer), dermis (inner layer) 
and hypodermis (inner most layer) (Figure 1.1). The epidermis can be further divided 
into an outer ‘dead’ layer and an inner ‘living’ cell layer [2]. The outer layer contains 
all the dead and peeling cells, and its major function is to maintain a barrier against 
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microbes and other environmental factors. The inner layer contains a higher 
proportion of keratinocytes (up to 90%)  and lower proportion (up to 10%) of other 
cell types known as melanocytes, Merkel cells and Langerhans cells [2]. The main 
function of the inner layer is to help in the formation of the main barrier, which protects 
against invasion of chemical substances and microbes. The majority of skin cancers 
originate in the epidermis [3]. Melanoma, the most aggressive form of skin cancer, 
originates from melanocytes or their precursor cells, melanoblasts, which are mainly 
present in the epidermis.  
1.1.1 Melanocytes 
In 1889, S. Meyerson first introduced the term ‘melanocyte’ to represent a dendritic 
cell which originates from the neural crest [4]. As described above, melanocytes are 
small subpopulations of cells located in the inner layer of the epidermis. A 
melanoblast is a precursor cell of melanocytes, and it is derived from the neural crest 
cells [4]. The melanoblasts differentiate from the neural crest cells and migrate 
extensively during embryonic development [1, 2]. Once melanoblasts have reached 
their terminal locations, most of these cells then differentiate into melanocytes. The 
process of differentiation from neural crest cell to becoming a melanocyte completes 
within the first 6 months of the gestation period [1, 2]. Most of the melanocytes 
migrate from dermis to epidermis and produce a pigment known as melanin. 
1.1.2 Melanin, melanogenesis and response to UVR 
 After a melanocyte has been formed, it starts producing an organelle known as the 
melanosome [4]. Melanosomes are the organelles that produce a pigment known as 
melanin. The variation in human skin colour is primarily due to variations in melanin. 
Melanin is classified into two types: eumelanin and pheomelanin [5, 6]. Eumelanin, a 
major source of pigmentation, is a high density dark pigment which is contained in 
eumelanosomes. Pheomelanin is a cysteine-derived compound which is 
reddish/yellow in colour that is largely responsible for the colour of red hair.  
The biological process of melanin synthesis is known as melanogenesis. After 
melanoblasts have differentiated into melanocytes, the melanosome formation is 
initiated. During melanogenesis, tyrosinase and tyrosinase-related proteins 1 and 2 
(TRP1 and TRP2) catalyse the synthesis of melanin [6]. After producing melanin, it 
is transferred to keratinocytes, where melanin plays an important role in protecting 
the skin from harmful ultraviolet radiation (UVR) [6]. Generally, in humans, one 
melanocyte is in contact with ~35 neighbouring keratinocytes [7]. Melanin is 
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transferred to keratinocytes located on the inner layer of the epidermis, and it is 
degraded before keratinocytes migrate to the outer dead layer [6]. 
UVR exposure increases melanin production, which causes tanning of the skin [4-6]. 
A sudden increase in pigmentation in response to UVR, also referred to as immediate 
tanning, is achieved by darkening and shifting pre-existing melanosomes from the 
nuclear region to the dendritic region. Delayed tanning is caused by a gradual 
increase in production of melanin (i.e. eumelanin) over 2-3 weeks after UVR 
exposure. Overall, in both immediate and delayed  tanning, a pigment is produced 
that protects the skin from UVR. In pale skin, melanin levels increase by 500 to 1000 
fold, in comparison to dark skin where the levels only increase by 10 to 15 fold [8, 9]. 
1.1.3 Melanocytes to melanoma  
The transition from melanocyte to the most readily recognisable form of melanoma, 
i.e. superficial spreading melanoma, occurs in five different phases as follows: benign 
naevi; dysplastic naevi; radial growth phase (RGP); vertical growth phase (VGP); 
metastatic melanoma [3]. This superficial spreading melanoma is typified by change 
in shape, size and colour and is the commonest form of melanoma in pale-skinned 
populations. As described above, many superficial spreading melanomas originate 
in naevi, although some melanoma may arise de novo from normal skin.   
Benign naevi are the normal moles present on the skin: they are benign proliferations 
of melanocytes such that the proliferation step is self-limiting. A small proportion of 
these benign naevi undergo continued cellular proliferation which leads to formation 
of an asymmetric dysplastic (or atypical)  naevus.  Even though the majority of such 
naevi eventually cease, a proportion of them emerge into RGP melanoma.  In RGP, 
the cells contained in the epidermis invade the outer dermis layer. In VGP, the 
malignant cells invade further into the inner dermis and subcutaneous fat layers. The 
melanoma at this stage has a high metastatic potential and can metastasize to distant 
organs. In the metastatic phase, the melanoma metastasizes both by lymphatics 
(probably the most frequent) but also via the blood vessels and then subsequently to 
different organs in the human body, such as the lungs, liver or brain [3].   
1.2 Cutaneous melanoma  
Melanoma is a cancer that arises from genetic changes in melanocytes and 
melanoblasts leading to an uncontrolled growth of these cells. Melanoma occurs 
most frequently on the skin, also referred as cutaneous melanoma, but also on body 
sites such as the uvea of the eye, mucosa, and leptomeninges. Although cutaneous 
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melanoma represents only 5% of skin cancer cases but it accounts for 80% of skin 
cancer related mortality [3]. 
Cutaneous melanoma most commonly presents as a mole in clinical settings, and 
initial diagnosis is based on the ABCDE criteria, where A stands for asymmetrical 
nevi, B for irregular border, C for multiple colours, D for diameter >5mm, and E for 
evolving shape and size [10]. Melanoma is further divided based on these criteria into 
four distinct subtypes: superficial spreading melanoma, nodular melanoma, lentigo 
maligna melanoma, and acral lentiginous melanoma [11]. Superficial spreading 
melanoma is the most common melanoma subtype and accounts for ~70-75% of 
melanoma cases; it occurs mostly on the limbs and trunk of the body [11]. The 
ABCDE criteria best describe this sort of melanoma. Nodular melanoma accounts for 
~20-25% of melanoma cases and can appear on any body site, including the sites 
mentioned for superficial spreading melanoma [11]. Lentigo maligna melanoma is 
the least frequent melanoma and accounts only for ~5-10% of melanoma cases [11]. 
It occurs mostly at older age and, unlike previous subtypes, it does not originate from 
an existing naevus but occurs as a result of prolonged sun exposure. The previous 
three melanoma subtypes are mostly observed in the Caucasian population. 
However, the fourth subtype, acral lentiginous melanoma, is rarely observed in this 
population, and the majority of cases are individuals with darker skin; it occurs mostly 
on non-sun exposed sites, such as feet, finger nail beds, and toes [11]. 
1.3 Melanoma epidemiology 
Cutaneous melanoma is the 5th most common form of cancer in the UK and is ranked 
19th worldwide [12, 13]. In the last 50 years, the world wide incidence of melanoma 
has risen sharply, with greatest incidence observed in pale-skinned populations. In 
the UK, the incidence rates have increased by 50% over the last decade [13], and 
males have had a higher increase (64%) in the incidence rate in comparison to 
females (39%). Across Europe, approximately 100,000 new cases of melanoma were 
diagnosed in 2012, and the incidence rate in the UK was ranked 9th in Europe [14]. 
In the UK, every year (2012-2014) ~15,000 patients are diagnosed with melanoma 
[13]. Melanoma is predominantly an adult cancer with very few cases prior to puberty. 
The risk factors for melanoma are a history of severe sunburn, a higher number of 
dysplastic naevi, older age, family history of melanoma, pale skin, and light hair 
colour [15-19]. A pooled analysis of 15 case-control studies showed that sun 
exposure increases melanoma risk [18]. This study provides stronger evidence for 
intermittent sun exposure than cumulative sun exposure [18], but  a so-called UVR 
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signature, i.e. C>T somatic mutations in the tumour [16], implicates sun exposure as 
the major environmental factor in pathogenesis. Along with sun exposure, greater 
numbers of melanocytic naevi, also known as “moles”, increases melanoma risk, and 
individuals with ≥ 100 moles have 7 fold increased risk of melanoma in comparison 
to individuals with <100 moles. Along with melanocytic naevi, the presence of 
dysplastic naevi further increases melanoma risk [17]. Age is an important risk factor 
for melanoma, and growing old increases the relative risk of melanoma [16, 19]. 
Family history of melanoma increases the risk 2 fold [16, 17]. A systematic review of 
10 case-control studies showed that hair colour predicts melanoma risk, as blond hair 
individuals had 1.8 fold increased risk, red hair individuals had 2.4 fold increased risk 
in comparison to black and dark brown hair individuals [20]. A recent study of a 
Norwegian-Swedish cohort reported consistent findings, as red haired, blond haired 
and brown haired individuals had increased risk of melanoma in comparison to dark 
brown and black haired individuals [21]. 
1.4 Melanoma genetics 
A family history of melanoma is reported in approximately 8% of melanoma cases 
[16]. In families with 3 or more cases, almost 40% of cases carry a germline mutation 
in the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene [16, 22-25]. Linkage 
studies of melanoma have also identified other high penetrance genes such as 
CDK4, BAP1, POT1, and TERT [26-31]. GenoMEL, a consortium of familial 
melanoma research, led one of the biggest studies to examine these mutations and 
reported that these mutations characterise only a proportion of melanoma families, 
and mutations in more than 50% of families remain unexplained [25].  
Completion of the Human Genome Project has enabled development of cost effective 
genome-wide genotyping technologies. In addition to the previous linkage-based 
studies used to identify highly penetrant susceptibility genes, genome-wide 
association analysis studies (GWAS) have further characterised the genetic 
architecture of melanoma by identifying genes with intermediate and low penetrance. 
Several GWAS have identified a total of 20 loci associated with different melanoma 
phenotypes (physical characteristics associated with melanoma), such as 
pigmentation phenotypes, naevi in the skin and telomere length [32-39]. The variants 
mapping to the CDKN2A/MTAP, PLA2G6 and IRF4 regions were associated with 
development of naevi. The variants mapping to the MC1R, ASIP, OCA2, SLC45A2 
and TYR regions were observed to be associated with pigmentation phenotypes such 
as hair colour and eye colour. Variants in the TERT, PARP1, ATM and OBFC1 
regions were observed to be associated with telomere length. Several other variants 
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mapping to the CCND1, RMDN2, CDKAL1, ARG3, TMEM38B, ARNT1, MX2, and 
CASP8 regions were not associated with any specific melanoma phenotype despite 
being strongly associated with increased melanoma risk.  
1.5 Melanoma histopathological classification, prognostic 
factors and survival 
Melanoma has the highest mortality rate among the skin cancers, but if detected 
early, the majority of the patients survive for more than 10 years [40]. In clinical 
settings the initial diagnosis of melanoma is made using visual examination of the 
mole with the naked eye and then using a magnifying system (dermoscopy). 
Suspicious moles are then removed by performing a surgical excision [10, 11]. 
Several histopathological factors of melanoma and host factors (site, sex and age) 
have been shown to be determinants of melanoma prognosis [41-43]. After clinical 
diagnosis of melanoma, the extent (stage) of cancer is decided based on 
histopathological classification described in the AJCC (American Joint Committee on 
Cancer) staging system [44].  
1.5.4 AJCC staging system  
The final version of the 7th edition of the AJCC staging system classifies melanoma 
tumours using TNM staging, where T is primary tumour characteristics, N is the 
number of regional lymph nodes and M is metastasis of tumours to distinct organs 
[44]. The T staging is based on three main histopathological factors as follows: 
Breslow thickness, mitotic rate and ulceration status of tumours.  
Mitotic rate provides an estimate of the proliferation rate of cells [45] and is defined 
as the number of tumour cell divisions per square millimetres (mm) of the tissue slide. 
An increase in mitotic rate significantly reduces survival time [44]. In primary 
melanoma, mitotic rate has been identified as an independent predictor of poor 
prognosis in thin melanomas (stage I, Table 1.1, Table 1.2). The proposed threshold 
for mitotic rate is <1 /mm2 or ≥1 /mm2, classifying patients into T1a and T1b stages 
respectively (Table 1.1, Table 1.2). Several studies have shown an association of 
mitotic rate with poor prognosis in thicker melanomas as well, but when jointly 
analysed with other clinical predictors, mitotic rate did not reach the significance 
threshold. Therefore, mitotic rate was not included in the AJCC classification of 
thicker melanomas [44, 46, 47]. In fact, mitotic rate has been dropped in the 8th edition 
[48] but this system is only now being applied, and therefore in this study the 7th 
Edition was used [44].  
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Breslow thickness is a well-established, independent prognostic factor for melanoma 
which is used in TNM staging of primary tumours [44, 45, 47, 49, 50]. Breslow 
thickness measures the thickness of the tumour in mm from the surface of the skin 
(granular cell layer) to the deepest part of the tumour (Figure 1.2).  As shown in Table 
1.1 Breslow thickness is divided into four categories in the AJCC staging system, as: 
≤1mm, 1.01-2.0mm, 2.01-4.0mm, >4.0mm, and these categories classify primary 
tumours in T1, T2, T3, and T4 stages respectively. The recently published 8th edition 
of the AJCC staging system [51] uses  ≤0.8 mm as a cut-off for T1 stage, in 
comparison to the previous ≤1.0mm cut-off [48]. 
Ulceration status of the tumour is another prognostic indicator used in TNM 
classification and has been identified as an independent predictor of prognosis when 
jointly analysed with other clinical predictors of melanoma [44, 52]. The presence of 
ulceration increases the T stage (Table 1.1), and ulceration of the tumour also confers 
an increased risk of metastasis in comparison to non-ulceration. However, the 
detection of ulceration is associated with some interobserver variation, and several 
attempts has been made to standardise this variable [53].  
The advanced stage classification (AJCC stage IV) utilises additional information 
from N and M stages which are based on detection of regional lymph node 
metastases, distant organ metastases and lactate dehydrogenase levels respectively 
(Table 1.1, Table 1.2) [44].  
 
Figure 1.2 Measurement of tumour thickness across the T stages in the AJCC 
staging system 
Adapted from Macmillan Cancer support [54]   
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Table 1.1 TNM staging of cutaneous melanoma 
Adapted from Balch et al. [44].    
Primary Tumour Characteristics 
T stage 
T1 
T1a: ≤ 1.0 mm in thickness without ulceration, mitoses < 
1/mm2 
T1b: ≤ 1.0 mm in thickness with ulceration or mitoses ≥ 1/mm2 
T2 
T2a: 1.01-2.0 mm in thickness without ulceration 
T2b: 1.01-2.0 mm in thickness with ulceration 
T3 
T3a: 2.01-4.0 mm in thickness without ulceration 
T3b: 2.01-4.0 mm in thickness with ulceration 
T4 
T4a: >4.0 mm in thickness without ulceration 
T4b: >4.0 mm in thickness with ulceration 
Regional Lymph Nodes (N) 
N stage 
N0 No regional metastases detected 
N1 
N1a: Micrometastases in one lymph node 
N2b: Micrometastases in one lymph node 
N2 
 
N2a: Micrometastases in 2-3 lymph nodes 
N2b: Micrometastases in 2-3 lymph nodes 
N2c: In-transit metastases/satellites without metastatic lymph 
nodes 
N3 ≥ 4 metastatic lymph nodes, or matted lymph nodes, or in-transit metastases/ satellites with metastatic lymph node (s) 
Distant metastases (M) 
M stage 
M0 No evidence of distant metastases 
M1a Metastases to the skin, subcutaneous tissue, or distant lymph nodes, normal serum lactate dehydrogenase (LDH) level 
M1b Lung metastases, normal LDH level 
M1c Metastases to all other visceral sites or distant metastases to any site combined with an elevated serum LDH level 
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Table 1.2 Clinical staging of cutaneous melanoma 
 Adapted from Balch et al. [44]. See Table 1.1. for definition of the TNM stages. 
Staging T N M 
Stage I 
IA T1a N0 M0 
IB T1b T2a 
N0 
N0 
M0 
M0 
Stage II 
IIA T2b T3a 
N0 
N0 
M0 
M0 
IIB T3b T4a 
N0 
N0 
M0 
M0 
IIC T4b N0 M0 
Stage III Any T N>N0 M0 
Stage IV Any T Any N M1 
 
1.5.5 Prognostic factors in primary melanoma 
As described before, histopathological factors such as tumour thickness, ulceration 
and mitotic rate were determined to be strong independent prognostic factors in 
melanoma and have been included in the calculation of the AJCC staging system 
[44]. Host factors such as sex, age at diagnosis and site of melanoma have also 
shown strong association with melanoma prognosis after adjusting for the 
histopathological factors of melanoma. 
Sex is a well-known predictor of melanoma prognosis with males being consistently 
identified as a poor prognostic group in comparison to females [55, 56]. However, the 
underlying biological reasons to explain the survival advantage for women are still 
not clear. It was also reported that men have increased propensity to develop 
metastases and have higher mutation burden in their metastases in comparison to 
females [57]. The 5 year survival for males is around 70% and for females it is around 
82% [13]. 
Age at diagnosis predicts poor prognosis, with the age group >70 years having the 
poorest prognosis [58]; this group also has a lower rate of sentinel lymph node 
positivity, which may imply that the poor prognosis of this group is due to the high 
morbidity [59, 60], or because of blood borne metastases which are more common 
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in older patients. Furthermore, older patients are less likely to have a strong immune 
system, leading to poor ability to mount an appropriate anti-tumour response  [61]. 
The site of melanoma is another strong prognostic factor for melanoma. The site of 
primary melanoma is usually classified as limbs, head and neck, trunk, and other rare 
sites on the body, e.g. on genital skin or the sole of the foot. Melanoma occurring on 
the trunk has a worse prognosis in comparison to melanoma on the limbs or head 
and neck [62]. Melanoma most commonly occurs on the trunk and lower limbs for 
males and females respectively [13]. 
The other relevant histopathological features of melanoma that are not included in 
the AJCC staging system are tumour infiltrating lymphocytes (TILs), the presence of 
vascular or lymphatic invasion and the presence of tumour regression. The 
histopathological classification of tumours based on TILs was developed by Clark et 
al., and it quantifies presence of immune cell populations surrounding and infiltrating 
the tumour [63]. Clark et al. categorised TILs as absent (when no lymphocyte 
aggregation is detected), non-brisk (presence of few lymphocytes) and brisk (when 
the lymphocyte population is large and lymphocytes have surrounded the tumour). 
The TILs classification has been shown to predict melanoma prognosis, with brisk 
TILs predicting good prognosis and the absence of TILs predicting the worst 
prognosis, independent of age, sex, tumour site, and the AJCC staging system [63, 
64] [65]. Vascular or lymphatic invasion is the presence of tumour cells in blood 
vessels, which has been shown to be associated with a higher Breslow thickness, 
ulceration of the tumour, mitotic rate and a nodular melanoma subtype; furthermore 
it predicts poor prognosis [66-68]. Tumour regression is the disappearance of tumour 
cells, most likely as a consequence of interactions between the tumour cells and 
immune cells leading to replacement of the tumour tissue with non-malignant tissue 
[69-71]. A few studies have shown that tumour regression predicts prognosis in thin 
melanomas and is associated with other clinical prognostic variables such as sex, 
older age at diagnosis, head and neck or trunk site of melanoma [69, 70, 72]. 
However other studies have found no evidence to indicate that regression influences 
survival [73, 74]. 
1.5.6 Melanoma survival based on the AJCC stage 
In the UK, the 5-year survival rate for patients diagnosed with melanoma is more than 
95% for AJCC stage I [40]. The survival rate decreases by ~20% for the patients 
diagnosed at AJCC stage II [40]. The survival for AJCC stage III patients is 50%; at 
this stage the tumour has reached the lymph nodes. The survival further drops down 
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to 15-17% for AJCC stage IV melanoma [40]. At stage IV, the tumour has already 
metastasized to different organs in the body.  
1.6 Genomic classification of melanoma 
The AJCC staging system is a powerful tool for predicting melanoma prognosis, but 
it only considers the pathological state of the tumour and does not include the 
genomic changes that contribute to driving tumour progression. Advances in cost-
effective DNA microarray and next-generation sequencing technologies have paved 
the way to discovery of biomarkers predicting disease outcome or response to 
treatment. These technologies have been broadly applied to detect changes in the 
tumour DNA to help in characterising the genomic landscape of melanoma. 
1.6.1 Mutational subtypes of melanoma 
BRAF and NRAS oncogenes have been identified as the most commonly mutated 
genes in melanoma [75-78]. Mutations in these genes are effectively mutually 
exclusive [79], and both activate the Mitogen-Activated Protein Kinase (MAPK) 
pathway [80]. In 2015, a study by The Cancer Genome Atlas consortium (TCGA) 
identified four mutation subtypes in a cohort predominantly of metastatic melanoma 
tumours [81]. The four mutation subtypes were named as BRAF, RAS, NF1 and triple 
wild type mutant groups. In this study, among 318 tumours, 52% (n=166) harboured 
a BRAF mutation, with 144 tumours specifically having a BRAFV600E mutation. The 
RAS subtype tumours harboured mutations mainly in NRAS (28%), and only a few 
tumours had mutation in other RAS-family member genes such KRAS and HRAS. 
Fourteen percent of tumours harboured NF1 mutation, classified as the NF1 subtype. 
The triple-wild type group contained a heterogeneous group of tumours harbouring 
mutations in different genes and was characterised based on the lack of mutation in 
BRAF, NRAS and NF1 [81]. 
Melanoma when classified based on body site showed different mutation patterns on 
chronically sun-damaged skin (CSD) in comparison to non-chronically sun damaged 
skin (non-CSD) sites [82]. Early stage tumours of the CSD class harboured NF1, 
BRAF, NRAS or KIT mutations in the tumour, and the non-CSD class harboured only 
BRAF mutations [83-85]. In both groups, metastatic stage melanomas harboured 
somatic mutations in genes associated with key signalling pathways relating to cell 
proliferation (NRAS, BRAF, NF1), cell growth (PTEN and KIT), cell identity (ARID2), 
resistance to apoptosis (TP53) and cell cycle control (CDKN2A) [86, 87].  
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A study led by Shain et al. showed that mutation in the BRAF gene is acquired at an 
early stage when the tumour is benign [88]. Mutation in the NRAS gene is a 
characteristic feature of intermediate stage, along with mutations in other genes such 
as TERT and PPP6C. Overall, the sequence of mutations that lead to melanoma 
initiation are still unclear because different individuals harbour different mutations 
which lead to activation of different pathways. This supports the view that there are 
several biological routes to melanoma progression, and only a few of them are 
highlighted by these analyses [86]. The research on melanoma genomes continues 
with an expectation that understanding of disease biology and routes of melanoma 
progression can be improved by examining other data types such as copy number 
alterations, gene expression, and methylation status of the tumours.  
1.6.2 Somatic copy number association with mutational subtypes  
In melanoma, genomic regions associated with genes such as CCND1, KIT, CDK4, 
TERT and MITF are frequently amplified, and regions associated with CDKN2A, 
PTEN are frequently deleted [86]. The level of amplifications and deletions are a 
measure to estimate whether regions of the genome are duplicated or deleted during 
cell replication. In the TCGA study, analyses testing the association between the 
mutational subtypes and copy number alterations revealed that the BRAF mutational 
subtype had significantly higher copy number gains in BRAF, MITF and PD-1, PDL-
1 genomic regions of the tumour DNA than other mutational subtypes. The NRAS 
subtype had significantly more copy number gains in the NRAS genomic region in 
comparison to other mutational subtypes. The NF1 subtype had significantly higher 
deletions in the PTPRD region. The triple-wild type mutational subtype had 
amplifications in KIT, PDGFRA, KDR, CDK4, CCND1 and MDM2 regions. Overall, 
the amplifications in CCND1 and TERT, and deletions in CDKN2A and PTEN 
genomic regions were observed across all the mutational subtypes, suggesting that 
these copy number alterations are an intrinsic characteristic of metastatic melanoma 
tumours [81]. 
1.7 Gene expression profiling technologies 
Gene expression is a process by which the genetic code or the nucleotide sequence 
of a gene is used in the synthesis of a functional gene product during transcription. 
Expression profiling at whole genome level is achieved using DNA microarray or 
RNA-sequencing technologies.  
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1.7.1 DNA microarrays  
Microarray based gene expression profiling captures the molecular state of the cell 
by quantifying expression of thousands of genes simultaneously (Figure 1.3) [89-91]. 
In this high throughput technique, mRNA extracted from tissues samples is further 
amplified using PCR (Polymerase Chain Reaction), and then reverse transcribed into 
cDNA using reverse transcriptase enzyme (Figure 1.3). The cDNA sequences are 
stained using a fluorescent dye. As a next step, the stained cDNA sequences are 
hybridised to the unique short fragments of single stranded DNA bound to the plates, 
known as probes. After the hybridisation step, the plates are washed to retain the 
strong probe-cDNA binding sequences. The fluorescently labelled cDNA bound to a 
probe generates a signal, and the intensity of signal provides an estimate of the gene 
expression (Figure 1.3). There exist two main techniques for DNA microarray: 
oligonucleotide microarray and cDNA microarray. The oligonucleotide microarray 
uses short probe sequences which are 25 to 70 bases in length, and the cDNA 
microarray used probes of 200 to 2000 bases in length [89].   
Gene expression profiling of disease using tissue specimens (such as blood, fresh 
tumour or archived Formalin Fixed Paraffin Embedded (FFPE) tumour) can lead to 
the discovery of biomarkers with prognostic potential that go beyond the 
histopathological classification [92]. Extracting RNA from FFPE samples stored over 
a long time yields low-quantity RNA, and analysing it is difficult because formalin 
fixation leads to crosslinking of RNA with proteins and causes nucleic acid to 
fragment [93]. To overcome these problems Fan et al. developed a gene expression 
assay known as DASLâ (cDNA mediated Annealing, Selection, extension and 
Ligation) [94], which had locus specific probes designed for probe-cDNA 
hybridisation. The limitation of this assay was the limited number of probes, but 
introduction of a whole-genome DASLâ assay has allowed profiling of approx. 29000 
transcripts [92]. The RNA from the frozen FFPE samples is partially degraded but 
studies have shown that transcriptome signature based disease subtyping is still 
feasible using this technique [92, 95]. 
1.7.2 RNA-sequencing 
RNA-sequencing (RNA-seq) is a another widely used technique for gene expression 
profiling which is based on next-generation sequencing (NGS) [96, 97]. In this 
technique, the mRNA extracted from the tissue sample is annealed to oligo-dT 
magnetic beads, and then a fragmentation agent is added to generate multiple 
fragments of mRNA. The fragments are reverse transcribed into single stranded 
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cDNA sequences. The opposite strands of cDNA are synthesized, and the resultant 
product is a double stranded cDNA. The double stranded cDNA sequences are end-
repaired, ligated to adaptors, and PCR amplified to generate a library that is ready 
for sequencing. The sequences in the library are then sequenced using a NGS 
platform, and reads of ~30-500 bases long are generated. The reads are then aligned 
to a reference genome to produce a genome-wide transcriptional state which 
determines the level of expression for each gene [96, 97].   
 
Figure 1.3 Summary steps of a microarray experiment 
Adapted from [98].  
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Malone et al. compared DNA microarray and RNA-sequencing technologies and 
reported that both the technologies had a comparable performance and provided a 
reliable estimate of gene expression [99]. Both the technologies showed poor 
performance in detecting genes with low expression. RNA-seq has an advantage 
over DNA microarrays as one can study a lot of other characteristics (e.g. splicing, 
gene/isoforms, gene fusions, structural variations) apart from studying gene 
expression. The limitation of RNA-seq is that it is an expensive and more time-
consuming technology than DNA microarrays [99].  
Along with the advantages of high-throughput profiling techniques come various 
challenges: how to deal with the variability due to the use of different platforms, 
variability due to heterogeneous sources of material, and different ways of analysing 
the data. 
1.8 Gene expression based classification of melanoma 
Previously, numerous studies have used supervised and unsupervised classification 
approaches to generate gene expression-based signatures which predict melanoma 
tumour outcome (Table 1.3) [84, 100-109]. The unsupervised classification approach 
identifies novel subgroups by exploring distinct patterns in the dataset. The 
supervised classification, including machine learning, on the other hand mine the 
knowledge from known subgroups or outcomes and develop prediction models to 
classify new observations into these groups [110-112].  
1.8.1 Supervised classification using gene expression 
In 2006, Winnepenninckx et al. published the first study (Table 1.3) that analysed the 
gene expression data from primary melanoma tumours and generated a 254 gene-
based signature predictive of metastasis free survival for 4 years (Agilent 
oligonucleotide microarray)  [100]. When comparing the prediction performance of 
this signature with histopathological factors like tumour stage based on TNM staging, 
the  signature misclassified 29% of samples in comparison to 28% misclassification 
when using histopathological factors alone. Overall the gene signature had similar 
prognostic value in comparison to the histopathological factors [100]. 
In 2007, Alonso et al. analysed the gene expression data from 34 vertical growth 
melanomas with every patient followed for at least 36 months (OncoChip DNA 
microarray) (Table 1.3) [101] . The study compared the patients who developed nodal 
metastases (n=21) with those who did not (n=13) and generated a 243 gene-based 
signature that predicted risk of metastasis. The biological pathway enrichment 
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analyses revealed that genes in the signature were associated with the epithelial-
mesenchymal transition pathway, and these findings were further confirmed in an 
independent dataset [101]. 
In 2008, John et al. performed molecular profiling of 29 patients diagnosed at AJCC 
stages IIIB and IIIC with clinical outcome defined as melanoma progression in 2 years 
(oligonucleotide microarray) (Table 1.3) [102]. Thirteen patients did not experience 
disease progression in 2 years whereas 16 patients experienced disease 
progression. Comparing gene expression differences between the two groups 
identified 21 genes, which were experimentally validated and used to generate a 
predictive risk score. This score was applied on two independent datasets, and it 
accurately predicted outcome in 90% and 85% of patients respectively [102].  
In 2009, Bogunovic et al. analysed gene expression data, mitotic rate and TILs from 
38 melanomas to explore the molecular basis for metastasis and to generate 
biomarkers of melanoma survival (Affymetrix Human Genome microarray) (Table 
1.3) [103]. Comparing gene expression differences between patients with prolonged 
survival and patients with short survival led to the generation of a 266 gene-based 
signature. For the 266 genes, pathway enrichment analysis revealed that immune 
response related genes were enriched in the good prognosis groups and cell 
proliferation related genes were enriched in the poor prognosis group. The prognostic 
value of the gene signature was validated in an independent dataset of comparatively 
similar size [103].  
Conway et al. (former PhD student in the Leeds research group) performed gene 
expression profiling using archived FFPE tumour blocks of 254 melanoma patients 
(part of Leeds Melanoma Cohort described in chapter 2) diagnosed at AJCC stages 
I, II, and III (DASL microarray cancer chip based on 502 genes) (Table 1.3) [104]. 
Increased expression of the Osteopontin gene (SPP1) was identified as a prognostic 
biomarker predicting relapse-free survival in the training set. When jointly analysed 
with other clinico-histopathological factors of melanoma in a multivariable analysis, 
this gene remained a significant predictor of relapse-free survival. The prognostic 
significance of this gene was validated in an independent dataset (n=218). A follow 
up study in 2010 by Jewell et al. (another PhD student in the group) jointly analysed 
the two datasets analysed in Conway et al. (n=472) and identified that genes 
associated with DNA repair mechanisms as significant predictors of relapse-free 
survival [113]. The increased expression of DNA repair mechanism genes in 
progressive tumours supported the view that melanoma progression requires genetic 
stability.  
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In 2013, Mann et al. analysed the mutational and gene expression data generated 
from 73 melanoma patients diagnosed at AJCC stage III and identified a 46 gene-
based signature that predicted outcome (Expression BeadChips microarray) (Table 
1.3) [84]. Pathway enrichment analysis revealed overrepresentation of immune 
response mechanisms. The gene signature showed independent prognostic value 
when jointly analysed with clinico-pathological variables. The prognostic value of the 
signatures was validated in two previously published cohorts of AJCC stage III 
melanoma. The study concluded that BRAF and NRAF mutation, along with absence 
of immune related gene expression, is associated with poor prognosis in stage III 
melanoma [84]. 
In 2015, Gerami et al. analysed the differences between primary and metastatic 
melanoma tumours using available gene expression datasets and selected the 28 
most discriminatory genes (Table 1.3) [109]. These 28 genes were used to developed 
a classification model to predict risk of metastasis using training set observations 
(n=164). When applying the classification model to the validation set (n=104), the 
model robustly predicted risk of metastasis (area under Receiver Operating 
Characteristic (ROC) curve =0.91) [109]. 
In 2018, Brunner et al. developed a classification model that predicted Melanoma-
Specific Survival (MSS) based on expression values of 8 genes (Table 1.3) [108]. 
The classification model was developed using tumours in the training set (n=125) and 
was validated on the tumours in the test set (n=211). Both the sets were a mixture of 
primary tumours from AJCC stages I, II and III. The generated classification model 
significantly predicted MSS in both the training set and the test set observations. 
When the gene signature was jointly analysed with the AJCC staging system, the 
area under the ROC predicting MSS increased by 4% in the training set and 6% in 
the test set when compared to the AJCC staging system alone [108].  
 
 Table 1.3 Summary of studies investigating prognostic signatures of melanoma 
Study Cohort Outcome Gene signature and prognostic performance 
Winnepenninckx et al. 
(2006) [100] 
38 AJCC stage I-IV melanoma 
tumours 
≥ 4 years distant metastasis-
free survival versus < 4 year 
distant metastasis free survival 
259 gene-based signature, signature 
misclassified 29% cases and histopathological 
variables misclassified 28% cases 
Alonso et al. (2007) [101] 
34 vertical phase melanoma 
tumours (21 with metastasis 
and 13 without) 
Metastasis versus without 
metastasis 
243 gene-based signature, only 3 genes were 
validated and showed association with survival 
John et al. (2008) [102] 29 AJCC stage III and stage IV melanoma tumours 
≥2 years to tumour progression 
versus <2 years to tumour 
progression 
21 gene-based signature, no prognostic impact 
shown 
Bogunovic et al. (2009) [103] 38 AJCC stage III and stage IV melanoma tumours 
≥ 1.5 years of survival versus 
<1.5 years of survival 
266 gene-based signature, independent 
prognostic indicator of survival when jointly 
analysed with mitotic rate and TNM stage 
Conway et al. (2009) [104] 254 primary melanoma AJCC stage I-III 
Relapse free survival and 
overall survival 
1 gene, Osteopontin (SPP1) expression, gene 
expression did not maintain significance in the 
validation set 
Jonsson et al. (2010) [106] 57 AJCC stage IV melanoma tumours 
Overall survival difference in 
four groups 
503 gene-based signature, strong association 
with overall survival in four groups and 
association of increased immune response with 
good prognosis. 
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 Study Cohort Outcome Gene signature and prognostic performance 
Harbst et al. (2012) [105] 223 AJCC stage I and stage II melanoma tumours 
Overall survival (OS) and 
relapse-free survival (RFS) 
difference in two groups 
1864 gene-based signature, strong association 
with OS and RFS in two groups. Association of 
increased immune response with good prognosis 
Mann et al. (2013) [84] 79 AJCC stage III melanoma tumours 
<1 year survival versus survival 
> 4 years post-surgery 
46 gene-based signature, strong over 
representation of immune response gene with 
good prognosis 
The Cancer Genome Atlas 
Network (2015) [81] 
331 primary and metastatic 
melanomas, AJCC stage I-IV 
Overall survival difference 
between three groups 
1500 gene-based signature, increased immune 
gene expression predicted good prognosis 
Gerami et al. (2015) [109] 268 AJCC stage I-III melanoma tumours Risk of metastasis 
28 gene-based signature predicted risk of 
metastasis in the training and validation cohorts 
Brunner et al. (2018) [108] 336 AJCC I-III melanoma tumours 
Melanoma-specific survival 
(MSS) 
8 gene-based signature predicted MSS in the 
training and validation dataset 
19 
20 
1.8.2 Unsupervised classification using gene expression 
The other studies have taken an unsupervised classification (clustering) approach to 
identify gene signatures of melanoma (Table 1.3). In 2010, Jonsson et al. (a group 
from the University of Lund with whom we collaborate) performed unsupervised 
hierarchical clustering on gene expression of 57 metastatic melanoma tumour 
samples; data was generated using an Illumina bead microarray [106]. The clustering 
identified four distinct classes: High-Immune, Normal-like, Proliferative and 
Pigmentation. This 4-class signature based on 503 genes will be referred to as the 
Lund 4-class signature in this report. The Lund 4-classes significantly predicted 
survival in stage IV melanoma as high-immune and normal-like class tumours had a 
good prognosis, and pigmentation and proliferative class tumours had significantly 
poorer prognosis. Histopathological factors such as Breslow thickness, mitotic rate, 
ulceration and AJCC stage were not observed to be associated with the Lund 4-
classes, which could have been due to the small sample size (n=57) and the 
advanced stage of those tumours [106].  
In 2012, the same group published another study where the Lund 4-class signature 
was validated in 223 melanoma primaries [105], and the signature collapsed into a 
2-grade signature. The survival curves of Lund 4-classes showed a convergence into 
just two significantly different survival curves; furthermore this led to generation of a 
2-grade signature, high-grade and low-grade (Figure 1.4A-B), from now on referred 
to as the Lund 2-grade signature [105]. The high-grade reflected metastatic tumours 
from proliferative and pigmentation classes, and the low-grade contained localised 
tumours from high-immune and normal-like classes [105].  
In 2015, our group validated the Lund 4-classes and 2-grades on a subset of the 
Leeds dataset observing the previously reported association with survival [114].  
In 2015, another study by the TCGA group clustered a mixture of metastatic and 
primary melanomas into three distinct classes [81]. The tumour classes were named 
as: immune, keratin and MITF-low. Survival analysis illustrated that patients from the 
immune class had better survival, while patients from the MITF-low and keratin class 
had intermediate and worse survival (Figure 1.4C) [81].  
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Figure 1.4 Melanoma tumour subtypes identified by the Lund group 
Adapted from Harbst et al. [105], Kaplan–Meier curves showing overall survival 
of patients in (A) the Lund 4-classes and (B) the Lund 2-grades. (C) Adapted 
from the TCGA study [81], Kaplan-Meier curve showing survival of the TCGA 
3-classes. The survival comparison was done using the log-rank test.  
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1.8.3 Overlap between the signatures 
In 2011 Schramm et al., conducted a systematic review of some of the previously 
published gene signatures of melanoma (between 2006-2010) and performed cross-
validation of these signatures on different datasets from the respective studies [107]. 
A direct comparison of gene lists of these signatures identified only a few genes in 
common, but pathway enrichment analysis revealed consistent enrichment of 
immune response related mechanisms. Although some differences in classification 
by gene signatures was observed, the gene signatures consistently predicted 
prognosis in the majority of the datasets [107]. The analysed gene signatures did not 
outperform the clinico-histopathological characteristics in predicting prognosis, and 
therefore it was noted that the prognostic value of new gene signatures in future 
should continue to be assessed in a multivariable model including existing prognostic 
factors of melanoma [107]. 
In 2013, Liu et al., analysed four previously published microarray based studies and 
made similar observations, as they also found that only a few genes were common 
across the published gene signatures [115]. The meta-analysis of the four datasets 
revealed a 200 gene-based signature that distinguished melanoma cells from normal 
skin cells. Comparison with other studies and gene enrichment analysis led to 
selection of a 12 gene-based signature which was validated experimentally. This 
study did not test the association of the signature with melanoma prognosis [115]. 
In 2016, Lauss et al. compared the molecular signatures of melanoma from 
unsupervised clustering [116]. It was reported that only 34 genes overlapped from 
the Lund and TCGA signatures, but pathway enrichment analysis revealed a good 
overlap of the biological pathways [116]. The Lund and TCGA signatures were 
developed agnostically using a similar clustering algorithm but were based on 
different types of analysis platform (array-based platform in Lund, RNA-sequencing 
in TCGA). Their convergence supports the view that transcriptomic data can indeed 
produce stable results. This indicated that even though gene signatures were 
generated from different platforms, they identify similar biological differences across 
tumours. 
All the three studies mentioned above highlighted that different classification or 
clustering methods may select different genes, but an overlap of the biological 
pathways associated with these genes suggests that the methods might be selecting 
genes which are highly correlated and also belong to the same pathway. Hence a 
direct comparison of gene lists may not be useful in analysing the overlap between 
the signatures. 
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1.9 Outline of this study 
Previous studies on unsupervised and supervised classification of melanoma have 
analysed gene expression datasets of comparatively small size, generated 
predominantly from advanced stage primary tumours, i.e. AJCC stages II and III. In 
2015, our group had published a validation of the Lund 4-class and 2-grade 
signatures on a subset of LMC (Leeds Melanoma Cohort) tumours [114]. This study 
was based on 224 tumours of the LMC that were transcriptome-profiled at the time.  
Currently the gene expression profiling has been done for 702 tumours of the LMC. 
In this study, various unsupervised and unsupervised classification approaches will 
be applied to the LMC dataset with an aim to identify molecular and prognostic 
signatures of melanoma. 
1.9.1 Aims and objectives 
Aim 1: Previously, melanoma tumours have been classified into 2-grades and 4-
classes by the Lund group and into 3-classes by the TCGA group. The tumour groups 
have been shown to predict prognosis in metastatic and primary melanoma cohorts. 
To extend this further the current research has the following objectives,  
Objective 1: To assess the prognostic value of the Lund and TCGA gene signatures 
in the whole LMC dataset (702 tumours)  
Hypothesis: The gene signatures with prognostic value in the published literature will 
also predict survival in the LMC  
Objective 2: To assess the prognostic value of the Lund and TCGA gene signatures 
across the AJCC stages 
Objective 3: To cluster tumours of the LMC dataset using different methods to those 
used in deriving the existing signatures 
Hypothesis: De novo cluster analysis of a comparatively larger dataset (up to 3 times 
larger than previous studies) may reveal novel tumour classes  
Objective 4: To use an independent measure of cluster separation to assess stability 
of the newly identified tumour classes referred to as the LMC classes (Leeds 
Melanoma Cohort classes)  
Objective 5: To test association of the LMC classes with clinico-histopathological 
features of melanoma  
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Objective 6: To test prognostic significance of the LMC classes in the whole LMC 
dataset and in the stage I subset  
Objective 7: To generate a reduced signature of the LMC classes and replicate 
prognostic significance of the LMC classes in an independent dataset from Lund, 
Sweden 
Objective 8: To explore biological differences between LMC classes using pathway 
enrichment analysis and using melanoma-specific biological modules 
Aim 2: Supervised classification can be used to develop models to predict outcome 
in future patients using analyses from existing data where the outcome is known. 
Classification models will be developed using Random Forest (RF) and Support 
Vector Machine (SVM),  
Objective 9: To apply RF to develop a classification model for predicting outcome in 
the LMC. The performance of the model will be assessed using sensitivity, specificity, 
and the kappa index 
Objective 10: To apply SVM using linear and non-linear kernel functions to develop 
classification models for predicting outcome in the LMC. The performance of SVM 
model will be compared with the RF model 
Objective 11: To generate a RF model after combining clinical information and gene 
expression data and compare its performance with a clinical information based RF 
model 
Objective 12: To generate a refined RF model by performing variable selection 
Hypothesis: The refined RF model using top predictor genes will predict prognosis 
similarly to the model using all genes 
Objective 13: To validate the prognostic value of the refined RF on an independent 
dataset of primary melanoma from Lund, Sweden  
Objective 14: Biological interpretation of the refined model using pathway enrichment 
analysis 
1.9.2 Outline of the chapters 
Chapter 2 provides a general methodological overview of the LMC cohort, generation 
and pre-processing of gene expression dataset and definition and analysis of MSS.  
In Chapter 3, the Lund and TCGA signatures were applied to the LMC gene 
expression dataset, and association with MSS was tested across the AJCC stages 
especially in stage I tumours. It was hypothesized that clustering of LMC tumours 
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may identify novel molecular signatures of melanoma. Therefore, LMC tumours were 
clustered using three different clustering algorithms and the stability of clusters and 
agreement with the Lund and TCGA signatures was calculated. The clusters 
identified by an algorithm that demonstrated highest cluster stability were further 
explored. 
In Chapter 4, the identified clusters, referred to as the LMC classes, were tested for 
association with clinico-histopathological characteristics and MSS stratified by the 
AJCC stages. To validate the prognostic value of the LMC classes on an independent 
dataset of primary melanoma (Lund dataset) generated by the Lund group, a refined 
gene signature was developed using the LMC data. This gene signature was applied 
to the Lund dataset to classify tumours into the LMC classes and association with 
prognosis was tested. The independent prognostic value of the LMC classes was 
assessed in both the datasets (LMC and Lund) using the AJCC staging system as a 
baseline. 
In Chapter 5, two supervised classification approaches (Random Forest and Support 
Vector Machine) were applied to the gene expression dataset to develop 
classification models to predict outcome. The outcome was defined as MSS up to a 
selected time point. The classification models were generated using unbalanced and 
balanced training datasets, and performance was compared on a separate test 
dataset. To appraise the performance of the best performing classification model, 
several permutation-based classification models were generated and performance 
was compared with the best performing gene expression-based model. 
In Chapter 6, performance of the selected gene expression-based model was 
compared with the classification model generated using clinical variables alone. It 
was hypothesized that combining the gene expression and clinical variables datasets 
may further improve prediction performance. Hence, the gene expression dataset 
and clinical variables were combined, and prediction of the combined model was 
compared to a clinical variable based model. Variable selection was performed to 
generate a final refined model which was further applied on the Lund dataset to 
predict outcome. Finally, the LMC classes identified in chapters 3 and 4 were 
compared with the predicted classes of the final refined model in this chapter. 
Chapter 7 summarizes the main findings, sets them in context, presents a final 
discussion of the results, and highlights the strengths, limitations, and future 
perspectives of this study
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Chapter 2 
General Methods 
2.1 Leeds Melanoma Cohort (LMC) 
The Leeds Melanoma Cohort (LMC) is a population-based sample cohort of 2184 
primary melanoma patients recruited from Yorkshire and the northern region of the 
United Kingdom [114, 117]. The melanoma cases in the LMC study were identified 
by clinicians, pathologists and from the cancer registry. The recruitment took place 
between 2000 and 2012.  
The study was designed to understand the role of genetic and environmental factors 
on melanoma risk and on patient survival. After consenting to participate in the study, 
participants were asked to complete postal and telephone questionnaires. This 
generated detailed information about lifestyle factors and lifetime environmental 
exposures. Blood samples of the participants were collected during recruitment, for 
extraction of plasma, serum and DNA.  
Participants in the LMC study were followed annually for first 5 years (active follow-
up). General practitioner records and linkage to Office for National Statistics (ONS) 
death data was also used (passive follow-up). At the annual follow-up, research 
nurses contacted the consented participants to complete an extended questionnaire 
and sought their consent for donating another blood sample for studying blood 
constituents that are likely to be relevant for melanoma prognosis. Participants were 
consented for assessing formalin-fixed paraffin-embedded (FFPE) primary tumour 
blocks stored in the NHS (UK National Health Service) department where they had 
surgery for tissue sampling.  
The approval for this study was granted by the Multi-centre Research Ethics 
Committee (MREC) and the Patient Information Advisory Group (PIAG 3-
09(d)/2003). An amendment was sought from the Northern and Yorkshire Research 
Ethics Committee (01/3/057) for using the plasma samples for biomarker discovery 
[114, 117]. 
The variables used in this research were the genome-wide gene expressions 
extracted from a subset of FFPE tumours of the LMC and the clinical characteristics 
of these primary melanomas. 
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2.2 Gene expression data  
Gene expression data was generated from the FFPE tumour blocks of 702 patients 
of the 2184 total cohort [117]. The data was generated from a selected group of 
participants in the cohort based on two criteria: 1) Breslow thickness greater than 
0.75mm, and 2) patients with the longest follow-up time, to increase statistical power 
in survival analyses. Tumour less than 0.75mm thick were not selected due to 
difficulties in sampling. As a result, not all incident cases were sampled from the LMC. 
Among 702 patients, only 16 were treated with targeted therapies or 
immunotherapies, so the LMC data effectively reflects the outcome in treatment-
naïve patients.  
2.2.3 Tumour core generation 
The tumour cores were extracted from FFPE blocks using a 0.6mm diameter tissue 
microarray (TMA) needle. A standard protocol has been developed by our group for 
managing and sampling tissues from FFPE blocks. The Human Tissue Act manager, 
Ms. Sandra Tovey led the process of tracing the FFPE blocks. The tissue sectioning, 
staining and sampling was performed by Dr. Filomena Esteves and Dr. Jonathan 
Laye. The sectioned tissues were stained using Mayer’s Haematoxylin and 1% Eosin 
(H&E) to allow identification of areas for sampling after review. Prof. Julia Newton-
Bishop and Dr. Jonathan Laye reviewed the H&E slides under a microscope and 
selected the areas for sampling. Up to two cores were sampled from each block, and 
to increase the comparability between tumours, the samples were consistently drawn 
from the regions with highest tumour content and least inflammation. All the tumour 
blocks were reviewed prior to sampling, and if there was a small amount of tumour 
left in the block then the block was not sampled, lest a clinically very important block 
be destroyed. 
2.2.4 RNA extraction and Expression data generation 
RNA was extracted from the tumour cores for the whole-genome gene expression 
assay by the lab technicians, following a previously established protocol (1,2). Whole-
genome mRNA expression was profiled on Illumina’s DASL (cDNA-mediated 
Annealing, Selection, extension and Ligation) HT12-v4 array [92]. For quality control, 
the mRNA was extracted from multiple cores for a number of patients (117 duplicates 
in total). However, gene expression data was analysed from only one extraction per 
patient in subsequent analyses, selecting the sample showing the best performances 
in terms of the number of genes detected.  
28 
2.2.5 Data pre-processing 
Data pre-processing is a crucial step for removing technical variation or bias in the 
data [118-120]. This obscuring variation arises from different sources, for example 
differences in sample preparation, processing or scanning of the array. As described 
previously, the pre-processing of the gene expression data was conducted by Dr 
Jeremie Nsengimana (senior statistician) [117]. The pre-processing steps involved 
1) image extraction using GenomeStudio (Illumina, Inc., San Francisco), 2) 
background correction to adjust out non-specific hybridisation (as measured by the 
negative control probes that are present on the array), 3) quantile-normalisation 
(steps 2 and 3 were accomplished using the R-package Lumi [121]), and 4) batch 
correction.  
2.2.5.1 Sample quality control 
Quality control was performed by examining the density plots of log-intensity 
distribution for each sample before and after pre-processing of data. This allowed 
identification of samples that had an abnormal distribution, which were subsequently 
removed. Data were re-normalised after removing the samples with an abnormal 
distribution. In previous studies conducted in our group [104, 122], the number of 
probes detected at P<0.05 was shown to be correlated with sample quality and was 
a good measure of array performance. The detection P-value is the probability that 
the signal for a given probe is greater than the signal from the background noise, i.e. 
the average of negative controls. When sample duplicates existed, the sample with 
largest number of probes detected was chosen. 
2.2.5.2 Batch Correction 
Batch correction requires particular attention in microarray studies, in particular as 
not all samples were processed at the same time. They were run in 3 separate 
batches, each containing multiple plates which were loaded on multiple chips before 
scanning. As part of the normalisation process, Single Value Decomposition (SVD) 
was applied to the expression data to check for any biases. The top 25 principal 
components were tested for association with technical variables like chip, plate, batch 
number, age of the FFPE block, RNA concentration, and extraction assay. The 
principal components were found to be strongly associated with the chip, batch 
number and plate. The adjustment of expression data for batch number using a linear 
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model (R-package SWAMP [118]) removed the association with other technical 
variables. The data were converted to the log2 scale for variance stabilisation. 
2.2.5.3 Gene quality control 
The array included 29,262 probes corresponding to 20,715 unique genes. For genes 
with multiple probes, the probe detected in the higher proportion of tumours was 
retained. Genes were further selected on the basis of two additional filters: 1) genes 
which were detected at P-value <0.05 in at least 40% of tumours and 2) had standard 
deviation (SD) > 0.40 (this SD threshold was chosen based on the overall distribution 
across the 20,715 genes on the log2 scale, median 0.68) were selected for 
downstream analysis. Finally, the dataset contained 13,688 genes across 702 
tumour samples. The expression values were standardised so that for each gene the 
mean was 0 and SD was 1.  
 
2.3 Clinico-pathological characteristics 
The following clinico-pathological characteristics of melanoma patients from the LMC 
(Table 2.1) were used: 
1. Sex (male or female) 
2. Tumour site (limbs, trunk, head and neck, other rare sites). Rare sites are 
those rarely sun-exposed such as subungual, anal, penile, vulvar, etc. 
3. Presence of ulceration (yes or no) 
4. Tumour stage (American Joint Committee on Cancer, or AJCC staging 
system) 
5. Age at diagnosis (years) 
6. Breslow thickness (mm) 
7. Mitotic rate (per mm2) was stratified into two categories (<1/ mm2 and ≥1/ 
mm2) based on the 7th edition AJCC staging system guidelines [44]. 
8. BRAF and NRAS mutation status (yes or no – V600 for BRAF, codons 12, 13 
and 61 for NRAS) 
9. Tumour Infiltrating Lymphocytes (TILs) (absent, non-brisk, brisk ) 
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Table 2.1 Summary of clinico-histopathological characteristics of the LMC 
cohort 
Variable LMC cohort 
Sex 
females n(%) 384(55) 
males n(%) 318(45) 
Site 
limbs n(%) 298(42) 
head and neck n (%) 80(11) 
trunk n(%) 233(33) 
other sites n(%) 91(13) 
Ulceration status 
no n(%) 468(67) 
yes n(%) 234(33) 
AJCC stage 
I n(%) 233(34) 
II n(%) 355(51) 
III n(%) 106(15) 
Mitotic rate 
<1 n(%) 88(14) 
≥1 n(%) 521(86) 
BRAF mutant 
no n(%) 309(53) 
yes n(%) 273(47) 
NRAS mutant 
no n(%) 432(75) 
yes n(%) 142(25) 
TILS 
absent n(%) 76(15) 
non-brisk n(%) 340(68) 
brisk n(%) 82(16) 
Age at diagnosis, median(range) 58.4(18.3,81.3) 
Breslow Thickness, median(range) 2.3(0.3,20) 
 
2.4 Survival analysis 
The aim of survival analysis is to test whether independent variables are associated 
with an event of interest. In our case, the event of interest was death from melanoma, 
and the predictors were the clinico-pathological and gene expression features. The 
survival time was the time from diagnosis to death from melanoma. Observations are 
censored when information about their survival time are incomplete [123]. Censoring 
can be further classified into left and right censoring. Left censoring occurs when the 
event of interest occurs before observations begin. Right censoring occurs for the 
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following reasons: a) a patient has not experienced the event of interest by the end 
of the study, b) a patient is lost to follow-up during the study, c) a patient died due to 
some other reason [123]. Patients who did not experience death from melanoma 
within the period of the study were censored at the time of last follow-up or of death 
from another cause. Kaplan-Meier curves were used for visualising survival curves, 
and Cox proportional hazards models were used for estimating the hazard ratios. In 
this study, it was assumed that all survival times are independent of one another, left 
censoring is not an issue because all the patients were recruited soon after diagnosis, 
and censoring solely occurs as right censoring.  
2.4.1 Survival Outcome 
Melanoma-specific survival (MSS) was used as the survival outcome. The MSS time 
was calculated from the date of diagnosis to the date of death caused by melanoma. 
For censored patients, survival time was calculated from the date of diagnosis to the 
date of the last follow-up or death from causes other than melanoma. Survival status 
was determined by looking at the definitive cause of death from the Office of National 
Statistics (ONS) and from the death certificate 
2.4.2 Kaplan-Meier survival estimate  
The Kaplan-Meier method is a non-parametric approach to estimate and visualize 
survival probabilities as a function of time [123, 124]. The survival probability S(t) is 
the probability that an individual survives from the initial time (t0) (e.g. date of cancer 
diagnosis) to a specified future time t. Survival analysis models S(t) as a function of 
a set of predictor variables.   
The survival probability is estimated as follows: 
Suppose X patients have experienced the event of interest during follow-up at distinct 
times as t1<t2<t3<t4...<tn.  
Assuming that the events occurred independently of one another, the survival 
probability S(tj) at time tj (indexed j) is calculated from S(tj-1), the probability of survival 
at tj-1, by: 
 !"#$% = !(#$()) +1 − .$/$0 (2.1) 
where dj is the number of deaths at tj and, nj is the number of patients alive before tj. 
The value of S is constant along the time interval between events and changes only 
at the time of each event. At t0 the value of S is equal to 1. Therefore, S(t) is a step 
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function and this estimator includes each patient in the denominator for as long as 
they are known to be event-free. The graphical visualization of Kaplan-Meier survival 
probability against time provides a useful summary that can be used to estimate the 
median survival time.  
2.4.3 Log-rank test 
The Kaplan-Meier survival probabilities were compared across different groups using 
the log-rank test. This is a non-parametric test used for comparing survival times 
between two or more groups. The null hypothesis is that there is no difference 
between survival curves of the groups, and the alternative hypothesis is that there is. 
At each event time, this test calculates the expected number of events for each group 
since the previous event, under the null hypothesis. The expected values are 
summed over all the event times to give the total number of expected events (Ei) for 
each group (indexed i). The observed number of events (Oi) for that group are 
compared with their expectation under the null using the test statistic 
 
c1 =2(34 − 54)154647)  (2.2) 
where k is the total number of groups compared. 
The P value for this test statistic is derived from c2 distribution with (k-1) degrees of 
freedom. The log-rank test provides a P value for the difference between the groups 
but it offers no estimate of the actual effect size. Several other survival modelling 
strategies have been proposed to overcome these limitations. 
2.4.4 Cox Proportional Hazards model (CPH) 
The Cox Proportional Hazards (CPH) model is a semi-parametric approach for 
modelling survival data [124, 125]. It is a regression-based method which describes 
the relationship between an event’s occurrence and a set of covariates using a 
hazard function. All individuals who have not yet experienced the event of interest at 
any given time are considered to be at risk of experiencing it at a later time. The 
hazard function, usually denoted by h(t) or λ(t), is the probability that an individual will 
experience the event at time t, conditional on them having survived to t. 
Mathematically, the CPH model is written as 
 ℎ(#) = ℎ9(#) × ;<=>ß)<) + ß1<1 +⋯+ ßB<BC (2.3) 
33 
where the hazard function h(t) is dependent on the vector of p covariates (x1, x2,…, 
xp) whose effect sizes are measured by the coefficients (ß1, ß2,…, ßp). The coefficients 
are unknown and are estimated by maximum likelihood or, more precisely using 
partial likelihood. The partial likelihood approach considers the individuals with an 
event and not the not the ones which are censored and does not estimate the 
baseline h0(t): 
 D(ß) = 	F ;<=(ß<4)∑ exp"ß<$%$∈LMN47)  (2.4) 
Where D is the vector of failure times and Ri is the number of patients at risk at 
ordered time intervals t1 < t2 <…<tD. 
The baseline hazard function is estimated non-parametrically i.e. the survival times 
are not assumed to follow a particular statistical distribution. The function can vary 
with time but remains independent of the covariates, whence the assumption of 
proportional hazards. The quantity exp(ßi) is known as the hazard ratio (HR). HR>1 
corresponds to increased probability of the event of interest, while HR<1 implies a 
decreased probability, for presence (or increased level) of that covariate. The 
proportional hazards assumption of the Cox model can be tested using Schoenfeld 
residuals. The null hypothesis is that the slope of scaled residuals on time is zero and 
the alternate hypothesis is that slope is not zero. The Schoenfeld residual value for 
each predictor variable is the difference between the expected value and observed 
value of the predictor variable. The residual values are regressed against time to test 
independence between residuals and time.  
 
2.5 Statistical tests 
2.5.1 Mann-Whitney/Wilcoxon test 
The Mann-Whitney U test, also called Wilcoxon or rank sum test, is a non-parametric 
test equivalent of Student’s t-test, used to test whether two statistical samples comes 
from the same distribution [126]. The test assumes that observations in both groups 
are independent and have no relationship between and within each group. The null 
hypothesis is that the distributions of two populations are the same and the alternate 
hypothesis is that they are not. The test calculates the U statistic whose distribution 
is known under the null hypothesis. The observations from both groups are merged 
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in one data set and ordered from the smallest (rank 1) to the largest (rank n, where 
n=total number of observations). The sum of ranks, R, is calculated for each group. 
The U statistic is given by: 
 O) = P) − /)(/) + 1)2  (2.5) 
 
 O1 = P1 − /1(/1 + 1)2  (2.6) 
 
 O = min(O), O)) (2.7) 
where n1	and n2 is the number of observations in groups 1 and 2 respectively. R1 and 
R2 are the sums of ranks in groups 1 and 2. The U statistic follows a normal 
distribution, which is thus used to derive the significance level [126]. This test was 
used to compare groups of patients for dichotomous tumour and patient 
characteristics.  
2.5.2 Kruskal-Wallis test  
The Kruskal-Wallis test is an extension of the Mann-Whitney test for categorical 
variables with more than two categories. This is a non-parametric test used for 
comparing differences in more than two independent groups (k) [127]. The null 
hypothesis is the median of all groups are equal and the alternative hypothesis is that 
the median is different between at least two groups [127]. The observations from all 
groups are combined and ranked from lowest to highest with 1 being the lowest rank. 
The test statistic, H, is calculated as: 
 V = 12/(/ + 1)2W41/4647) − 3(/ + 1) (2.8) 
where n is the total number of observations, k is the total number of groups, ri  is the 
sum of ranks in group i and ni is the number of observations in group i. This statistic 
follows a c2 distribution with k-1 degrees of freedom under the null hypothesis [127].  
2.5.3 Pearson’s chi-squared test 
The Pearson’s chi-squared test is a non-parametric test for testing the association 
between two categorical variables [128]. The null hypothesis is that the two variables 
are independent and there is no association between them and the alternative 
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hypothesis is that there is an association. The test statistic utilises a contingency 
table for calculation and is calculated as: 
 Y1 =22"34$ − 54$%154$Z$7)[47)  (2.9) 
where r is the total number of rows, c is the total number of columns, Oij is the 
observed value in the ith row and jth column of the table, Eij is the expected value in 
the ith row and jth column of the table, computed as: 
 5!" = ∑\! ∗ ∑\"∑ ∑ \!"#"$%&!$%  (2.10) 
where ai	is the sum of ith row and aj is the sum of jth row, aij is the sum of all the values 
in the table. Under the null hypothesis the statistic follows a chi-squared distribution 
with degrees of freedom equal to product of r-1 and c-1.  [128].  
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Chapter 3 
Analysing existing melanoma gene signatures and 
devising a new one by clustering of LMC tumours 
The objectives of this chapter are:  
Objective 1: To assess the prognostic value of the Lund and TCGA gene signatures 
in the whole LMC dataset (702 tumours)  
Hypothesis: The gene signatures with prognostic value in the published literature will 
also predict survival in the LMC  
Objective 2: To assess the prognostic value of the Lund and TCGA gene signatures 
across the AJCC stages 
Objective 3: To cluster tumours of the LMC dataset using different methods to those 
used in deriving the existing signatures 
Hypothesis: De novo cluster analysis of a comparatively larger dataset (up to 3 times 
larger than previous studies) may reveal novel tumour classes 
 
3.1 Introduction 
3.1.1 Gene expression based cluster analyses in melanoma  
Previously, gene expression based cluster analysis of cutaneous melanoma has 
generated gene signatures with demonstrated prognostic value. Two studies led by 
the Lund [106] and the TCGA group [81] have identified biologically distinct classes 
of melanoma (Lund 4-classes and TCGA 3-classes) using similar clustering 
algorithms, i.e. hierarchical clustering. Both studies were conducted using the gene 
expression data derived from predominantly metastatic melanoma tumours. In 2012, 
Harbst et al. showed the prognostic value of the Lund signatures in primary tumours 
from the Lund cohort [114]. In 2015, our group replicated the prognostic value of the 
Lund signatures in the LMC. In 2016, a study led by the Lund group reported the 
overlap of biological pathways between the Lund and TCGA signatures [116]. 
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3.1.1.1 Lund 4-class signature  
As described previously (Section 1.8.2), the cluster analysis performed by the Lund 
group identified four tumour classes from the Swedish metastatic melanoma cohort 
(n=57 FFPE tumours), referred to as the Lund 4-class signature [106]. Hierarchical 
cluster analysis was used to generate this signature on the basis of the ~9,000 genes 
with the best detection performance on the Illumina DASL HT8 array [106]. The four 
classes were named high-immune, normal-like, pigmentation and proliferative [106]. 
The high-immune class was associated with higher expression of genes involved in 
different immunologic processes. The normal-like class expressed genes involved in 
epidermis and ectodermal development. The pigmentation class had higher 
expression of genes associated with melanin synthesis and melanocyte 
differentiation. The proliferative class had higher expression of genes involved in cell 
cycle related mechanisms. The four classes were also associated with BRAF and 
NRAS mutation status in metastatic tumours [106]. The proliferative and 
pigmentation class had a higher proportion of cases with BRAF and NRAS mutations 
in comparison to high-immune and normal-like classes [106]. In terms of prognosis, 
the high-immune class predicted good prognosis and proliferative class predicted 
poor prognosis, whereas the pigmentation and normal-like classes were predictive of 
intermediate prognosis [106]. 
3.1.1.2 Replication of Lund 4-class signature 
The Lund 4-class signature was replicated in a cohort of primary melanoma tumours, 
referred to as the Lund primary melanoma cohort, composed of 223 patients 
diagnosed at AJCC stages I and II [105]. The signature robustly predicted prognosis 
in these primary tumours, with high-immune and normal-like classes associated with 
good prognosis, while proliferative and pigmentation classes predicted poor 
prognosis [105]. The Lund 4-classes were associated with clinico-pathological 
variables like Breslow thickness, ulceration status, mitotic rate, tumour site, AJCC 
stage, and tumour infiltrating lymphocytes (TILS) [105]. The high-immune and 
normal-like class tumours were thin, non-ulcerated and were predominantly 
diagnosed at AJCC stage IIA [105]. The proliferative and pigmentation class tumours 
were thick, ulcerated and were diagnosed predominantly at AJCC stage IIB [105]. 
The high-immune and normal-like tumours had lower mitotic rate in comparison to 
proliferative and pigmentation class tumours. The high-immune class had higher 
incidence of brisk TILs and the pigmentation class had absence of TILs [105]. The 
normal-like and proliferative class had intermediate levels of non-brisk TILs. Brisk 
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TILs are those infiltrating the tumour core to attack it, while non-brisk tend to remain 
at the tumour periphery and are low in number. The Lund 4-classes were not 
associated with NRAS and BRAF mutation status in primary melanoma [105].  
3.1.1.3 Lund 2-grade signature 
The survival curves of the Lund 4-classes converged into two groups in the Lund 
primary melanoma cohort (Section 1.8.2) [105]. Further examination of histological 
parameters, overlap between upregulated genes and survival across the four classes 
led to refining the 4-class signature into a new two-grade signature, referred to here 
and throughout as the Lund 2-grades. The Lund 2-grades were high-grade and low-
grade. High-grade tumours were an aggressive class of tumours which overlapped 
with tumours from the proliferative and pigmentation classes [105]. Low-grade class 
tumours overlapped with high-immune and normal-like class tumours. In contrast to 
Lund 4-classes, the Lund 2-grades showed significant association with BRAF 
mutation status and borderline association with NRAS mutation status [105]. Overall, 
the Lund 2-grades signature is an extension of Lund 4-classes, with higher statistical 
power to detect associations with survival and clinical variables. This new signature 
was not obtained by merely merging pairs of groupings from the Lund 4-classes; 
rather it was generated from 1864 genes, although many of these were also among 
the 503 defining the Lund 4-classes. 
3.1.1.4 Independent replication of Lund signatures 
In 2015, our group applied the Lund 4-class and Lund 2-grade signatures to a subset 
of LMC tumours (n=204 FFPE primary tumours profiled at the time) and an additional 
set of 76 melanomas (predominantly metastases from the Leeds Chemotherapy 
Study, LCS) using the nearest centroid classification (NCC) approach [114]. The 
expression data was generated on the DASL HT12.4 array. Both signatures were 
well replicated in these independent cohorts.  In keeping with previous reports, high-
immune and normal-like classes were predicted good prognosis, while proliferative 
and pigmentation groups predicted worse prognosis. In Lund 2-grades, high-grade 
predicted worse prognosis and low-grade predicted good prognosis. The Lund 4-
classes and Lund 2-grades were associated with clinico-pathological features like 
ulceration status, mitotic count, age at diagnosis, Breslow thickness, and AJCC 
stage. These observations were consistent with previous studies [105, 106]. The 
Lund 4-classes and Lund 2-grades were not associated with BRAF and NRAS 
mutations in the LMC tumours [114]. 
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3.1.1.5 TCGA 3-class signature  
In 2015, The Cancer Genome Atlas (TCGA) network published a study which 
identified three classes of melanoma in a predominantly metastatic cohort (262 
metastases and 58 primaries from fresh frozen tumours) (Section 1.8.2) [81]. The 
three TCGA classes were named as immune, keratin and MITF low. The immune 
class was associated with good prognosis and the keratin class was associated with 
poor prognosis, whereas the MITF low class had intermediate prognosis. The 
immune class tumours had increased expression of genes involved in immune 
response mechanisms. The keratin class had increased expression of genes 
involved in keratin, epithelial and neuronal development mechanisms. The MITF low 
class tumours had increased expression of genes associated with embryonic 
development, nervous development, cell adhesion, and extracellular matrix protein 
organisation [81].  
3.1.1.6 Overlap between Lund and TCGA signatures 
In 2016, a collaboration between the Leeds and Lund groups compared the Lund 4-
class signature with the TCGA 3-class signature (Figure 3.1) [116]. Although the 2 
signatures have only 34 genes in common (among the 503 of Lund 4-classes and 
1500 of TCGA), the gene ontology of both signatures showed a good overlap of the 
associated biological pathways (Figure 3.1) [116]. The Lund 4-class and TCGA 3-
class signatures were applied to the TCGA (n=254, metastases), Lund (n=124, stage 
III primaries), Leeds (n=204, primaries) and Bergen (n=54, metastases) melanoma 
datasets using the supervised NCC approach [116] and it was observed that Lund 4-
classes highly overlapped with the TCGA 3-classes in each of these datasets (Figure 
3.1B). The tumours classified in the high-immune class of the Lund 4-classes 
overlapped with the immune class of TCGA 3-classes. Similarly, the normal-like class 
overlapped with the keratin class. The proliferative class overlapped with MITF low 
class. The pigmentation class overlapped with immune and keratin classes of the 
TCGA 3-classes. Overall, the study suggested that even though Lund and TCGA 
signatures were developed using different sample types (archived tissue in Lund and 
fresh-frozen tissue in TCGA), and different technologies (microarray-based platform 
in Lund, RNA-seq in TCGA) (see Section 1.8.3), the convergence of signatures 
supports the view that transcriptomic data do produce stable results [116]. These 
data also confirmed that similar mechanisms can be observed in primary tumours 
and in more advanced disease. 
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Figure 3.1 Comparison of Lund and TCGA melanoma subtypes. 
Adapted from Lauss et. al. [116]. (A) A Venn diagram showing the common 
genes between the Lund and TCGA gene signatures and histogram showing 
the gene expression level across the Lund and TCGA gene sets. (B) The 
overlap between the Lund 4 classes and the TCGA classes when the 
signatures were applied across 4 different datasets. 
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3.1.2 Replication of Lund and TCGA signatures in the whole 
dataset  
The above-mentioned studies using the Lund and TCGA signatures have been 
conducted on melanoma cohorts containing mainly AJCC stages II-IV tumours. 
Therefore, the prognostic significance of these signatures has not been assessed in 
patients diagnosed at AJCC stage I. At the time of replication in LMC [114], 
expression data was available for only 204 tumours, including 58 stage I tumours. 
Now, with a dataset three times larger (n=702, including at 233 stage I), the first 
objective of this research was to test the utility of these signatures in the whole LMC 
dataset, especially in stage I tumours. As a second objective, since the whole LMC 
dataset had more power, it was hypothesised that re-clustering tumour 
transcriptomes of LMC could identify novel prognostic signatures. As described in 
this chapter, a consensus-based approach was applied to cluster gene expression 
data of primary melanomas from LMC using three different unsupervised 
classification algorithms. The results from these algorithms were compared for 
cluster stability and for their agreement with the Lund and TCGA signatures. 
 
3.2 Methods 
3.2.1 Replicating Lund 4-class and Lund 2-grade signatures in 
LMC 
Supervised Nearest Centroid Classification (NCC) approach was used to classify the 
702 primary tumours from the LMC into the Lund 4-classes [114]. The Lund 4-class 
signature contains the centroid values for each class. The centroid values are an 
average expression value of 503 genes in the signature. Among the 503 genes of 
the signature, 449 genes were present in LMC (incomplete overlap due to using 
different versions of DASL array).  
In the NCC approach, the tumour expression values of the matching 449 genes were 
extracted from the LMC gene expression dataset. Each tumour sample was 
correlated with the Lund 4-class centroids, and the sample was put into the class 
corresponding to the largest correlation. The samples for which the largest 
Spearman’s rank correlation coefficient value was less than 0.10 were considered 
unclassified. 
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Similarly, LMC tumours were classified into the Lund 2-grades using the supervised 
NCC approach. The Lund 2-grades centroids are average expression value of 1864 
genes, among which 1586 were present in the LMC dataset. The classification of 
LMC tumours using the TCGA 3-class signature had already been performed by Dr 
Jérémie Nsengimana using the same NCC approach. 
3.2.2 The Lund and TCGA signatures association with clinico-
histopathological variables 
The association of LMC tumours classified into the Lund 4-classes, Lund 2-grades, 
and TCGA 3-classes with clinico-histopathological variables was tested. The clinico-
histopathological variables used for analyses were age at diagnosis, sex, AJCC 
stage, Breslow thickness, site of tumour, tumour ulceration status, mitotic rate, TILs, 
and BRAF and NRAS mutation status. The mitotic rate calculation for the LMC 
tumours was done by Dr Sally O’Shea (former PhD student in the group). Pearson’s 
chi-squared test was used for testing categorical variables. Non-parametric Mann-
Whitney test and Kruskal-Wallis rank sum test were used for testing continuous 
variables (refer to 2.5). Association analyses excluded the unclassified tumours.  
3.2.3 Lund and TCGA signatures association with melanoma-
specific survival 
CPH models (refer to 2.4.4) were used to test the association of the Lund and TCGA 
signatures with melanoma-specific survival (MSS), and the survival differences 
between tumour classes were plotted in Kaplan-Meier curves (refer to 2.4.2). The 
differences in these curves were tested using a log-rank test (refer to 2.4.3). These 
analyses were conducted using R-packages survival [129], ggplot2 [130] and ggkm 
function. The high-immune class from the Lund 4-classes, low-grade from the Lund 
2-grades, and immune class from the TCGA 3-classes were used as the baseline 
comparison group. The analyses excluded the unclassified tumours. 
3.2.4 Statistical interaction test between the Lund grade and AJCC 
stage 
The Lund and TCGA signatures were generated from cohorts of AJCC stage II-IV 
melanomas. Since LMC dataset includes a high proportion of stage I patients (33.5% 
of data), the utility of the Lund and TCGA signatures was tested across stages. To 
check whether the signature’s prognostic value was maintained at all disease stages, 
and having observed no evidence of prognostic values in Stage I, we conducted a 
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formal statistical interaction test between the AJCC stage and the Lund 2-grades in 
the CPH regression was tested using Wald’s test. This signature was chosen due to 
its higher statistical power among the three signatures. Following the same line of 
reasoning, because the signature is known to be prognostic in the AJCC stages II 
and III, these two levels were merged, i.e. the AJCC stage variable had two levels: 
stage I or higher (there was no stage IV, so higher means II or III). The AJCC stage 
I and low-grade from Lund 2-grades were chosen as baseline comparison groups.  
3.2.4.1 Power calculation in LMC stage I 
Power and sample size calculations were performed to ascertain whether the stage 
I sample size is large enough to draw valid conclusions. The equation used for 
calculating power is [131]: 
 . = ^_1` + _ab1c)c1dL1  (3.1) 
where za/2 and zb are values taken from standard normal distribution at a given level 
of significance (or type I error), a; b is the type II error and 1-b is the statistical power 
of the test. The p1, p2 are the proportion of patients in the two groups (i.e. low- or high-
grade). Parameter qR is the log-hazard ratio (natural base) and d is the total number 
of melanoma-specific deaths in AJCC stage I patients.   
3.2.5 Clustering gene expression data of LMC tumours 
The clustering of gene expression data was performed for 702 tumours of LMC. The 
whole transcriptome contained expression of 20,715 unique genes. The gene were 
further filtered prior to cluster analysis, based on two criteria: genes had to be 
detected with P<0.05 in at least 40% of tumours and had to have a standard deviation 
(SD)>0.40. This SD threshold was chosen based on the overall distribution across 
all the genes on the log2 scale. The median SD was 0.68. The data were 
standardized to give each gene a mean of 0 and SD of 1. After filtering, the final 
dataset contained expression of 13,688 genes, larger than the 7,200 genes used in 
the Lund study [106] and the 1,500 genes used in the TCGA study [81]. We chose a 
larger number in order to cover more biological variation. The LMC tumours were 
clustered using a consensus-based approach with implementation of Hierarchical 
clustering (HC), k-means (KM) and Partitioning Around Medoids (PAM) algorithms.  
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3.2.5.1 Hierarchical clustering (HC) 
HC is a data partitioning method that generates hierarchical series of nested clusters 
using a distance metric e.g. correlation coefficient, dissimilarity (1-correlation 
coefficient), Euclidean distance etc. [132]. The tree-based graphical representation 
of these nested clusters is called a dendogram. The dendogram records the 
information about similarity between the clusters. The k clusters are generated by 
cutting the dendogram at a specified threshold of distance/similarity. HC can be done 
using a divisive or agglomerative approach  [132]. The divisive approach, also known 
as top-down, starts with placing all the samples in one big cluster. It then iteratively 
divides the big cluster into smaller clusters until the final clusters contains only one 
sample per cluster. The agglomerative approach, also known as the bottom-up, starts 
with placing all samples into individual clusters, which are then merged in successive 
steps based on the similarity between them. This process is repeated until all clusters 
are merged together to form one big cluster. In my thesis, an agglomerative approach 
was used. The similarity D between the clusters is calculated using UPGMA 
(Unweighted Pair Group Method with Arithmetic mean) as follows: 
 e(f, g) = 1|f|. |g|22.(<, j)		k∈lm∈n  (3.2) 
where A and B are the two clusters, |(| is the total number of samples in cluster ( 
and |)| is the total number of samples in cluster B. The symbol d(x, y) is the distance 
(here I used dissimilarity) between sample x from cluster A and sample y from cluster 
B. Although HC provides good visualisation of similarity between samples, it is 
computer-intensive. The limitation of HC is that it does not provide the number of 
clusters: it progressively groups or splits samples based on similarity, and users, 
often subjectively, decide the number of clusters based on the dendrogram. Another 
limitation is that a small perturbation in the dataset can greatly change the end results 
of the clustering, and it is sensitive to outliers [132, 133]. 
3.2.5.2 k-means clustering (KM) 
The KM clustering algorithm aims to partition data into a predetermined (i.e. user 
input) number of clusters, k, into which the samples are placed based on their 
similarities [132]. The mean value of samples in a cluster is known as the cluster 
centroid. The clustering process has two main steps: 1) initialisation of centroid 
values; 2) iterations to find optimal centroid values. In the initialisation step, k samples 
are randomly selected and assigned to different clusters (i.e. one sample per cluster). 
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In the iteration step, each of the remaining n-k samples is classified into the cluster 
with nearest centroid. Then for each cluster, the mean value is re-calculated and 
assigned as the new centroid of the cluster. The samples are re-classified using the 
new centroids and re-assigned to the cluster with the nearest centroid. These steps 
are repeated until the centroid values do not change. The iteration step minimises 
the sum of squared distances (S) between samples within a cluster and its centroid 
as 
 ! =22|< − o4|1m∈pM
6
47)  (3.3) 
where k is the number of clusters, x are samples in cluster Ci, ui is the centroid of 
cluster Ci. The KM method is computationally efficient, but like HC it is sensitive to 
outliers and a small change in starting position can change the clustering results. 
Also, the number of clusters, k, has to be provided as an input when the user rarely 
has much information on which to base this choice [132, 133].  
3.2.5.3 Partitioning Around Medoids (PAM)  
Partitioning around medoids (PAM), also known as k-medoid clustering, aims to 
minimise the within cluster distance W 
 q =22 .(<,r4)m∈pM
6
47)  (3.4) 
where k is the number for clusters, x are the samples in cluster Ci, mi is the medoid 
(central element) of cluster Ci, and d(.) is the distance function (here I used Euclidean 
distance) [134, 135]. It is constructed in a similar way to k-means but uses the cluster 
medoid (i.e. the most central element) instead of the average of all samples in a 
cluster, thereby avoiding the influence of outliers. The clustering solution of the data 
is at the minimum value of W. The algorithm performs clustering in two phases, 1) 
build phase; 2) swap phase. In the build phase, PAM randomly assigns k samples as 
the medoids (i.e. 1 sample per cluster). The rest of the samples are classified into a 
cluster based on their nearest medoid, and W is calculated. In the swap phase, a new 
medoid is determined for each cluster by finding a sample that minimizes the 
dissimilarity with other samples of the cluster. The samples are reclassified into the 
clusters based on the new medoids. The swapping phase is repeated until the W 
value stabilizes. The usage of medoids in PAM makes it more robust to outliers in 
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the dataset compared to KM [136], although like KM, PAM requires a priori 
information on the number of clusters, k. 
3.2.5.4 Consensus-based clustering 
All the methods described above, HC, KM and PAM are sensitive to starting 
positions. Hence, a method was needed to help inform the choice of k. Consensus-
based clustering is an iterative technique for identifying stable clusters in high-
dimensional datasets [137]. It sub-samples data to generate multiple datasets over 
N iterations (Figure 3.2). At each iteration, the sampled dataset is clustered into a 
varying number of clusters k using the specified clustering algorithm and distance 
metric. In the sampled dataset, each pair of samples is assigned a consensus value 
of 1 if they are classified in the same cluster or 0 otherwise. Across N iterations (re-
samples) and for each k value, the sample pair consensus is the proportion of 
iterations in which the pair is put in the same cluster by the chosen clustering 
algorithm. This consensus information is stored in an n*n consensus matrix where n 
is the total number of samples (Figure 3.2). Finally, the consensus matrix values are 
clustered using hierarchical clustering and the resulting dendogram is split at the 
appropriate threshold to give k clusters. In this study, at each iteration, we sampled 
80% of genes and samples and varied k values from 2 to 12. 
 
Figure 3.2 Consensus clustering workflow  
The LMC data contained expression values for 702 tumours. A random subset 
of 80% of genes in 80% of tumours were sampled with 1000 repetitions. These 
data were clustered using different algorithms for k=2 to 12.  
Consensus clustering of LMC tumours was performed with HC, KM and PAM 
algorithms in the consensus clustering workflow. The correlation coefficient-based 
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metric has been reported to perform well with HC and Euclidean distance has been 
observed to have higher performance when applied with KM and PAM algorithm 
[138]. The analysis was performed using the R-package ConsensusClusterPlus [137, 
139] with the distance metric 1-Spearman’s correlation coefficient for HC and 
Euclidean distance for KM and PAM.  
3.2.5.4.1 Selecting the number of clusters k  
As stated above, the consensus clustering was performed by varying k from 2 to 12 
and a consensus matrix obtained at each k was stored for downstream analysis. The 
consensus matrix contains the calculated consensus score for each pair of samples. 
The consensus score, M(i,j), is the proportion of times that samples i and j are 
observed in the same cluster out of all the times these 2 samples were both observed 
in the sampled subset, over N iterations. The choice of k was determined by 
visualising a number of graphics, 1) the consensus matrix heatmap; 2) the cumulative 
density function (CDF) of the consensus score values in consensus matrix; 3) relative 
change (delta) in the area under the CDF curves. The consensus matrix heatmap is 
generated for each k value. For a consensus matrix, the CDF(c) can be defined as 
the proportion of pairs whose consensus score is less than or equal to c (0 ≤c ≤ 1). 
The term A(k) is the area under CDF curve of a consensus matrix at k clusters. The 
delta graph contains relative changes in A(k) in comparison to A(k-1).  
The CDF and area under the CDF was calculated as: 
 *+,(.) = ∑ 1{4(5, 7) ≤ .}!:" ;(; − 1)2  (3.5) 
 
 ((>) = 	@[B! − B!C%]*+,(B!)E!$F  (3.6) 
where 1{ }denotes the indicator function, n is the total number of samples, k is the 
number of clusters being tested, M is the consensus matrix obtained at that k and (x1, 
x2, . . .,xm) is the sorted set of entries of the consensus matrix M (with m= n(n-1)/2, i.e. 
the total number of possible sample pairings). The relative change in the CDF, ∆(k), 
was computed as  
 ∆(>) = H ((>), 5I	> = 2[((>) − ((> − 1)]((> − 1) , 5I	> > 2 (3.7) 
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Finally, the k value is selected on the basis of the ∆(k) value by choosing the k when 
there is a minimal increase in area from A(k-1) to A(k), and hence little improvement 
in cluster stability as the number of clusters decreases.  
3.2.6 Comparing the HC, KM and PAM based clusters  
The tumour clusters derived with consensus HC, KM and PAM were compared for 
stability and agreement with previous signatures. The stability of the clusters was 
calculated as the average consensus score of the samples in the clusters. The 
agreement between these new tumour clusters and those obtained by applying 
previously published Lund and TCGA gene signatures in a supervised NCC manner 
(see section 3.2.1) was calculated using Cramer’s V statistic [140]. Cramer’s V, an 
extension of Cramer’s Phi, is a statistic used to measure the strength of association 
between two nominal variables. Cramer Phi is used when a contingency table has 
size 2 C 2. For larger tables, Cramer’s V is used and it is calculated as: 
 *KLMNKOP	Q = R SF.(M − 1) (3.8) 
where, c is the total cell count from the contingency table, m is the minimum value 
between the number of rows and the number of columns and c2 is the chi-squared 
statistic. Cramer’s V varies between 0 and 1 regardless of the dimension of the 
nominal variables. A value of 1 represents the maximum agreement, while 0 
represents no agreement. The calculations were performed using R-package VCD 
[141]. 
 
3.3 Results 
3.3.1 Applying the existing signatures to the whole LMC dataset 
The Lund (4-class and 2-grade) and TCGA signatures (3-class) were applied to the 
whole LMC dataset (n=702) using the NCC approach. The LMC tumours which could 
not be classified were labelled unclassified. 
With the Lund 4-class signature, the NCC method classified 25% of tumours into the 
high-immune class, 28% into the normal-like class, 32% into the pigmentation class, 
and 12% into the proliferative class (Table 3.1), while 3% of tumours could not be 
classified. The high-immune class (median r=0.40), normal-like class (median 
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r=0.40) and pigmentation class tumours (median r=0.38) had similar level of 
correlation with their class centroids (Table 3.1), while the proliferative class tumours 
had a much lower correlation with the proliferative class centroid (median r=0.26). 
With the Lund 2-grade signature, 38% of LMC tumours were classified into the low-
grade (Table 3.1) and 42% into the high-grade, whereas 20% of tumours were 
unclassified. The low-grade (median r=0.31) and high-grade (median r=0.31) tumour 
has similar correlation with their respective class centroids (Table 3.1). 
The classification of LMC tumours based on TCGA 3-class signature was performed 
by Dr Jeremie Nsengimana. Twenty seven percent of tumours were classified in the 
immune class, 35% in the keratin class and 21% in the MITF low class, while 16% 
could not be classified into any of the classes. The immune class (median r=0.25) 
and keratin class (median r=0.25) had comparatively higher correlation with their 
respective class centroids and MITF low class (median r=0.22) had slightly lower 
correlation with its class centroid (Table 3.1). 
Table 3.1 Summary statistics of the LMC tumour classification using the Lund 
and TCGA signatures  
Three percent, twenty percent and sixteen percent of LMC tumours could not 
be classified using the Lund 4-class, Lund 2-grade and TCGA 3-class 
signatures respectively. The r value is the median correlation in each of the 
classes.  
Signature Class n(%) r 
Lund 4-class 
High-immune 175(25) 0.40 
Normal-like 198(28) 0.40 
Proliferative 222(32) 0.38 
Pigmentation 84(12) 0.26 
Unclassified 23(3) 0.07 
Lund 2-grade 
Low-grade 266(38) 0.31 
High-grade 296(42) 0.31 
Unclassified 140(20) 0.05 
TCGA 3-class 
Immune 192(27) 0.25 
Keratin 247(35) 0.25 
MITF low 150(21) 0.22 
Unclassified 113(16) 0.06 
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3.3.2 Clinico-histopathological association with the Lund and 
TCGA signatures 
Previous studies have shown the association of the existing signatures with 
melanoma prognostic factors such as Breslow thickness, AJCC stage and ulceration 
status [105, 106, 114]. It was tested whether these associations can be reproduced 
in the LMC dataset.  
In LMC dataset, the Lund 4-class signature was significantly associated with patient 
sex, tumour site, age at diagnosis, Breslow thickness, AJCC stage, ulceration status, 
mitotic rate, TILs, and NRAS mutation status (Table 3.2). The high-immune and 
normal-like tumours were thin, non-ulcerated, early stage tumours, whereas the 
proliferative and pigmentation tumours were thicker, ulcerated and diagnosed at an 
advanced stage. The high-immune and normal-like tumours occurred more 
frequently on limbs while the proliferative and pigmentation tumours were observed 
more frequently on other body sites. The high-immune tumours had a higher 
incidence of brisk TILs than the proliferative tumours, while pigmentation and normal-
like tumours had intermediate levels of brisk TILs. BRAF mutation status showed 
weak evidence of association with the Lund 4-classes (P=0.07), but NRAS mutation 
status was significantly associated (P=0.01), with the proliferative tumours having 
more frequent NRAS mutations (Table 3.2). The normal-like and pigmentation 
tumours showed a relatively lower fraction of patients with NRAS mutations in 
comparison to the proliferative class, while the high-immune tumours contained the 
lowest proportion of NRAS mutated tumours (Table 3.2). 
Similar to the Lund 4-classes, and unsurprisingly, the Lund 2-grades also showed 
significant association with tumour site, age at diagnosis, Breslow thickness, AJCC 
stages, ulceration status, mitotic rate, TILs, BRAF and NRAS mutation status (Table 
3.2). The low-grade tumours were thin, non-ulcerated and diagnosed at an early 
stage compared to the high-grade tumours. The low-grade tumours also occurred 
more frequently on limbs and were more frequently BRAF mutated. By contrast, the 
high-grade tumours had a higher mitotic rate, absence of TILs and more NRAS 
mutations (Table 3.2).  
The TCGA 3-classes were also significantly associated with patient’s sex, age at 
diagnosis, Breslow thickness, AJCC stage, ulceration status, mitotic rate and TILs 
(Table 3.3). The immune and keratin types of tumours were thin in comparison to the 
MITF low type. The keratin tumours were more frequently diagnosed at AJCC stage 
I. MITF low had a higher mitotic rate in comparison to other types (Table 3.3). The 
immune class had higher incidence of brisk TILs, and MITF low class had the lowest. 
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The TCGA classes showed no association with the BRAF and NRAS mutation status 
(Table 3.3). 
 
 
 
Table 3.2 Lund signatures association with clinico-pathological characteristics of LMC primary tumours  
The associations were tested using Pearson’s chi-squared test for categorical variables and the Mann-Whitney Kruskal-Wallis test for 
continuous variables. The symbol n is the number of samples, m is the median and r is the range. Unclassified tumours were excluded from 
the analysis.  
Clinico-pathological variables 
Lund 4-classes 
P 
Lund 2-grades 
P HI 
n(%) 
NL 
n(%) 
Pigm. 
n(%) 
Prolif. 
n(%) 
High-grade 
n(%) 
Low-grade 
n(%) 
Sex: male 85(49) 72(36) 107(48) 41(49) 0.04 141(48) 118(44) 0.5 
Tumour site: limbs 85(49) 98(50) 81(37) 27(32) 0.004 112(38) 126(47) 0.03 
Age at diagnosis, (years) m(r) 59(21, 76) 57(20, 75) 59(28, 82) 58(19, 82) 0.001 60(20, 81) 58(19,76) 0.04 
Breslow thickness(mm), m(r) 1.9(0.7, 18) 1.8(0.3, 10) 3(0.8, 20) 3(1.1, 15) 8 x 10-24 3(0.5, 20) 1.8(0.7, 18) 5 x 10-19 
AJCC stage(%): I 70(40) 103(52) 34(16) 18(23) 
8 x 10-14 
56(19) 129(49) 
8 x 10-13 II 86(49) 76(38) 137(63) 45(56) 172(60) 112(42) 
III 19(11) 19(10) 48(22) 17(21) 61(21) 25(9) 
Ulceration(yes) 57(33) 30(15) 104(47) 37(44) 3 x 10-11 132(45) 56(21) 6 x 10-9 
Mitotic rate, =>1(%) 124(81) 131(78) 82(92) 67(94) 5 x 10-5 240(93) 175(76) 2 x 10-7 
TILs(%): Absent 8(6) 22(16) 30(19) 11(21) 
0.01 
40(19) 18(9) 
0.005 Non-brisk 97(72) 93(77) 106(67) 37(71) 144(69) 140(72) 
Brisk 29(22) 24(17) 23(15) 4(7) 24(12) 37(19) 
BRAF mutant, yes(%) 74(50) 79(51) 86(45) 23(33) 0.07 99(40) 110(50) 0.04 
NRAS mutant, yes(%) 23(16) 38(24) 50(27) 24(35) 0.01 75(32) 35(16) 2 x 10-4 
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Table 3.3 TCGA signatures association with clinico-pathological characteristics of LMC primary tumours.  
The associations were tested using Pearson’s chi-squared test for categorical variables and the Kruskal-Wallis test for continuous variables. 
The symbol n is the number of samples, m is the median and r is the range. Unclassified tumours were excluded from the analysis.  
 
Clinico-pathological variables 
TCGA 3-classes 
P 
Immune n(%) Keratin n(%) MITF low n(%) 
Sex: male 102(53) 98(40) 67(45) 0.02 
Tumour site: limbs 79(41) 121(49) 57(38) 0.07 
Age at diagnosis, (years) m(r) 61(21, 77) 56(18, 75) 60(20, 81) 1 x 10-4 
Breslow thickness(mm), m(r) 2.5(0.7, 20) 2.0(0.3, 10) 3.2(0.8, 18) 7 x 10-11 
AJCC stage(%): I 52(27) 107(44) 32(22) 
3 x 10-5 II 114(59) 105(43) 84(58) 
III 26(14) 33(13) 29(20) 
Ulceration(yes) 71(37) 64(26) 65(43) 0.001 
Mitotic rate, =>1(%) 147(86) 173(82) 119(95) 0.003 
TILs(%): Absent 9(7) 33(18) 23(22) 
7 x 10-4 Non-brisk 97(71) 113(63) 73(70) 
Brisk 30(22) 33(18) 8(8) 
BRAF mutant, yes(%) 73(44) 94(49) 63(49) 0.6 
NRAS mutant, yes(%) 38(24) 53(28) 31(24) 0.7 
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3.3.3 Lund and TCGA signatures association with survival in the 
LMC primary tumours 
In keeping with previous studies [81, 105, 106, 114], the association of Lund and 
TCGA signatures was tested with melanoma-specific survival (MSS) in this larger 
dataset. The association with MSS was assessed using CPH and survival differences 
were visualised using Kaplan-Meier plots. 
3.3.3.1 Lund 4-classes 
Previously, high-immune and normal-like tumours were shown to predict better 
survival than proliferative and pigmentation tumours. In this analysis, 18% of high-
immune class and 19% of normal-like class patients died from melanoma, and the 
corresponding rates were at least twice as high in pigmentation (40%) and 
proliferative (38%) classes (hazard ratio 2.5 in each case), (Table 3.4, Figure 3.3). 
These results replicate earlier reports from smaller datasets. 
Table 3.4 Unadjusted Cox proportional hazard analysis of the Lund 4-classes 
The pigmentation and proliferative class had increased hazard of melanoma-
specific deaths in comparison to the baseline high-immune class. All deaths 
were caused by melanoma. CI is confidence interval. HR is the hazard ratio. 
Lund 4-classes HR 95% CI P 
High-immune 
(n=175, deaths= 32) 1.0 - - 
Normal-like 
(n=198, deaths= 38) 1.0 0.6-1.6 0.96 
Pigmentation 
(n=222, deaths= 88) 2.5 1.7-3.8 8 x 10
-6 
Proliferative 
(n=84, deaths=32) 2.5 1.5-4.0 2.9 x 10
-4 
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Figure 3.3 Melanoma-specific survival for the Lund 4-classes  
(HI- high-immune, NL- normal-like, Pigm- pigmentation, Prolif- proliferative). 
The high-immune class and normal-like class predicted a better survival than 
the pigmentation and proliferative classes (P value from log-rank test). The risk 
table below the plot shows the number of patients at risk at a given time. 
3.3.3.2 Lund 2-grades 
Previously high-grade of the Lund 2-grades has been shown to be associated with 
poor survival in melanoma compared to low-grade [105, 114]. These observations 
were recapitulated in this analysis: 38% of patients in high-grade and 18% of 
patients in low-grade have died from melanoma, with a hazard risk ratio of 2.5 in 
unadjusted CPH model (Table 3.5, Figure 3.4). 
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Table 3.5 Unadjusted Cox proportional hazard analysis of the Lund 2-grades 
Low-grade was chosen as baseline, all deaths were caused by melanoma. CI 
is confidence interval. HR is the hazard ratio. 
Lund 2-grades HR 95% CI P 
Low-grade  
(n=266, deaths= 48) 1.0 - - 
High-grade  
(n=296, deaths= 113) 2.5 1.8-3.5 1 x 10
-7 
 
 
Figure 3.4 Melanoma-specific survival for the Lund 2-grades  
Low-grade was associated with better survival than the high-grade (P value 
from log-rank test). The risk table below the plot shows the number of patients 
at risk at a given time. 
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3.3.3.3 TCGA 3-classes 
The TCGA 3-classes had been shown to predict survival in metastatic melanomas 
[81, 116]. In our dataset, 23% of patients in the immune class, 25% in keratin class, 
and 42% of patients in MITF low class have died from melanoma. MITF low class 
predicted therefore worse survival (HR=2.0) while the immune and keratin class 
predicted good survival (Figure 3.5). Unlike in metastatic tumours where the keratin 
class tumours had a survival close to MITF low [81], the keratin class had similar 
survival profile to the immune class in this primary melanoma dataset (Table 3.6 and 
Figure 3.5).  
Table 3.6 Unadjusted Cox proportional hazard analysis of the TCGA 3-classes  
Immune class was chosen as baseline, all deaths were caused by melanoma. 
CI is confidence interval. HR is the hazard ratio.  
TCGA 3-classes HR 95% CI P 
Immune  
(n=192, deaths= 44) 1.0 - - 
Keratin  
(n=247, deaths= 61) 1.0 0.7-1.5 0.8 
MITF low  
(n=150, deaths=63) 2.0 1.4-3.0 4 x 10
-4 
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Figure 3.5 Melanoma-specific survival for the TCGA 3-classes  
The MITF low class was associated with poor survival compared to the immune 
and keratin class (P value from log-rank test). The risk table below the plot 
shows the number of patients at risk at a given time. 
3.3.4 Signature’s prognostic value when stratified on AJCC stage 
The LMC dataset contains 34% stage I tumours, 51% stage II tumours and 15% 
stage III tumours. The patients were stratified into two groups: AJCC stage I group 
and AJCC stage II & III pooled group. The prognostic values of the Lund and TCGA 
signatures was assessed across these two groups. In stage I, 14% of patients died 
from melanoma, while in stages II & III 35% of patients died. The Lund and TCGA 
signatures showed distinct prognostic properties across these two groups.  
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3.3.4.1  Prognostic value of the signatures in AJCC stage I  
In the AJCC stage I group, none of the 3 signatures (Lund-4 class, Lund 2-grade and 
TCGA-3class) showed a significant association with MSS (Table 3.7 and Figure 3.6). 
In Lund 4-classes, 11% of patients in high-immune class diagnosed at stage I died 
from melanoma, the normal-like class had 14% melanoma-specific deaths, 
pigmentation class had 24% and proliferative class had 5%. As shown on the Kaplan-
Meier curves, the proliferative class appeared to have the best survival profile, 
comparable to high immune (Figure 3.6A), which is the opposite of the result from 
whole data analysis (Figure 3.3). However this is only based on 18 cases in the 
proliferative class.  
In Lund 2-grades, 13% of AJCC stage I diagnosed patients classified in low-grade 
and 12% of patients in high-grade died from melanoma. These numbers are similar, 
and the Lund 2-grades did not show any association with MSS in the stage I group 
(Table 3.7 and Figure 3.6B). 
Similarly, the number of melanoma-caused deaths in patients diagnosed at stage I 
in TCGA 3-classes were: 15% in immune class, 12% in keratin class, and 21% in 
MITF low class, and there was no significant association with MSS in CPH model 
and the log-rank test (Table 3.7 and Figure 3.6C).  
Table 3.7 Unadjusted Cox proportional hazard models for the Lund 4-class, 
Lund 2-grades and TCGA 3-classes in the AJCC stage I group  
High-immune, low-grade, and immune classes were chosen as baseline, all 
deaths were caused by melanoma. CI is confidence interval. HR is the hazard 
ratio. 
Signature Class (n) HR 95% CI P 
Lund 4 classes 
(n=225, deaths=31) 
High-immune (70) 1.0 - - 
Normal-like (103) 1.2 0.5-2.9 0.6 
Pigmentation (34) 2.1 0.8-5.5 0.1 
Proliferative (18) 0.5 0.1-3.8 0.5 
Lund 2-grades 
(n= 185, deaths=24) 
Low grade (129) 1.0 - - 
High grade (56) 0.9 0.4-2.1 0.7 
TCGA 3-classes 
(n=191, death=28) 
Immune (52) 1.0 - - 
Keratin (107) 0.8 0.3-1.9 0.6 
MITF low (32) 1.3 0.5-3.7 0.6 
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Figure 3.6 Melanoma-specific survival for the Lund 4-classes, Lund 2-grades 
and TCGA 3-classes in the AJCC stage I group.  
P values were calculated from the log-rank test. The risk table below the plot 
shows the number of patients at risk at a given time. 
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3.3.4.2 Prognostic value of the signatures in AJCC stage II & III group  
Similar to the AJCC stage I group, the Lund and TCGA signatures were tested for 
association with MSS in the pooled AJCC stage II & III group. In Lund 4-classes, 23% 
of patients in high-immune, 25% of normal-like class died from melanoma. In the 
pigmentation (43%) and proliferative (47%) class, a higher proportion of people died 
from melanoma. Therefore, in advanced stage tumours, the Lund 4-classes 
significantly predicted MSS (Figure 3.7A) with the pigmentation and proliferative 
class having the worse survival (HR=2.1 and HR=2.4 respectively, Table 3.8).  
In Lund 2-grades, 23% of patients in low-grade and 45% of patients in high-grade 
died from melanoma; the Lund 2-grades were significantly associated with MSS 
(Figure 3.7B). The CPH model suggested that high-grade (HR=2.4) had increased 
hazard of death from melanoma in comparison to the baseline low-grade (Table 3.8).  
Similar to Lund 4-classes and 2-grades, the TCGA 3-classes were also significantly 
associated with MSS in the stage II & III group (Figure 3.7C). The Cox model 
indicated that MITF low class (HR=2.1) had increased hazard of death from 
melanoma in comparison to the baseline immune class (Table 3.8). The keratin class 
(HR=1.3) had a hazard ratio comparable to that of the immune class.  
Table 3.8 Unadjusted Cox proportional hazard models for the Lund 4-class, 
Lund 2-grades and TCGA 3-classes in the AJCC stages II & III 
CI is confidence interval. HR is the hazard ratio. 
Signature Class (n) HR 95% CI P 
Lund 4 classes 
(n=447, deaths=157) 
High-immune (105) 1.0 - - 
Normal-like (95) 1.0 0.6-1.7 0.9 
Pigmentation (185) 2.1 1.4-3.4 0.001 
Proliferative (63) 2.4 1.4-4.2 0.001 
Lund 2-grades 
(n= 370, deaths=135) 
Low-grade (137) 1.0 - - 
High-grade (233) 2.4 1.6-3.6 1.9 x 10-5 
TCGA 3-classes 
(n=391, death=138) 
Immune (140) 1.0 - - 
Keratin (138) 1.3 0.8-2.0 0.2 
MITF low (113) 2.1 1.4-3.2 4 x 10-4 
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Figure 3.7 Melanoma-specific survival for the Lund 4-classes, Lund 2-grades 
and TCGA 3-classes in the AJCC stages II&III 
P values were calculated from the log-rank test. The risk table below the plot 
shows the number of patients at risk at a given time. 
3.3.5 Statistical Interaction between the Lund signature and AJCC 
stage 
As shown above, the Lund and TCGA signatures strongly predicted MSS in stage II 
& III tumours but not in the stage I group. The AJCC stage I group tumours are thin, 
have lower mitotic rate and are mainly non-ulcerated [44], while AJCC stage II & III 
tumours are thicker, have higher mitotic rate and are mainly ulcerated.  
To rule out the possibility that the difference in prognostic value of the signatures 
might be solely due to limited power in the stage I group, a formal test of statistical 
interaction was conducted between the AJCC stage and the Lund 2-grades. This 
analysis (Table 3.9) confirmed AJCC stage as an independent prognostic factor 
(HR=1.9, P=0.03), but also showed an evidence of interaction with the Lund 2-grades 
(P=0.04), suggesting a heterogeneity of effect of the Lund 2-grades on the AJCC 
stage. 
0.00
0.25
0.50
0.75
1.00
0 3 6 9 12
Time(years)
Su
rv
iva
l P
ro
ba
bil
ity
Class
Immune
Keratin
MITF.low
140 108  69  36  14
138 109  66  39  18
113  70  45  21  10MITF.low
Keratin
Immune
Numbers at risk
Cl
as
s
TCGA 3-classes
P = 9 x 10-4
C
65 
Table 3.9 Test of interaction between AJCC stage and Lund 2-grade signature 
in Cox proportional hazards model of MSS 
Low-grade and AJCC stage I was chosen as baseline, all deaths were caused 
from melanoma, HR is the hazard ratio. 
Variable (n=555, deaths=159) HR 95% CI P 
Lund 2-grades 
Low-grade 1.0 - - 
High-grade 0.9 0.4- 2.1 0.7 
AJCC stage 
I 1.0 - - 
II&III 1.9 1.1-3.5 0.03 
High-grade: AJCC stage II&III 2.8 1.1-7.3 0.04 
3.3.5.1  Statistical power in AJCC stage I 
To test if the effect of Lund 2-grades on hazard of death is not limited by the number 
of deaths in AJCC stage I, a statistical power calculation analysis was performed. In 
AJCC stage I group, 70% of patients were classified in low-grade and 30% were high-
grade. The total number of deaths in AJCC stage I group was 33. Power and sample 
size calculations showed that the stage I group had 70% power to detect a hazard 
ratio of 2.6 at a significance level 0.05 (Figure 3.8). 
 
Figure 3.8 Sample size and power calculation 
There were 33 deaths among patients diagnosed at AJCC stage I, providing a 
reasonable statistical power for HR>2.5 (a=0.05).  
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3.3.6  Devising a new signature by consensus-based clustering 
The lack of prognostic effect in stage I tumours from the 3 published signatures was 
surprising since these signatures have been shown to predict prognosis in primary 
melanoma [105, 114]. Having shown this limitation, I sought to design a new 
signature based on a dataset with a good mixture of tumours at all stages. It was 
hypothesised that re-clustering the whole LMC dataset and exploring different 
clustering algorithms may reveal new melanoma molecular subtypes. Three different 
algorithms, HC, KM and PAM were applied in a consensus clustering approach.  
The optimal k was selected based on examination of cumulative density function 
(CDF) graph, relative change in area under the CDF (delta) graph and heatmap of 
the consensus matrices.  
Examining the HC CDF and delta graph suggested good k values at 4 and 5 (Figure 
3.9A, B). However, the consensus matrix heatmap did not show a clear separation 
between the clusters at k=4 or 5 (Figure 3.10A, B). The KM clustering CDF and delta 
graphs suggested good k values at 5 and 6 (Figure 3.9C, D) and the corresponding 
consensus matrix heatmaps showed a neater cluster separation at k=6 (Figure 
3.10C, D). On the other hand, PAM clustering suggested good k values at 6 and 7 
from the CDF and delta CDF (Figure 3.9E, F) and from the consensus matrix 
heatmap (Figure 3.10E, F). For further comparisons of clustering algorithms, k was 
selected as 5 for HC, 6 for KM and 7 for PAM algorithms.  
67 
 
Figure 3.9 Selecting k by examining the relative change in area under the CDF 
curve  
The LMC tumours were clustered using HC, KM and PAM based consensus 
clustering. The CDF plot shows the distribution of consensus indices for all 
possible pairings of tumours at each value of k. Typically, the majority of pairs 
have a low consensus index, reflecting their belonging to different clusters 
(panels A, C, E). The relative change in area under the CDF curves (delta 
graph) shows increments in the area under the CDF with increasing k (panels 
B, D, F). Arrows show suggested k value on the basis of flattening of the curves.  
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Figure 3.10 Consensus matrix heatmaps for HC, KM and PAM 
Row and columns represent tumours in their respective inferred clusters; each 
heatmap is symmetrical. The blue represents consensus index=1 (i.e. samples 
frequently clustered together), white colour represents consensus index=0 (i.e. 
samples rarely clustered together). 
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3.3.7  Comparing HC, KM, and PAM based clusters 
The clusters derived from the HC, KM, and PAM were compared using cluster 
stability measures, and their overlap with the Lund and TCGA signatures was 
evaluated.  
3.3.7.1  Measuring cluster stability 
The cluster stability was calculated as the average consensus score for samples in 
a given cluster. In HC derived clusters, median consensus score was 0.57 for cluster 
1, 0.62 for cluster 2, 0.65 for cluster 3, 0.65 for cluster 4, and 0.80 for cluster 5 (Figure 
3.11A). The overall median consensus score across the HC clusters was 0.64. 
Among KM derived clusters, median consensus score was 0.71 for cluster 1, 0.79 for 
cluster 2, 0.79 for cluster 3, 0.60 for cluster 4, 0.83 for cluster 5, and 0.95 for cluster 
6 (Figure 3.11B). The overall median consensus score across the KM derived 
clusters was 0.73. 
Among PAM derived clusters, median consensus score was 0.80 for cluster 1, 0.84 
for cluster 2, 0.7 for cluster 3, 0.79 for cluster 4, 0.75 for cluster 5, 0.71 for cluster 6 
and 0.94 for cluster 7 (Figure 3.11). The overall median consensus score was highest 
for the PAM derived clusters (0.76).  
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Figure 3.11 Comparing stability of HC, KM and PAM derived clusters  
(A-C) The boxplot shows the consensus score for samples in each cluster.  
3.3.8 Agreement with Lund and TCGA signatures 
The HC, KM, and PAM derived clusters were assessed for agreement with the Lund 
and TCGA signatures in the LMC dataset (Table 3.10). Cramer’s V statistic was used 
for measuring the agreement between the signatures. As described earlier, the Lund 
2-grades largely overlap with Lund 4-classes [105]. We found that Cramer’s V 
statistic between them was 0.90, the highest of any comparison made (Table 3.10). 
The TCGA signatures were developed from a different platform (RNA seq) but they 
were shown to overlap with the Lund 4-classes in terms of biological significance, 
which was also reflected in a higher (0.63) Cramer’s V statistic (Table 3.10).  
Among our three clustering methods, HC (0.76) and KM (0.78) derived clusters had 
similar agreement with the Lund 2-grades. However, both had a clearly lower overlap 
with Lund 4-classes (Cramer’s V= 0.46 and 0.57 respectively) and with the TCGA 3-
classes (V=0.37 and 0.50 respectively). PAM derived clusters had weakest overlap 
with the Lund 2-grades (V=0.59) but agreement with TCGA 3-classes (V=0.54) was 
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slightly stronger. Among the three clustering methods, HC derived clusters had 
stronger agreement (V=0.67) with KM derived clusters in comparison to PAM 
(V=0.38) derived clusters (Table 3.10).  
Table 3.10 Cramer’s V statistic comparing agreement between HC, KM, and 
PAM derived clusters and the Lund and TCGA signatures  
 Lund 2-grades 
Lund 4-
classes 
TCGA 3- 
classes HC KM PAM 
Lund 2- 
grades 1 0.90 0.39 0.76 0.78 0.59 
Lund 4- 
classes  1 0.63 0.46 0.57 0.49 
TCGA 3-
classes   1 0.37 0.50 0.54 
HC    1 0.67 0.38 
KM     1 0.45 
PAM      1 
 
3.4 Discussion 
Previous studies have demonstrated the prognostic value of the Lund and TCGA 
signatures in smaller primary melanoma datasets [105, 114]. The Lund 4-classes 
initially developed from metastatic tumours have been applied to the primary 
melanoma datasets from Lund and Leeds [105, 114]. The Lund 2-grade is a 
derivative signature of Lund 4-classes which was applied on the primary cohort from 
Leeds and Lund [105, 114]. The TCGA signature had been developed from a mixture 
of primary and metastatic melanoma tumours [81].  
Previously, Dr Jeremie Nsengimana (senior statistician in the group) applied the Lund 
signatures to the subset of LMC tumours which were profiled at the time [114]. Now 
with a bigger LMC dataset, the first objective was to test the prognostic value of Lund 
and TCGA signatures in the whole LMC dataset. Secondly it was hypothesized that 
re-clustering the primary tumour transcriptomes of LMC may improve the existing 
signatures and could lead to the discovery of new signatures.  
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3.4.1 The Lund and TCGA signatures were reproducible in the 
Leeds Melanoma cohort 
The Lund 4-class and Lund 2-grade signatures were applied to the whole LMC 
dataset using the supervised NCC approach. Dr. Jeremie Nsengimana applied the 
TCGA signatures to the classify the LMC tumours using the same approach. Twenty 
and sixteen percent of LMC tumours could not be classified into the Lund 2-grades 
and TCGA 3-classes respectively, whereas only 3% of tumours could not be 
classified into the Lund 4-classes. The higher proportion of unclassified tumours in 
the Lund 2-grades and TCGA 3-classes may reflect the fact that these signatures 
were developed from more advanced stage tumours and have not captured all 
tumour subtypes in primary melanoma. 
In this larger and independent dataset, the Lund signatures showed similar 
associations with clinico-histopathological variables and MSS as previously reported 
[114]: the high-immune and normal-like class of Lund 4-classes predicted good 
prognosis in LMC, while the proliferative and pigmentation class predicted poor 
prognosis. The high-immune and normal-like classes contained thin, non-ulcerated 
early stage melanomas, whereas proliferative and pigmentation classes contained 
thicker, mainly ulcerated advanced stage melanomas. The pathological reports 
further indicated that good prognosis classes had a higher incidence of brisk TILs, 
and poor prognosis groups had fewer TILs. Also, consistent with previous reports, 
another pathological indicator, number of mitoses, was lower in the good prognosis 
groups compared to poor prognosis groups. In keeping with previous reports, low-
grade of Lund 2-grades predicted good prognosis and high-grade predicted poor 
prognosis. The low-grade tumours were thin, non-ulcerated early stage melanomas 
and high-grade tumours were thick, mainly ulcerated advanced stage melanomas. In 
TCGA 3-classes, the MITF low class predicted poor prognosis and keratin and 
immune class predicted good prognosis. This is consistent with the previous 
replication report of the TCGA signature [116]. However, in the TCGA study, keratin 
class was associated with poor prognosis. The differences in survival of keratin class 
may be driven by the differences in the nature of samples used in these studies 
(mostly metastatic tumours in TCGA dataset and exclusively primary tumours in the 
LMC study). Overall, the prognostic value of the Lund and TCGA signatures was 
successfully replicated in LMC dataset. 
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3.4.2  The Lund and TCGA signatures’ lack of association with 
AJCC stage 
Despite an apparent reproducibility when the LMC is analysed as one large dataset, 
the Lund and TCGA signatures showed different prognostic properties when the 
dataset was stratified on the basis of AJCC stage. None of the signatures predicted 
prognosis in AJCC stage I, but they all showed strong prognostic value in AJCC 
stages II & III. This was surprising because the Lund 4-class and Lund 2-grade 
signatures have been shown to predict prognosis in primary melanoma but these 
studies based on relatively smaller cohorts with only few stage I cases [105, 114]. 
The significant interaction between the Lund 2-grades and MSS provided further 
evidence that effect of Lund 2-grade signature is effectively different across the AJCC 
stages. The power calculation suggested that, although not very large, the data size 
for AJCC stage I patients is sufficiently powered (power=0.70) for detecting a hazard 
ratio greater than 2.5 (a=0.05). This magnitude of effect is reasonable since Lund 
signatures have a comparable effect in the full data. Hence, it was hypothesised that 
re-clustering the LMC dataset may identify novel signatures with prognostic value 
across all AJCC stages, including stage I. Identifying a prognostic signature in stage 
I melanoma would be of particular interest because there is no other biomarker 
known so far to be prognostic within these early-stage melanomas. Since most of 
melanoma research is conducted on advanced stage tumours, it was challenging to 
find a validation dataset that comprises stage I melanomas. 
3.4.3  Unsupervised clustering of the LMC dataset 
The Lund 4-class and TCGA signatures were generated using similar a clustering 
algorithm, hierarchical clustering [81, 106]. HC is a popular method for identifying 
disease subtypes in clinical research. The significant increase in the dataset size 
(more than 3-fold increase) compared to previous studies, provided an opportunity to 
derive a new signature by exploring several clustering algorithms. The integrated 
framework of clustering algorithms with a consensus based resampling approach 
was applied to the LMC dataset [137]. Multiple resamples and unsupervised 
clustering using HC, KM and PAM generated a consensus matrix which was further 
analysed and examined to identify the k value. Previous comparisons of clustering 
algorithms showed that none of the algorithms consistently outperformed the other 
algorithms in identifying known subgroups from the analysed microarray datasets 
[142, 143]. In this study, the three applied algorithms identified different number of 
clusters and the cluster stability examination allowed selection of 7 clusters identified 
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by the PAM algorithm. These classes (clusters) showed a reasonable agreement with 
Lund and TCGA signatures (Table 1.19) although they did not entirely overlap, which 
is an indication that the published signatures did not explain all the variability in our 
dataset.   
In conclusion, previous melanoma transcriptomic signatures predicted prognosis in 
the LMC dataset as a whole. However, when patients were stratified on the basis of 
AJCC stage, these signatures showed distinct prognostic properties and did not 
predict prognosis in patients diagnosed at AJCC stage I. Re-clustering the LMC 
dataset using three different clustering algorithms (HC, KM and PAM) identified new 
classes. The PAM classes had higher stability in comparison to the HC and KM 
classes and will be explored further in the next chapter.  
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Chapter 4 
Properties of the new tumour classes in primary 
melanoma: prognostic significance and biological 
characterisation 
The objectives of this chapter are: 
Objective 4: To use an independent measure of cluster separation to assess stability 
of the newly identified tumour classes referred to as the LMC classes (Leeds 
Melanoma Cohort classes)  
Objective 5: To test association of the LMC classes with clinico-histopathological 
features of melanoma  
Objective 6: To test prognostic significance of the LMC classes in the whole LMC 
dataset and in the stage I subset  
Objective 7: To generate a reduced signature of the LMC classes and replicate 
prognostic significance of the LMC classes in an independent dataset from Lund, 
Sweden 
Objective 8: To explore biological differences between LMC classes using pathway 
enrichment analysis and using melanoma-specific biological modules 
 
4.1 Introduction 
Previously, it has been shown that the Lund signatures have independent prognostic 
value in comparison to the AJCC stage [114], but this analysis was based on a subset 
of 200 tumours from the LMC. The area under the Receiver Operating Characteristic 
(ROC) curve increased by 4% when Lund signatures were added to the AJCC 
staging system [114]. It was shown in the previous chapter that, when applied to the 
whole LMC dataset, the Lund signatures were only prognostic at advanced stages of 
primary melanoma (refer to 3.3.4). Therefore, it was hypothesized that re-clustering 
LMC tumours may identify novel classes which are prognostic at all stages of 
melanoma. As described in Chapter 3, LMC tumours were clustered using a 
consensus clustering approach using three different clustering algorithms (HC, KM 
and PAM). The PAM clustering algorithm identified seven LMC classes which had 
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higher stability in comparison to HC and KM based classes, using a stability metric 
from the consensus clustering algorithm (refer to 3.3.7).  
In this chapter the PAM-derived classes (from now on referred to as the LMC classes) 
were further explored. An objective measure of cluster separation was used to select 
the number of classes. The identified LMC classes were tested for association with 
clinico-histopathological features of melanoma patients. The prognostic value of the 
LMC classes was assessed in the whole LMC dataset and in an independent dataset 
of primary melanoma from Lund, Sweden [105]. The tumour classes were also 
biologically characterised using pathway enrichment analysis and using melanoma-
specific biological modules [144]. 
4.2 Methods 
4.2.1 Identifying LMC classes using a cluster separation measure 
The approach to identifying the optimal number of classes, k, was further explored 
using an objective criterion, cluster separation index. The cluster separation index 
was calculated as the ratio of intra- to inter-cluster similarity at each k value (in this 
case from k =2 to k =12).  The intra-cluster similarity is the average consensus score 
of all pairs of sample observations in the respective clusters. The intra-cluster 
similarity has been previously described as the cluster stability in Chapter 3 (refer to 
3.2.6). The inter-cluster similarity is calculated as the consensus score of all pairs of 
sample observations in different clusters. The ratio of intra-cluster to inter-cluster 
similarity was estimated for various k values. The intra-cluster and inter-cluster 
similarity calculations were done using R-package FPC [145]. The cluster separation 
index generally increases with k, and the k value where the cluster separation index 
had minimal increase at k+1 and thereafter was selected as the number of clusters 
in the LMC dataset. 
4.2.2 Association of the LMC classes with clinico-
histopathological characteristics 
The LMC classes were tested for association with clinico-histopathological 
characteristics. The clinico-histopathological variables used in the analysis were age 
at diagnosis, patient’s sex, AJCC stage, Breslow thickness, site of tumour, ulceration 
status of tumour, number of mitoses, TILs, BRAF, and NRAS mutation status. 
Pearson’s chi-squared test (refer to 2.5.3) was used for testing categorical variables 
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and Mann-Whitney (refer to 2.5.1) or Kruskal-Wallis tests (refer to 2.5.2) were used 
for testing continuous variables.  
4.2.3 Association of LMC classes with MSS  
The LMC class association with melanoma-specific survival (MSS) was tested using 
CPH models (refer to 2.4.4). The survival differences between the classes were 
graphically visualised using Kaplan-Meier plots (refer to 2.4.2). The survival 
differences between the LMC classes were tested using the log-rank test (refer to 
2.4.3). The analyses were done using R-packages survival [129], ggplot2 [130] and 
ggkm [146]. In all the analyses, the LMC class 1 was chosen as the baseline. The 
independent prognostic value of LMC classes in the whole LMC data was tested by 
including age at diagnosis, sex, AJCC stage and number of mitoses in the 
multivariable CPH models. The TILs variable had 27% of missing values and was 
excluded from the survival analyses.  
4.2.3.1 Association of LMC classes with MSS in stage I tumours 
As described previously, mitotic rate, Breslow thickness and Ulceration status are a 
significant predictor of prognosis in the AJCC stage I melanoma (refer to 1.5.4). The 
LMC patients were stratified on the basis of AJCC stage. The association of LMC 
classes with MSS was tested in the AJCC stage I group. To test the independent 
prognostic value of LMC classes, mitotic rate, Breslow thickness, and ulceration 
status were included in the multivariable CPH models. The analyses were performed 
using R-package survival [129]. 
4.2.4 Refining the LMC class signature 
The consensus-based clustering of LMC tumours was conducted using 13,688 genes 
which passed the previously described filters (refer to 2.2.5.3). However, such a large 
gene signature would not be economically/technically feasible in clinical practice. To 
mitigate this, a reduced gene signature for LMC classes was generated. The 
signature reduction was done such that the reduced signature reclassified LMC 
tumours in their respective classes with minimal loss in accuracy. The reduced 
signature was derived as follows: 
1 The genes were tested for differential expression across the LMC classes 
using a Kruskal-Wallis test (refer to 2.5.2). 
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2 The P-values were adjusted for multiple-testing using a Bonferroni correction 
and genes with adjusted P <0.0001 were selected. 
3 The top n=1, 5, 10, 25 or 100 most significantly upregulated genes of each 
LMC class were selected to generate 6 reduced signatures. 
4 The average gene expressions for each gene in each of the 6 reduced 
signatures were calculated for each LMC class to generate the class 
centroids. 
The reduced signatures were applied to the LMC dataset to classify tumours into the 
LMC classes using the NCC approach (refer to 3.2.1). As a comparison baseline, the 
LMC tumours were also classified by including all genes in the signature. The 
classification using all genes in the signature may yield slightly different results in 
comparison to the initial consensus clustering results (refer to 3.2.5). This is because 
consensus clustering algorithm, when applied to the LMC dataset, identified the LMC 
classes by merging clustering results from the 1000 resampled subsets (by selecting 
only 80% of genes and samples in each subset) of the LMC dataset (refer to 3.2.5).  
The classification accuracy for each reduced gene signature was calculated by 
comparing new classification labels with original classification labels in a contingency 
table. The proportion of diagonal values in the table represents classification 
accuracy (degree of overlap between signatures). The overlap was plotted to 
appraise the performance of each reduced signature, and the best performing among 
the 6 signatures was chosen.  
4.2.5 Replicating the prognostic value of the LMC signature in the 
Lund cohort 
4.2.5.1 Lund primary melanoma cohort  
The cohort used for validation was generated from the melanoma study conducted 
in Lund University, Lund, Sweden [105]. The melanoma patients recruited into the 
study were diagnosed between 1995 and 2002 (n=223) [105]. The FFPE tumour 
blocks of these patients were retrieved, and up to 3 tumour core sections were 
generated for the extraction of mRNA. Expression profiling was done using the 
Illumina WG-DASL HT8 array [92], a similar array to the one used for the LMC study, 
but an earlier version. The generated gene expression data underwent background 
correction and cubic spline normalisation using GenomeStudio software from 
Illumina. After initial pre-processing steps, the effect of other technical variables like 
batch, chip, plate, etc., were removed using principal components analysis [105]. 
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Since this version of the array showed poor detection, the genes were filtered and 
only those detected at p<0.05 in at least 80% of samples were retained. The final 
gene expression data from the Lund cohort comprised expression values of 8932 
genes across 223 samples. In this cohort, 29% of patients were diagnosed at AJCC 
stage I, 28% patients were diagnosed at AJCC stage II, and for the remainder of the 
patients AJCC stage was not specified [105]. 
4.2.5.2 Applying reduced LMC signature to the Lund cohort 
The reduced LMC gene signature was applied to the gene expression data from the 
Lund primary melanoma cohort using the previously described NCC approach (refer 
to 3.2.1). Similar to LMC dataset, the gene expression data from the Lund cohort was 
standardised to give each gene mean 0 and standard deviation 1. The tumours which 
had correlation less than 0.1 were labelled as unclassified. 
Since cause of death was not reported in the Lund cohort, overall survival and 
relapse-free survival were used as outcomes. The relapse-free survival time is the 
time difference between age at diagnosis and age at recurrence of melanoma. The 
overall survival time is the time difference between age at diagnosis and age at death. 
The LMC class association with overall and relapse-free survival was tested using 
CPH models (refer to 2.4.4). The survival differences between the LMC classes were 
graphically visualised using Kaplan-Meier plots (refer to 2.4.2). The survival 
differences between the LMC classes were tested using the log-rank test (refer to 
2.4.3). The analyses were performed using R-package survival [129].  
4.2.5.3 Stratification of analysis by the AJCC stage in the Lund cohort 
The patients in the Lund primary melanoma dataset were stratified on the basis of 
the recorded AJCC stage. The prognostic value of LMC classes was tested across 
the AJCC stages using CPH models (refer to 2.4.4). The survival differences between 
groups were tested using the log-rank test and visualised using Kaplan-Meier plots 
(refer to 2.4.2). Overall survival was used as the outcome measure. The analyses 
were performed using R-package survival [129]. 
4.2.6 Area under Receiver Operating Characteristic Curve 
The prognostic value of the LMC signature in comparison to the AJCC stage was 
analysed using ROC analysis [147]. The conventional way of testing classifier 
performance is by calculating the accuracy value using a 2´2 contingency table 
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containing the disease status in columns and test prediction status in rows. However, 
this approach for calculating the accuracy of a classifier has limitations, as the 
prediction status values are influenced by the cut-off criterion which is often chosen 
arbitrarily. ROC analysis is not influenced by the arbitrary cut-off [147]. ROC analysis 
chooses a set of operating points that divides the data into groups [147]. The ROC 
graph is obtained by plotting the sensitivity values on the y-axis and 1- specificity 
values on the x-axis [147, 148]. The sensitivity is also referred to as the True Positive 
Fraction (TPF) and 1-specificity is referred to as the False Positive Fraction (FPF). 
The x and y axis values vary between 0 and 1 [147, 148]. The extreme values (0,0) 
& (1,1) in the graph are extremes of TPF and FPF. The points on the graph are 
connected to the extremes to complete the graph. A ROC curve lying on the diagonal 
line indicates that the performance of the classifier is not better than chance. A ROC 
curve lying towards the upper left corner indicates that performance of the classifier 
is much better than expected by chance. The area under the ROC curve (AUC) 
measures the accuracy of the classifier. This interpretation is based on the Mann-
Whitney U test statistic which is used in calculating the AUC. AUC values range 
between 0.50 and 1, where 1 indicates perfect separation between the diseased and 
non-diseased cases, and 0.50 is equivalent to expected by chance.  
The performance of two classifiers can be compared using the Z-score statistic. The 
null hypothesis is that there is no difference between the AUC’s of two classifiers and 
the alternate hypothesis is that the AUC of the two classifiers differ [147, 148]. The 
Z-score statistic is calculated as:  
 ! = #$%&' −#$%)'*+,#$%&' −#$%)'- (4.1) 
where, #$%&'  is area under ROC curve for first classifier and #$%)'  is area under ROC 
curve for second classifier, 
 *+,#$%&' −#$%)' -= ./01,#$%&'-+/01,#$%)'-− 2%45,#$%&' ,#$%)' - (4.2) 
The performance of the AJCC staging system and LMC signature in the LMC and 
Lund datasets were compared using the ROC analysis. The predicted probabilities 
for the ROC analysis was calculated from a logistic regression model predicting 
melanoma-specific deaths in the LMC dataset, and melanoma relapse and overall 
deaths in the Lund dataset. The time point cut-off was chosen at 6 years and patients 
censored before 6 years in both the datasets were excluded from the analysis. The 
univariable model was generated for the LMC classes and the AJCC stage. The 
82 
 
multivariable included both the LMC classes and the AJCC stage. The AUC 
calculation and plots were generated and compared using R-packages ROCR, 
plotROC and ggplot2 [130, 149, 150].  
4.2.7 Biological significance of LMC classes 
To understand the biological differences between the LMC classes, differentially 
expressed genes in each tumour class were identified. The differentially expressed 
genes in LMC classes were identified by comparing one class to all other classes 
combined. The comparison was done using the Significance Analysis of Microarrays 
(SAM) tool [151, 152]. Pathway enrichment analysis was performed for over- and 
under-expressed genes in each LMC class. 
4.2.7.1 Significance Analysis of Microarrays (SAM) 
Tusher et al. proposed the SAM method to identify genes with a significant difference 
in their expression under different experimental conditions (Figure 4.1) [152]. This 
method is widely applied in microarray-based studies. It performs a regularised t-test 
for each gene separately and calculates a score based on changes in gene 
expression value relative to standard deviation of repeated measurements for that 
gene [151, 152]. The False Discovery Rate (FDR) is calculated to estimate the 
percentage of genes identified as significant by chance, based on random data 
permutations. The permutations account for the correlation between the genes and 
avoid parametric assumptions about the distribution of genes [152]. After setting a 
threshold value (referred to as delta) for the amount of difference to consider as 
relevant, which is often done subjectively, the set of significant genes are identified, 
and the FDR (or q-value) is calculated for this gene list (Figure 4.1).  
For each gene i, the SAM statistic is calculated between 2 groups as  
 !" = $̅"& − $̅"()" + )+  (4.3) 
Where xi2 and xi1 are the expression values of gene xi in group 1 and group 2. The 
term s0 denotes a constant value called the exchangeability factor or regularisation 
factor. Without this factor, equation (4.3) becomes a standard t-test. The addition of 
term s0 stabilises si which tends to be smaller at lower gene expression levels, making 
di less sensitive to small changes in the expression levels. Ideally, when making a 
comparison across genes, the di should be independent of expression levels. 
Therefore, the value of s0 is set such that the dependence of di on si should be 
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minimal. The ideal value of s0 is such that the coefficient of variation of di is 
approximately constant as function of si. 
 
 
The parameters $̅"& and $̅"( are calculated as: 
 7̅9& = ∑ 7;<=∈?&@&  (4.4) 
 
 7̅9) = ∑ 7;<=∈?)@)  (4.5) 
where n1 and n2 are the total number of samples in class 1 (C1) and class 2 (C2), xij 
are samples observations for gene xi in each class. The variable si is calculated as:  
 A9 = BC 1@& + 1@)E F∑ ,79= − 7̅9&-)=∈?& + ∑ ,79= − 7̅9)-)=∈?) G(@& + @) − 2)  (4.6) 
The analysis was done using R-package samr [151]. Two-class comparisons were 
performed and 500 permutations were used. The significantly over-expressed and 
under-expressed genes with q value=0 were selected for pathway enrichment 
analysis. 
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Figure 4.1 Summary of SAM workflow 
Adapted from Chu et al. [153] . 
 
Calculate di statistic for each gene
Sort the di statistics:
d1 ≤ d2 ≤ d3 ≤ d3…. ≤ dp
Take P sets of permutations for response yi . For each permutation 
p, calculate dpi statistic and order them in increasing order. The 
expected order statistic is calculated as:!̅ #$ = 1'( !#$#
Fix a threshold (∆)!($) − !̅(#$) > ∆ : significantly positive genes!̅(#$) − !($)> ∆ : significantly negative genes
Calculate False Discovery Rate for each list of genes obtained at 
various ∆ values.
FDR = ,-./01 (12,3-4	67	8-1-9	70:9-:;	<0::-. 	)12,3-4	67	8-1-9	<0::-.	9/81/=/<01>	
At same threshold values, for each permuted set calculate!(#$) − !̅(#$) > ∆ : falsely positive genes!̅(#$) − !(#$)	> ∆ : falsely negative genes
Calculate q value for each gene
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4.2.7.2 Pathway enrichment analysis  
The significantly over-expressed and under-expressed genes identified from the 
SAM analysis were used for pathway enrichment analysis within ReactomeFIViz 
[154], a Cytoscape plugin [154, 155]. 
4.2.7.2.1 Reactome FIViz tool 
Reactome FI is a Cytoscape based plugin used to perform pathway and network 
analysis of high dimensional datasets [154]. This tool matches the input set of genes 
against the Reactome functional interaction network to generate the list of enriched 
pathways [154]. Reactome functional interaction network is a reliable, manually 
curated protein functional interaction network which covers more than 60% of human 
proteins [154]. This tool allows construction of a functional interaction network for a 
set of query genes and analyses the sources of underlying evidence for physical 
interaction between the genes. The tool performs a binomial test comparing the list 
of input genes to the number of genes associated with a specific pathway. The 
pathways are queried from KEGG, Reactome and other open source databases 
[154]. The FDR of the P values is calculated using the Benjamini-Hochberg method 
of multiple testing correction [156]. The over- and under-expressed gene sets were 
input into the Reactome tool to perform pathway enrichment. The pathways with FDR 
< 0.01 were selected and further analysed. 
4.2.8 Assessing the Lund module activity in LMC classes 
4.2.8.1 Lund biological modules 
Cirenajwis et al. performed transcriptional network analysis of highly correlated 
genes in an another cohort from Lund University, consisting of metastatic melanomas 
[144]. The pathways associated with highly correlated genes were summarised into 
five distinct modules named immune, stroma, MITF, cell cycle and interferon, from 
now on referred to as the Lund modules. These modules were found to be associated 
with the Lund 4-classes [144]. The high-immune class of Lund 4-classes had higher 
expression of the immune and stroma modules and lower expression of the MITF 
and cell cycle modules. The pigmentation class had higher expression of the MITF 
and cell cycle modules. The proliferative class had higher expression of the cell cycle 
module and lower expression of the immune and stroma modules. The normal-like 
class had increased expression of the stroma module and lower expression of the 
cell cycle module [144]. 
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4.2.8.2 Application of the Lund modules to the LMC dataset 
The LMC classes were characterised using the Lund modules. The immune module 
contained 231 genes, of which 215 were present in the LMC while 25/26 genes 
matched from the MITF module. All genes in the stroma (119 genes), cell cycle (11 
genes) and interferon (7 genes) modules were present. The module score was 
calculated for each LMC tumour sample as: 
 A9J =K 79LL∈M  (4.7) 
where m is the module (immune, stroma, MITF, cell cycle and interferon) and sim is 
the module score for ith sample, g is the gene in module gene set G and xig is the 
expression value of ith sample for gene g. The correlation between the modules was 
assessed using Spearman’s rank correlation. 
 
4.3 Results 
4.3.1 Identifying the number of classes in the LMC dataset 
As described in the previous chapter, seven classes were selected using a subjective 
criterion based on the consensus clustering matrix graphics (refer to 3.2.5.4). To 
further confirm k using an objective criterion, a cluster separation measure was 
defined: the ratio of intra-cluster similarity to inter-cluster similarity. The cluster 
separation generally increased with the k value (Table 4.1). However, it was lower 
for k=4 than at k=3. In keeping with previous observations from the consensus matrix 
graphics, k=7 had the maximum increase (from k=6) in cluster separation in 
comparison to other k values. This observation confirmed selection of k =7 as the 
number of classes.  
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Table 4.1 Summary of cluster separation measure at various k values  
The cluster separation generally increased with k values, with a maximum 
increase at k=7.  
k Cluster separation 
2 5.1 
3 5.5 
4 5.1 
5 5.9 
6 7.2 
7 9.1 
8 9.6 
9 9.9 
10 10.2 
 
4.3.1.1 Association of the LMC classes with Batch 
To test whether clustering of tumours was influenced by differences due to the batch 
in which the samples were processed, the association of the LMC classes with batch 
number was tested. The LMC tumours were sent for profiling in three batches to a 
service provider (Service XS, Leiden, The Netherlands). Apart from the LMC class 7, 
all other LMC class samples were distributed across the three batches (Table 4.2). 
The LMC class 7 had lower number of samples (n=15), and 14 out of 15 samples 
were processed in the same batch. The statistically significant (P=0.01) association 
between batch and LMC classes suggested that clustering of some LMC classes 
may have been affected by artefacts arising from the batch in which samples were 
processed. Further exploration of LMC class 7 tumour samples suggested that these 
tumours were mainly present on the edges of a plate. After excluding class 7 samples 
the LMC classes were not associated with the batch (P=0.2). 
  
88 
 
Table 4.2 Summary of LMC class tumours across the three batches sent for 
gene expression profiling  
LMC classes Batch 101998 Batch 102232 Batch 102503 
1 18 32 21 
2 31 60 31 
3 23 29 21 
4 36 78 29 
5 33 56 47 
6 38 75 29 
7 1 14 0 
 
4.3.1.2 Re-clustering the LMC tumours after removing 15 samples 
The above analysis suggested that the class with small sample size may be driven 
by artefactual features. The low sample sized class would also have limited power 
for downstream statistical analysis. For these reasons LMC class 7 samples were 
excluded from the LMC dataset, and the remaining samples were re-clustered using 
the same method as described previously (refer to 3.2.5.4) (consensus-based PAM 
clustering with the same parameters as before).  
Re-clustering the LMC tumours indicated k=6 as a good number of classes. The CDF 
of the consensus matrix and delta area graph suggested minimal increase in area at 
k=6 (Figure 4.2). The cluster separation measure also had maximum increase at k=6 
(Table 4.3). These observations clearly indicated that k=6 was the new optimal 
number of classes in the LMC dataset. These six classes largely overlapped with 
previously identified LMC classes with a very high agreement (Cramer’ V= 0.97) 
(Table 4.4).  
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Figure 4.2 Re-clustering of LMC tumours after excluding 15 samples, using 
consensus clustering PAM method  
(A) The heatmap of consensus matrix at k=5, 6 and 7. At k=7 only sample was 
classified into the new cluster. (B) Cumulative Distribution Function (CDF) of 
the consensus scores at various values of k. (C) Relative change (delta) in the 
area under the CDF curve comparing k with k-1.  
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Table 4.3 Summary of cluster separation measure at various k values after 
removing 15 samples  
k Cluster separation measure 
2 4.92 
3 5.73 
4 4.82 
5 6.62 
6 8.55 
7 9.18 
8 9.20 
9 9.48 
10 9.76 
Table 4.4 Comparing new classification with initial classification after removing 
15 samples  
Class 
Initial clustering  
1 2 3 4 5 6 
  Re-clustering after 
  removing 15 samples 
1 71 0 0 0 0 1 
2 0 122 0 0 1 3 
3 0 0 72 5 0 6 
4 0 0 1 135 0 0 
5 0 0 0 3 135 0 
6 0 0 0 0 0 132 
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4.3.2 The LMC class association with clinico-histopathological 
features 
As shown in Table 4.5, the LMC classes were significantly associated with tumour 
site, age at diagnosis, Breslow thickness, AJCC stage, ulceration status, TILs, NRAS, 
and BRAF mutation status. The LMC class 1, class 2 and class 5 tumours occurred 
more frequently on limbs. The LMC class 1 and class 5 tumours were most frequently 
non-ulcerated and thin while class 2 and class 4 tumours were thicker more likely to 
be ulcerated. The LMC class 3 and class 6 tumours were the thickest and mainly 
ulcerated. In term of AJCC stage, class 1 and class 5 tumours had a higher proportion 
of early stage tumours whereas class 3 and class 6 tumours had a higher proportion 
of advanced stage tumours (Table 4.5). LMC class 1 had a higher percentage of brisk 
TILs and LMC class 3 absence of TILs. LMC class 2 and class 6 had higher 
percentages of non-brisk TILs, and LMC classes 4 and 5 had intermediate levels of 
brisk and non-brisk TILs. The LMC classes also differed in NRAS and BRAF mutation 
status. LMC class 5 and class 6 were frequently BRAF mutated. LMC class 2, class 
3 and class 4 contained frequently NRAS-mutated tumours (Table 4.5).  
 
 Table 4.5 LMC classes association with clinico-histopathological variables 
 Where n is the number of samples, m is the median and r is the range.  
Histopathological variables 
Whole 
dataset 
n=687 (%) 
LMC class 
Class 1 
(n=71) 
Class 2 
(n=122) 
Class 3 
(n= 73) 
Class 4 
(n=143) 
Class 5 
(n=136) 
Class 6 
(n=142) P 
Sex : male n (%) 310 (45) 39 (55) 51 (42) 34 (47) 56 (39) 55 (40) 75 (52) 0.07 
Tumour site: limbs n (%) 289 (42) 37 (52) 58 (48) 26 (36) 58 (41) 64 (47) 46 (32) 0.03 
Age at diagnosis (years), m(r) 58 (18, 81) 59 (21,76) 59 (22,79) 60 (20,77) 58 (18,81) 53 (25,76) 59 (22,81) 0.03 
Breslow thickness (mm) 
n=691 m(r) 2.3 (0.3, 20) 1.7 (0.7, 5.5) 2.1 (0.8, 8.9) 3.2 (0.8, 20) 2.3 (0.3, 15) 1.8 (0.7, 12) 3.0 (0.8, 18) 9.5 x 10
-14 
AJCC stage n=680 (%)       I 
                                            II 
                                           III 
230 (34) 
344 (51) 
106 (15) 
37 (52) 
29 (41) 
5 (7) 
41 (34) 
59 (49) 
21 (17) 
10 (14) 
46 (65) 
15 (21) 
46 (33) 
77 (55) 
16 (12) 
69 (51) 
47 (34) 
20 (15) 
27 (19) 
86 (61) 
29 (20) 
5.2 x 10-9 
Ulceration (present) n (%) 228 (33) 16 (23) 26 (32) 30 (41) 53 (37) 38 (28) 59 (42) 0.01 
Number of mitoses (n= 577) ³1 358 (62) 30 (50) 53 (58) 43 (70) 83 (64) 74 (64) 75 (64) 0.2 
TILs n=490 (%)          Absent 
         Non-Brisk 
         Brisk 
76 (15) 
333 (68) 
81 (17) 
2 (4) 
30 (60) 
18 (36) 
13 (14) 
65 (71) 
14 (15) 
17 (32) 
32 (60) 
4 (8) 
14 (16) 
60 (68) 
14 (16) 
15 (16) 
63 (66) 
17 (18) 
15 (13) 
83 (74) 
14 (13) 
5.5 x 10-4 
BRAF mutant (n = 568) yes (%) 266 (47) 26 (43) 38 (30) 23 (40) 44 (36) 63 (59) 72 (61) 5.6 x 10-5 
NRAS mutant (n= 561) yes (%) 138 (25) 8 (14) 35 (34) 17 (30) 41 (34) 20 (19) 17 (15) 3.2 x 10-4 
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4.3.3 Prognostic value of the LMC signature 
4.3.3.1 Prognostic value in the whole LMC dataset 
LMC classes strongly predicted MSS in the LMC dataset (Figure 4.3, Table 4.6). The 
proportion of deaths from melanoma ranged from 14% in LMC class 1 patients to 49% 
in class 3, with 20% in class 2, 30% in class 4, 20% in class 5 and 36% in class 6. 
In univariable analysis, LMC class 1 patients had good prognosis. LMC class 2 (HR=1.8 
compared with class 1), class 5 (HR=1.6) and class 4 (HR=2.3) patients had 
intermediate prognosis (Figure 4.3). LMC class 3 (HR=5.0) and class 6 (HR=3.2) 
patients had the worst prognosis (Figure 4.3). Clinical variables such as the AJCC 
stage, age at diagnosis, tumour site, sex, and number of mitoses also significantly 
predicted MSS in the LMC dataset (Table 4.6).  
In a multivariable model adjusting for clinical variables, LMC class 3 (HR= 3.6), class 4 
(HR=2.2) and class 6 (HR= 2.2) maintained an independent association with survival 
(Table 4.6).  
 
Figure 4.3 Melanoma-specific survival for the LMC classes on the whole LMC 
dataset 
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 Table 4.6 Summary of the univariable and multivariable analysis of the LMC signature with melanoma-specific survival in the whole LMC 
dataset  
The variable n is the total number of samples, deaths are the number of melanoma-specific deaths. CI is confidence interval and HR is the 
hazard ratio.  
 Univariable  Multivariable (n=571, deaths=157) 
Class (n) HR 95% CI P Class (n) HR 95% CI P 
LMC class 
(n=687, 
deaths=194) 
1 (71) 1.00 - - 
LMC class 
 
 
1 (61) 1.00 - - 
2 (122) 1.8 0.9-3.7 0.1 2 (91) 0.9 0.4-2.0 0.7 
3 (73) 5.0 2.5-10.1 8 x 10-6 3 (59) 3.6 1.7-7.6 0.001 
4 (143) 2.3 1.8-4.7 0.02 4 (126) 2.1 1.0-4.4 0.04 
5 (136) 1.6 0.8-3.2 0.2 5 (116) 1.4 0.7-3.1 0.3 
6 (142) 3.2 1.6-6.2 9 x 10-4 6 (188) 1.9 0.9-3.7 0.08 
AJCC stage 
(n= 680, 
deaths=192) 
I (230) 1.00 - - 
AJCC stage 
 
I (182) 1.0 - - 
II (344) 2.5 1.7-3.7 5 x 10-6 II (301) 1.6 1.0-2.6 0.04 
III (106) 6.0 3.8-9.2 2 x 10-15 III (88) 4.7 2.8-7.9 5 x 10-9 
Sex 
(n=687, 
deaths=194) 
F (377) 1.0 - - 
Sex 
F (310) 1.0 - - 
M (310) 1.5 1.1-1.9 8 x 10-3 M (261) 1.2 0.8-1.7 0.3 
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 Univariable  Multivariable (n=571, deaths=157) 
Class (n) HR 95% CI P Class (n) HR 95% CI P 
Age at 
diagnosis 
(n=687, 
deaths=194) 
years 1.03 1.01-1.04 4 x 10-6 Age at diagnosis years 1.03 1.01-1.05 1 x 10
-5 
Mitotic rate 
(n=577, 
deaths=158) 
<1 (219) 1.0 - - 
Mitotic rate 
<1 (216) 1.0 - - 
>=1 (358) 1.9 1.3-2.7 4 x 10-4 >=1 (355) 1.6 1.2-2.3 0.01 
Site of tumour 
Limbs (289) 1.0 - - 
Site of tumour 
Limbs (240) 1.0 - - 
Head (80) 1.1 0.6-1.9 0.6 Head (74) 1.0 0.5-1.7 0.9 
Trunk (230) 1.8 1.3-2.5 6 x 10-4 Trunk (187) 1.8 1.2-2.7 0.007 
Other (88) 2.9 1.9-4.3 3 x 10-7 Other (70) 2.0 1.2-3.2 0.002 
 
95 
96 
4.3.3.2 Prognostic value of LMC signature in stage I tumours 
As described in the previous chapter, the Lund and TCGA signatures did not predict 
survival in stage I tumours (refer to 3.3.4.1). To test the prognostic value of the LMC 
signature in stage I tumours, a univariable analysis and multivariable analyses 
(adjusting for the effect of clinical predictors) were performed.  
In the univariable analysis, the LMC class 6 had relatively poor survival (Figure 4.4, 
Table 4.7). The overall survival difference between the six LMC classes was not 
significant (Figure 4.4) but the LMC class 6 had a significantly higher melanoma death 
hazard ratio (HR=6.6) than class 1 at P=0.02 (Table 4.7). LMC class 3 (HR=4.0) and 
class 4 (HR=3.1) had similar hazard ratios in AJCC stage l compared to the whole LMC 
dataset, although these did not reach the significance threshold of 0.05 due to the much 
reduced sample size. Among the clinical variables, mitotic rate (HR=2.4), Breslow 
thickness (HR=3.1), Sex (males: HR=2.2) and Site (limbs: HR=2.1) significantly 
predicted survival in the AJCC stage I group (Table 4.7).  
In a multivariable model after adjusting for clinical variables (mitotic rate, Breslow 
thickness, Sex and Site), although not significant (P=0.07) but the LMC class 6 
maintained a higher melanoma death hazard ratio (HR=7.8) (Table 4.7). 
 
Figure 4.4 Melanoma-specific survival for the LMC classes on the AJCC stage I 
group
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 Table 4.7 Summary of the univariable and multivariable analysis of the LMC signature with melanoma-specific survival in the AJCC stage 
I group  
The other tumour site variables like head and other rare site were excluded as only few samples were classified into these categories. The 
variable n is the total number of samples, deaths are the number of melanoma-specific deaths. CI is confidence interval and HR is the hazard 
ratio.  
 Univariable 
 
Multivariable (n=158, deaths=25) 
Class (n) HR 95% CI P Class (n) HR 95% CI P 
LMC class 
(n=230, deaths=33) 
1 (37) 1.0 - - 
LMC class 
 
1 (26) 1.0 - - 
2 (41) 3.5 0.7-17.3 0.1 2 (22) 5.7 0.6-54.1 0.1 
3 (10) 4.0 0.6-28.5 0.2 3 (7) 4.6 0.3-80.2 0.3 
4 (46) 3.1 0.7-15.2 0.2 4 (34) 5.5 0.7-46.4 0.1 
5 (69) 2.3 0.5-10.7 0.3 5 (50) 3.2 0.4-27.0 0.3 
6 (27) 6.6 1.4-31.0 0.02 6 (19) 7.8 0.9-70.7 0.07 
Sex 
(n=230, deaths=33) 
F (134) 1.0 - - 
Sex 
F (94) 1.0 - - 
M (96) 2.2 1.1-4.5 0.02 M (64) 2.6 1.1-6.5 0.05 
Age at diagnosis 
(n=230, deaths=33) Years 1.01 0.98-1.04 0.3      
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 Univariable 
 
Multivariable (n=158, deaths=25) 
Class (n) HR 95% CI P Class (n) HR 95% CI P 
Breslow thickness 
(n=230, deaths=33) mm 3.1 1.2-8.2 0.02 
Breslow 
thickness mm 1.32 0.4-4.2 0.6 
Site  
(n=201, deaths=32) 
Limbs 
(115) 1.0 - - Site 
Limbs (90) 1.0 - - 
Trunk (86) 2.1 1.0-4.2 0.04 Trunk (68) 1.6 0.6-4.2 0.3 
Mitotic rate 
(n=182, deaths=25) 
<1 (96) 1.0 - - Mitotic rate <1 (96) 1.0 -  
>=1 (86) 2.4 1.0-5.5 0.04  >=1 (86) 2.6 1.1-6.3 0.04 
Ulceration of 
tumour 
(n=230, deaths=33) 
No 1.0 - -      
Yes 1.1 0-Inf 0.9      
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4.3.4 Comparing LMC signatures with Lund 4-classes and TCGA 3-
classes 
The LMC signatures overlapped with previously described Lund 4-classes and TCGA 
3-classes (Figure 4.5). The LMC class 1 tumours overlapped to a large extent with high-
immune class, class 3 overlapped with pigmentation class, class 5 overlapped with 
normal-like class of Lund 4-classes (Figure 4.5A). The LMC class 2, class 4 and class 
6 were a mixture of the Lund 4-classes (Figure 4.5A).  
Similarly, for TCGA 3-classes, the LMC class 1 overlapped with the Immune class, LMC 
class 3 overlapped with MITF low class and LMC class 5 overlapped with Keratin class 
(Figure 4.5B). LMC class 2, class 4 and class 6 were a mixture of the TCGA 3-classes. 
 
Figure 4.5 Overlap between the LMC signatures and the Lund 4-classes and 
TCGA 3-classes  
Lund 4-classes: HI- high immune, NL- normal-like, Pigm.- pigmentation, Prolif.- 
proliferative; TCGA 3-classes: immune, keratin and MITF low. Unclassified 
samples are shown in black. 
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4.3.5 Replicating prognostic value of LMC signature 
4.3.5.1 Generating a refined LMC signature 
The initial LMC signature comprised ~13,000 genes. Applying this gene signature in 
clinical practice would not be feasible. To mitigate this, the gene signature was reduced 
to form multiple smaller subsets by selecting the top n (1, 5, 10, 25, 100 and 500) ranked 
upregulated genes in each of the LMC classes, resulting in signatures of 6, 30, 60, 150, 
600 (599 unique) and 3000 (2908 unique) genes (refer to 4.2.4). For all signatures, the 
LMC classes 1, 3 and 5 had lower misclassification rate and LMC classes 2, 4 and 6 
has higher misclassification rate (Figure 4.6). The 6 gene-based, 30 gene-based and 
60-gene based signature sets had low accuracy in classifying LMC tumours into their 
respective classes (Figure 4.6). All other gene set signatures had a comparatively 
similar performance to the all gene-based signature. Among these gene signatures, the 
signature with fewer genes, the 150 gene-based signature, was selected for validation 
on an external dataset (Figure 4.6; Appendix I Table 8.1).  
 
Figure 4.6 Refining the LMC class gene signature  
The six gene signatures were generated by combining the top n (1, 5, 10, 25, 50, 
100 and 500) highly expressed genes from each LMC class. The LMC tumours 
were reclassified into the LMC classes based on these signatures using the NCC 
approach. The plot compares the proportion of samples in each class in the 
original classification classified in the same way by the reduced signature. 
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4.3.5.2 Prognostic value of LMC signature in Lund cohort  
The 150-gene based LMC signature was applied to the independent cohort of primary 
melanomas from Lund, Sweden. Among 150 genes in the LMC signature, 73 genes 
were present in the gene expression dataset from the Lund cohort. In the Lund cohort, 
27% of tumours were classified into LMC class 1, 4% in class 2, 23% in class 3, 9% in 
class 4, 18% in class 5 and 14% tumours in class 6. The LMC class 1 tumours (r=0.44) 
had the highest median correlation with LMC class 1 centroids. The LMC class 2 
(r=0.37) and class 3 (r=0.40) tumours had a similar correlation with their respective 
centroids. The LMC class 4 (r=0.26), class 5 (r=0.32) and class 6 (r=0.28) tumours had 
comparatively lower correlation with their respective class centroids. Three percent of 
tumours in the Lund cohort could not be classified. 
The LMC classes significantly predicted relapse-free and overall survival in the Lund 
cohort (Figure 4.7, Table 4.8). In LMC class 1, 33% patients died, 27% in class 2, 75% 
in class 3, 71% in class 4, 35% in class 5 and 58% in class 6. The survival plot indicated 
that LMC class 1, class 2 and class 5 predicted good prognosis in the Lund cohort 
(Figure 4.7). The LMC class 3, class 4 and class 6 predicted worse prognosis with 
increased hazard for relapse and overall deaths in the Lund cohort (Figure 4.7, Table 
4.8). 
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Figure 4.7 Relapse-free survival and overall survival for the LMC classes on the 
Lund dataset 
Since melanoma-specific survival was not available, (A) relapse-free survival and 
(B) overall survival were used as clinical outcomes for survival analysis. 
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Table 4.8 Summary of the univariable analysis of the LMC signature with relapse-
free survival and overall survival in the Lund cohort  
The variable n is the total number of samples, e is the event (relapsed or death) 
and HR is the hazard ratio. 
LMC class 
Relapse-Free Survival 
(n=200, relapsed=75) 
Overall Survival 
(n=215, deaths=109) 
HR 95% CI P HR 95% CI P 
Class 1 1.0 - - 1.0 - - 
Class 2 1.5 0.4-5.4 0.5 0.8 0.2-2.7 0.7 
Class 3 6.3 3.1-12.9 6 x 10-7 4.0 2.3-6.9 6 x 10-7 
Class 4 4.2 1.7-10.1 0.001 3.6 1.8-7.0 2 x 10-4 
Class 5 1.1 0.4-3.0 0.8 1.2 0.6-2.3 0.6 
Class 6 3.7 1.6-8.4 0.001 2.1 1.1-4.0 0.02 
 
4.3.5.3 Prognostic value of LMC signature in AJCC stage I group  
The LMC classes showed no significant association with relapse-free survival or overall 
survival in the AJCC stage I group of the Lund cohort (Table 4.9). In AJCC stage I, 7 
out of 28 people in LMC class 1, 3 out of 5 people in class 3, 4 out of 18 people in LMC 
class 5, and 2 out of 6 people in LMC class 6 died. The LMC classes 2 and 4 had less 
than 5 samples in AJCC stage I and were excluded from the survival analysis. The CPH 
model analysis indicated that class 3 had increased hazard for melanoma relapse 
(HR=2.3) as well as death (HR=3.5) in comparison to baseline LMC class 1 (Table 4.9), 
although this was not statistically significant. The hazard for relapse and death was also 
slightly higher in LMC classes 5 and 6 compared to class 1. 
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Table 4.9 Summary of the univariable analysis of the LMC signature with relapse-
free survival and overall survival in the AJCC stage I group of Lund cohort.  
The LMC classes 2 and 4 had less than 5 samples in AJCC stage I and were 
excluded from the analysis, n is the number of samples, e is the event (relapsed 
or death), CI is confidence interval, and HR is the hazard ratio. 
LMC 
class 
Relapse-free Survival 
(n=54, relapsed= 8) 
Overall Survival 
(n=74, deaths=16) 
n, e HR 95% CI P n, e HR 95% CI P 
Class 1 26, 4 1.0 - - 28, 7 1.0 - - 
Class 3 5, 1 2.3 0.2-21.3 0.5 5, 3 3.5 0.9-14.0 0.07 
Class 5 18, 3 1.7 0.3-8.5 0.5 18, 4 1.1 0.3-3.9 0.8 
Class 6 6, 1 1.2 0.1-12.1 0.8 6, 2 1.2 0.2-6.1 0.8 
 
4.3.5.4 Independent prognostic value of the LMC signature 
To assess the independent prognostic value of the LMC signature, ROC analysis was 
performed predicting melanoma-specific deaths in the LMC dataset and melanoma 
relapse  and overall deaths in the Lund dataset (Figure 4.8). The time point cut-off was 
chosen at 6 years and patients censored before 6 years were excluded from the 
analysis.  
The AJCC classification system showed an AUC of 70% in the LMC dataset (Figure 
4.8A) and 81% and 78% in the Lund dataset (Figure 4.8B-C). The LMC signature had 
similar performance to the AJCC staging system in the LMC dataset (AUC=65%) and 
the Lund data (AUC= 78%-79%) (Figure 4.8). Combining the two i.e. the AJCC staging 
system with the LMC signature showed 4% improvement of AUC in the LMC dataset in 
comparison to the AJCC staging system alone (Figure 4.8A). The improvement for the 
combination improved by 5% and 7% in the Lund dataset for the two outcomes, 
melanoma relapse and overall deaths respectively (Figure 4.8B-C). The improvement 
in AUC for both the datasets was statistically significant (LMC MSS P=0.001, Lund 
relapse P=0.02, Lund overall deaths P=0.02).   
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Figure 4.8 Independent prognostic value of the LMC signature 
ROC curves of the LMC classes and the AJCC staging system predicting (A) 
melanoma-specific deaths in the LMC dataset and (B) melanoma relapse and (C) 
overall deaths in the Lund dataset. 
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4.3.6 Biological significance of the LMC classes 
4.3.6.1 Pathway enrichment analyses of LMC classes 
The biological differences between the LMC classes were explored using differentially 
expressed genes identified from SAM analysis [151, 152]. These genes were input into 
ReactomeFIViz tool [154] for identifying the associated biological pathways. All 
pathways reported here were significant at FDR <0.01. 
The LMC class 1 tumours had increased expression of genes in the immune response 
pathways (Figure 4.9). The most significant pathways were NF-KB signalling, 
chemokine signalling, osteoclast differentiation, T-cell receptor signalling, etc. (Figure 
4.9). The LMC class 1 tumours had decreased expression of genes in the cell cycle 
related pathways (Figure 4.9), such as mitotic G1-G1/S phase, cell cycle checkpoints, 
cell cycle, etc. The LMC class 2 tumours had increased expression of genes in the 
eukaryotic translation and with nonsense-mediated decay pathways and decreased 
expression of genes in the PLK1 signalling and FOXM1 transcription factor network 
pathways (Figure 4.10). 
The LMC class 3 tumours mirrored class 1 tumours and had increased expression of 
genes in the cell cycle related pathways and decreased expression of genes in the 
immune response pathways (Figure 4.11). The LMC class 4 tumours had very few 
genes with significantly increased expression. The associated pathways were 
assembly of the primary cilium and RNA polymerase II transcription (Figure 4.12).  
The LMC class 5 tumours had increased expression of genes in the Cell junction 
organisation and extra cellular matrix-receptor interaction (Figure 4.13). These tumours 
had decreased expression of genes in the Wnt signalling, Cadherin signalling and 
assembly of primary cilium pathways. 
The LMC class 6 showed some characteristics of LMC class 1 and class 3 tumours. 
The class 6 tumours had increased expression of genes in the cell cycle related, focal 
adhesion and immune response pathways (Figure 4.14). These tumours had 
decreased expression of genes in the eukaryotic translation and nonsense-mediated 
decay pathways. 
The complete list of the associated biological pathways is provided in Appendix I (Table 
8.2 - Table 8.13). 
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Figure 4.9 Summary of biological pathways associated with the LMC class 1  
The upregulated pathways are represented in red and downregulated pathways 
are represented in blue. The font size is based on the significance level, with most 
significant pathways shown in larger fonts. The bracket indicates the database 
used for each pathway (K- KEGG, R- Reactome, N- NCBI database).   
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Figure 4.10 Summary of biological pathways associated with the LMC class 2  
The upregulated pathways are represented in red and downregulated pathways 
are represented in blue. The font size is based on the significance level, with most 
significant pathways shown in larger fonts. The bracket indicates the database 
used for each pathway (K- KEGG, R- Reactome, N- NCBI database).   
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Figure 4.11 Summary of biological pathways associated with the LMC class 3  
The upregulated pathways are represented in red and downregulated pathways 
are represented in blue. The font size is based on the significance level, with most 
significant pathways shown in larger fonts. The bracket indicates the database 
used for each pathway (K- KEGG, R- Reactome, N- NCBI database).   
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Figure 4.12 Summary of biological pathways associated with the LMC class 4  
The upregulated pathways are represented in red and downregulated pathways 
are represented in blue. The font size is based on the significance level, with most 
significant pathways shown in larger fonts. The bracket indicates the database 
used for each pathway (K- KEGG, R- Reactome, N- NCBI database).   
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Figure 4.13 Summary of biological pathways associated with the LMC class 5  
The upregulated pathways are represented in red and downregulated pathways 
are represented in blue. The font size is based on the significance level, with most 
significant pathways shown in larger fonts. The bracket indicates the database 
used for each pathway (K- KEGG, R- Reactome, N- NCBI database). 
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Figure 4.14 Summary of biological pathways associated with LMC class 6  
The upregulated pathways are represented in red and downregulated pathways 
are represented in blue. The font size is based on the significance level, with most 
significant pathways shown in larger fonts. The bracket indicates the database 
used for each pathway (K- KEGG, R- Reactome, N- NCBI database).  
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4.3.6.2 Characterising LMC classes using Lund modules 
The LMC classes were further characterised using Lund modules identified by 
Cirenajwis et al. [144] in an independent cohort of metastatic melanoma from Lund, 
Sweden. In keeping with observations from pathway enrichment analysis (refer 
previous section), the LMC classes demonstrated distinct Lund module activity. The 
LMC class 1 tumours had higher immune, stroma and interferon module activity and 
lower MITF and cell cycle module activity (Figure 4.15A-E). The LMC class 2 tumours 
had higher MITF module activity and lower cell cycle module activity. As observed in 
pathway enrichment analysis, LMC class 3 tumours mirrored LMC class 1 tumours and 
had higher MITF and cell cycle module activity and lower immune, stroma and 
interferon module activity (Figure 4.15A-E). The LMC class 4 tumours had higher MITF 
module activity and lower immune and stroma module activity. The LMC class 5 
tumours had higher immune and interferon module activity. The LMC class 6 tumours 
had higher immune and cell cycle module activity (Figure 4.15A-E).  
When comparing modules scores with one another, the immune module scores were 
positively correlated with stroma and interferon modules and negatively correlated with 
MITF and cell cycle module scores (Figure 4.15F). The MITF module scores were 
positively correlated with cell cycle module score and negatively correlated with 
immune, stroma and interferon modules (Figure 4.15F). 
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Figure 4.15 Characterising LMC classes using the Lund modules  
The dot and boxplot show the distribution of scores for (A) immune, (B) stroma, 
(C) MITF, (D) Cell cycle and (E) interferon modules across the LMC classes. (F) 
Spearman’s correlation coefficient between these modules [144].   
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4.4 Discussion 
In this study, six melanoma tumour classes were defined using one of the largest 
cohorts of primary melanoma. The LMC classes were associated with distinct clinical 
features of melanoma and independently predicted survival. Unlike previous 
signatures, the LMC classes strongly predicted outcome in the whole LMC dataset 
including in stage I tumours. The prognostic value of LMC classes was recovered in an 
independent cohort of primary melanomas from Lund, Sweden. The biological 
differences were explored using genome-wide gene expression and candidate 
functional modules. 
Previously, consensus clustering using the PAM algorithm identified seven classes of 
melanoma (refer to chapter 3). Applying a novel cluster separation method confirmed 
selection of seven classes in the LMC dataset. Interestingly, one of the classes 
contained only a few samples which were later identified to be processed in the same 
batch. At the time, it was not clear whether this class may represent technical bias, and 
these samples were excluded from the downstream analysis. Consensus clustering has 
been shown to be robust for obtaining a stable number of clusters [137, 157]. This was 
true in LMC, as re-clustering the dataset after removing the small class robustly 
recovered the previously observed six LMC classes with a very large agreement 
(Cramer V=97%). 
4.4.1 Clinical-pathological characteristics of the LMC classes  
Similar to Lund and TCGA signatures, the LMC classes were significantly associated 
with clinico-pathological features of melanoma patients like age, Breslow thickness, 
tumour site, AJCC stage, ulceration of tumour and TILS. The LMC class 1 and class 5 
tumours were thin, non-ulcerated and presented at early stages. The LMC classes 2 
and 4 had increased tumour thickness and ulceration of tumours. The LMC class 3 and 
class 6 were the thickest and were advanced stage tumours. In melanoma, BRAF and 
NRAS mutations have been reported to be mutually exclusive with strong therapeutic 
implications [77, 78, 83, 84, 158-162]. Interestingly, unlike previous signatures, the LMC 
classes were strongly associated with BRAF and NRAS mutation status [81, 106]. LMC 
class 5 and class 6 were frequently BRAF mutated and LMC class 2, class 3 and class 
4 were frequently NRAS mutated. 
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4.4.2 Prognostic significance of the LMC classes in stage I 
melanoma 
In keeping with Lund and TCGA classes, the LMC classes were also predictive of 
outcome in the whole LMC dataset. However, as shown previously, the Lund and TCGA 
signatures did not predict prognosis in the AJCC stage I tumours, and one of the 
objectives of this research was to devise a prognostic signature for these early stage 
tumours. Although the 5-year survival rate is about 95% for patients diagnosed at stage 
I [44], it remains of clear importance to predict those at risk of dying from their disease. 
In the LMC classes, LMC class 6 predicted significantly worse outcome in the AJCC 
stage I in the univariable model. When jointly analysed with other clinical variables the 
LMC class 6 still had increased melanoma death hazard for stage I tumours but it did 
not reach the significance threshold in the multivariate model. The lack of significance 
in the multivariate model could be due to the fact that this analysis was done on 
comparatively smaller set of samples as many samples had missing clinical information, 
and therefore were removed from the analysis. The comparable hazard ratios in the 
univariable and multivariable models suggests that the LMC class 6 predicts poor 
outcome in stage I group, and this class may have potential clinical relevance.  
It has been shown that metastatic melanoma has distinct gene expression signatures 
in comparison to primary cutaneous melanoma [122, 163-165]. However, the LMC 
classes from primary melanoma showed an overlap with the Lund and TCGA 
signatures derived from metastatic melanoma. This suggests that primary and 
metastatic melanoma tumours do converge and share common biological 
characteristics which can be very well captured using the transcriptomic data. The good 
prognosis groups of LMC classes overlapped with good prognosis groups from Lund 4-
classes and TCGA 3-classes. Similarly, the poor prognosis group LMC class 3 
overlapped with the poor prognosis group from the Lund and TCGA classes. However, 
LMC class 2, class 4 and class 6 were novel in that they could not be distinguished 
using the Lund 4-classes and TCGA 3-classes. 
The prognostic value of LMC classes was assessed in an independent cohort from 
Lund, Sweden [105]. Before this step, and to mimic real time clinical application, a 
reduced signature of the LMC classes was generated and trained in the LMC dataset. 
The reduced signature comprising 150 genes was found optimal in terms of using the 
smallest number of genes without loss of performance. 
The reduced signature maintained similar association with outcome in the Lund cohort 
as it did in the Leeds dataset. The LMC classes 1 and 5 predicted good prognosis, and 
classes 3 and 6 predicted worse prognosis in both the cohorts. The LMC class 2 and 
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class 4, which had intermediate prognosis in the Leeds dataset, showed good and 
worse in the Lund dataset respectively. When stratifying patients on the basis of AJCC 
stage, the LMC classes showed no association with survival in stage I patients from the 
Lund dataset. As shown previously, (refer to 3.3.4.1), the Lund and TCGA signatures 
showed no association with prognosis in the stage I group of the Leeds dataset and 
had different hazard ratios in stage I when compared to the whole dataset (confirmed 
as a significant interaction). Although LMC classes were prognostic in the stage I group 
of the Leeds dataset, these classes showed no association with prognosis in the stage 
I group of the Lund dataset. Unlike the Lund and TCGA signatures, the hazard ratios 
for the LMC classes were comparable in the stage I group and the whole Lund dataset. 
Therefore, the lack of association for the LMC classes in the stage I group of the Lund 
dataset could be due to limited sample size (Leeds stage I group n=233, Lund stage I 
group n=74).  
The gene expression data in the Lund cohort was generated using a different array 
platform and different pre-processing steps in comparison to Leeds data. Despite half 
of the genes in the LMC signature not being present in the Lund dataset, the LMC 
classes still demonstrated prognostic significance which supports the view that these 
classes are robust and capture meaningful biological information about melanoma 
tumours. In future, the genes that were not present on the Lund dataset will be imputed 
using the correlated genes selected from the LMC dataset. 
AJCC stage is a strong predictor for melanoma outcome, and very few additional 
variables have shown an improvement in AUC by more than 2% [44, 114]. The LMC 
classes predicted prognosis independent of the AJCC staging system. The area under 
ROC value of LMC classes was comparatively similar to the AJCC classification system 
in the LMC and Lund datasets. However, a significant improvement in AUC by 4-7% 
was observed when combining the LMC classification system with AJCC staging in 
comparison to AJCC staging system alone.   
4.4.3 Biological interpretation of the LMC classes 
The LMC classes showed distinct gene expression profiles. Previously it has been 
shown that increased immune gene expression predicts good prognosis and good 
response to treatment in melanoma [81, 104-106, 117, 166, 167].  In keeping with the 
literature, classes associated with upregulation of immune response mechanism had 
the best prognosis and classes associated with increased cell cycle mechanism and 
low immune response had the worst prognosis in the LMC data. However, the novel 
non-overlapping LMC classes (LMC classes 2, 4 and 6) showed association with 
gradient of immune gene expression, cell cycle, cell communication, and cell 
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metabolism related pathways. The LMC class 4 tumours showed low immune response 
and had poor prognosis. In contrast, LMC class 6 tumours showed evidence of 
increased immune response along with cell proliferation activity but still had worse 
prognosis in comparison to class 4 tumours. This is interesting, as LMC class 6 
highlights a class of tumours who have poor prognosis despite relatively high immune 
expression. Further work is required to understand the role of immune response in 
driving the poor prognosis of LMC class 6 tumours.   
Overall, this chapter defined six molecular classes of melanoma. The classes were 
prognostic in the whole LMC dataset and in an independent dataset from Lund. Unlike 
previous signatures, LMC class signature showed prognostic value at the AJCC stage 
I. However, due to limited sample size in the Lund cohort this finding has not yet been 
replicated. 
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Chapter 5 
Machine learning applications to predict melanoma 
prognosis using gene expression 
The objectives of this chapter are: 
Objective 9: To apply Random Forest (RF) to develop a classification model for 
predicting outcome in the LMC. The performance of the model will be assessed using 
sensitivity, specificity, and the kappa index 
Objective 10: To apply Support Vector Machine (SVM) using linear and non-linear 
kernel functions to develop classification models for predicting outcome in the LMC. 
The performance of SVM model will be compared with the RF model 
 
5.1 Introduction 
The advances in cost-effective next-generation sequencing and gene expression 
profiling techniques have brought about an era of large biomedical datasets. The 
unsupervised classification methods described previously identify novel subgroups 
by exploring distinct patterns in these datasets. Supervised methods, including 
machine learning, on the other hand mine the knowledge from known subgroups or 
outcomes and develop prediction models to classify new observations into these 
groups [110-112]. Machine learning techniques are now being widely applied to learn 
complex relationships in these datasets and forecast health and disease outcomes 
[168-170]. Previously, a comprehensive performance comparison of machine 
learning algorithms on different datasets indicated that performance was primarily 
dependent on data quality, and showed that in good quality datasets the majority of 
these algorithms made similar predictions [170].  
In this chapter two widely applied machine learning algorithms, RF and SVM, were 
used to predict prognosis in primary melanoma [171, 172]. The RF and SVM 
prediction models were generated using the training subset of LMC, and the 
performance of these models was assessed on the test subset of LMC.  
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5.2 Methods 
5.2.1 Devising a supervised classification framework 
The supervised classification framework presented in Figure 5.1 was applied to 
develop prediction models using gene expression data of LMC tumours. The gene 
expression dataset was divided into training (70%) and test (30%) sets based on 
random sampling of observations. RF and SVM algorithms were applied to the 
training set to develop prediction models across N number of iterations. The model 
with minimal classification error during training was tested on the test set (Figure 5.1). 
 
Figure 5.1 Summary of supervised classification framework  
5.2.2 Defining a dichotomous outcome in the LMC 
The prediction outcome was melanoma-specific survival (refer to section 2.4.1). The 
life table shows statistics for the numbers of deaths, people censored, people still 
alive, and number of people eligible for this analysis in the LMC (Table 5.1). The 
censored observations are patients whose cause of death was not recorded, who left 
the study or who have been followed up for a shorter time. In this study, to create a 
dichotomous outcome status, a survival time threshold was selected by aiming to 
maximise number of deaths and not losing many samples to censoring (Table 5.1). 
Therefore, melanoma-specific survival up to 6 years was chosen as a threshold. 
Patients who survived up to 6 years post-diagnosis were put in class 0 and those 
who died from their melanoma within 6 years were assigned to class 1. Patients 
Gene expression dataset
Test
Training
Minimal error
model
Predicting outcome
Classification algorithm
- Random forest
- Support vector machine
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censored before 6 years follow-up were excluded. As Table 5.1 shows, 168 patients 
have died of melanoma within 6 years post-diagnosis (class 0) while 368 were still 
alive in that period (class 1), making a total of 536 patients.  
Table 5.1 Life table of patients in LMC for 16-year time interval  
Follow up 
time (years) 
Died from 
melanoma Censored Alive 
Patients eligible 
for analysis 
1 10 3 689 699 
2 55 12 635 690 
3 95 54 553 648 
4 122 97 483 605 
5 144 128 430 574 
6 168 166 368 536 
7 174 217 311 485 
8 178 267 257 435 
9 181 322 199 380 
10 186 347 169 355 
11 187 384 131 318 
12 190 435 77 267 
13 193 483 26 219 
14 196 503 3 199 
15 196 506 0 196 
16 196 506 0 196 
5.2.3 Creating the training and test sets in LMC 
Although transcriptomic data were available for all 536 patients retained for the 
dichotomised outcome, a small number were lost to gene expression quality-control 
(refer to section 4.3.1.1), leaving 525 patients as the final dataset. This dataset was 
randomly divided into 70% and 30% referred to as training and test sets respectively. 
The genes in the training set were scaled to give each gene a mean 0 and standard 
deviation 1. The genes in test set were scaled using mean and standard deviation 
measures from the training set. 
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5.2.4 Prediction performance measures 
The prediction performance was assessed using the sensitivity, specificity, negative 
predictive value (NPV), positive predictive value (PPV) and kappa index. These 
measures are defined below in Figure 5.2 and in the equations below. 
 
Figure 5.2 Summary of reference terms when comparing actual status with 
predicted status 
 
The performance measures are calculated as follows: 
 !"#$%&%'%&( = *+(*+ + ./) (5.1) 
 
 !1"2%3%2%&( = */(*/ + .+) (5.2) 
 
 +4$%&%'"	+6"7%2&%'"	89:;"	(++8) = *+(*+ + .+) (5.3) 
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In unbalanced datasets, the accuracy is not a useful performance measure [173]. 
The Cohen’s kappa index is used for measuring the agreement between the actual 
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and predicted outcome by accounting for agreement by chance [174, 175]. This index 
is calculated as: 
 > = 1? − 1A1 − 1A  (5.6) 
where po is the observed agreement and pe is the expected agreement by chance, 
derived from the Figure 5.2 as: 
 !A = [(DEFGE)(DEFGH)]F[(GHFDH)(GEFDH)](DEFGEFDHFGH)J   (5.7) 
Kappa varies between 0 and 1, with 0 indicating no agreement, 0-0.20 a slight 
agreement, 0.21- 0.40 a fair agreement, 0.41-0.60 a moderate agreement, 0.61-0.80 
a substantial agreement, and 0.81-1.00 almost perfect agreement between the actual 
and predicted classes [174, 176]. In this thesis, kappa was used to assess the 
prediction performance of classification models. 
5.2.5 Developing classification models using Random Forest (RF) 
In 2001, L Breiman  formulated a classification method, known as the Random 
Forest, that is an aggregation of a large number of classification trees [171]. From a 
given set of training observations, a series of bootstrap datasets S of size X are drawn 
with replacement, where X is the number of observations [171, 177, 178]. For each 
bootstrap dataset, a decision tree is grown, and after S iterations the resultant S 
decision trees are collectively referred to as the Random Forest (RF). At each branch 
(node) of each tree, m input variables are randomly selected as potential predictors 
on which the bootstrap dataset is split. In each bootstrap dataset, the observations 
that were not included from the training set are referred to as the out-of-bag (OOB) 
samples.  
Each OOB sample receives a classification “vote” from every decision tree that was 
grown independently of that sample. Finally, the RF algorithm chooses a 
classification label that receives the most votes, and the proportion of trees choosing 
that classification provides a measure of certainty about the classification. Since each 
training set observation has a probability of 1-e-1 (~0.632) of being included in the 
bootstrap dataset of size X, so there will be approximately S/3 decision trees which 
will have that training observation as OOB. Similarly, a new observation can be 
classified in the same way using all the trees in the forest.  
RF algorithm is a slight modification of the bagging algorithm [178, 179]. The bagging 
algorithm generates decision trees in a similar way to the RF algorithm, but in the 
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bagging algorithm each tree node is split using a large number of predictor variables. 
Hence, if a dataset has a very strong predictor variable, the bagging algorithm will 
make the split using this variable across most of the decision trees. This may lead to 
generation of decision trees which are strongly correlated [178]. The RF algorithm 
reduces, but does not eliminate, correlation by random selection of predictor 
variables at each node. 
As described above, from a training set, S bootstrap datasets are generated and for 
each dataset the RF algorithm repeats the three following steps for constructing a 
decision tree (Figure 5.3):  
1) randomly select a predefined number (m, which is usually chosen as the square 
root of total number of predictor variables in the dataset) of variables from the data 
at each node  
2) among m variables, select the variable which gives the best data split according to 
the outcome status at that node 
3) the node is split into two daughter nodes. 
These steps are repeated until the terminal node size is just greater than a predefined 
minimum node size (Figure 5.4). The number of observations at each node is referred 
to as the node size. Figure 5.4 shows an example of a decision tree with 100 
observations. In this example, observations are divided into smaller subsets until the 
daughter node contains just over 14 observations.  
 
Figure 5.3 Workflow of RF algorithm  
Adapted from James et al. [178] 
Random Forest basic workflow
Training dataset (X observations)
Boostrap datasets S of size X
Generate a decision tree by repeating the following  steps, until the 
minimum node size is reached:
1) Randomly select m variables 
2) Among m variables, select the variable that gives the best split of the 
    dataset at that node
3) Split the node into two daughter nodes
Classify the OOB samples 
Calculate OOB error rate
Each Bootstrap dataset
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Figure 5.4 Example of a RF decision tree.  
The minimum node size is 14. 
After generating a decision tree, the prediction is made on OOB samples and a 
classification error is calculated, referred to as OOB error (Figure 5.3). The RF also 
calculates an importance measure for each predictor variable in the training set [177, 
178]. The importance measure indicates the contribution of that variable in correctly 
classifying each OOB observation. 
5.2.5.1 OOB error 
During training, the RF algorithm does not require cross-validation or a separate test 
set to evaluate the error rate of a prediction model [171, 177, 178]. The classification 
error rate is calculated during the iteration steps as follows: 
5 Each ith decision tree is constructed using observations in the bootstrap 
dataset generated from random sampling of training set. 
6 The OOB observations for the bootstrap dataset are classified using the ith 
decision tree.  
7 After S iterations, jth observation classification label is decided based on 
majority vote from the decision trees that were grown independently of this 
observation. 
n=100
n=50n=50
n=15 n=35 n=20 n=30
n=15 n=20 n=15 n=15
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8 Finally, after classifying all OOB observations, the proportion of OOB 
observations that were incorrectly classified is referred to as the OOB error of 
the RF model.  
5.2.5.2 Variable importance measure 
The RF algorithm calculates the variable importance using a permutation-based 
approach and Gini index [171, 178]. In the permutation-based approach, OOB 
samples are used to measure the prediction strength of each variable. When the ith 
tree is grown, the OOB samples are passed down this tree and a prediction accuracy 
is calculated. Values for the gth variable are permuted in the OOB set and the 
prediction accuracy is re-calculated. The difference in accuracy after permutation is 
averaged over all the trees and normalised using the standard deviation of 
differences, and this measure is used as an importance measure of the  gth variable 
[178].  
Another importance measure, decrease in Gini index, is calculated every time the 
split is made at each node. This measure does not require permutations and is 
therefore less computer-intensive and gives often similar results as the permutation-
based measure described above. The Gini index is calculated for the parent node 
and each of two daughter nodes. The Gini index is calculated as: 
 K = 1 −L1MNOMPQ  (5.8) 
where pk is the proportion of observations at each node that belong to k class and K 
are the total number of classes. Values of this index varies between 0 and 0.5. G=0 
when all observations belong to the same class and G=0.5 when all classes contain 
the same number of observations. The difference in Gini index is calculated between 
the parent and the two daughter nodes and more informative variable will associate 
with larger decrease in Gini index value. The decrease in Gini index measure for gth 
variable is calculated by averaging over all the nodes that have used that variable to 
make the split. Finally, this value is averaged over all the trees in the forest. 
5.2.5.3 Properties of RF 
RF works well with high dimensional datasets containing many predictors [178] and 
gives an unbiased estimate of the prediction error as the forest trees are grown [177]. 
It also provides an estimate of which variables are important in the classification. It 
can deal with unbalanced datasets by assigning different weights to the minority 
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classes. The algorithm also calculates a proximity matrix or “similarity” measure 
between the observations which can be used in clustering or detecting outliers in the 
dataset. Overall the random nature of selecting variables and observations for 
constructing decision tree makes this method less prone to overfitting. Like other 
methods, however, RF also has a limitation: as it uses a large number of trees for 
making prediction, it can be very computer-intensive, although this can be alleviated 
by using the Gini index instead of a permutation-based approach to assess variable 
importance. 
5.2.5.4 Application of the RF to LMC 
The RF algorithm was applied on the LMC training set to develop prediction models. 
The number of trees was set to 20,000, which means that 20,000 bootstrap datasets 
were generated. The number of predictor variables selected at each node of the 
decision tree was set as the square root of the total number of predictor variables in 
the training set (mTry=117). The variable importance was calculated using the mean 
decrease in Gini index [177]. The analysis was performed using R-packages Caret 
[180] and randomForest [181]. The generated RF model was applied on the test set 
and performance measures were calculated for both the training and test sets.  
5.2.5.5 Dealing with class imbalance using undersampling 
The training set was not balanced, i.e. the majority of observations were in class 0 
(n=253) in comparison to class 1 (n=115). To overcome class imbalance, the under-
sampling scheme was applied on the majority class [182, 183] using sampsize 
function in randomForest R-package [181]. This function randomly selected equal 
number of observations (number of observations in minority class 1 was chosen in 
this case) from both classes at each iteration to generate bootstrap datasets. The 
same parameters were used for the RF application as described in the previous 
section. 
5.2.6 Developing classification models using SVM 
The SVM is a supervised classification approach developed in the 1990s [184]. This 
technique is a non-linear extension of the maximum margin classifier, which is 
applicable when classes are linearly separable [185]. The SVM algorithm uses a 
training set to identify a hyperplane separating observations, which is used to make 
predictions on future observations.  
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5.2.6.1  Maximum Margin classifier 
The maximum margin classifier in p dimensions identifies a hyperplane in a subspace 
of p-1 dimensions that separates and maximizes the distance from the training set 
observations [178]. In the special case of a two-dimensional space the hyperplane 
would be a straight line (Figure 5.5), which is defined as the set of points X = (x1, x2) 
such that 
 3(R) = ST + SQRQ + SNRN = 0 (5.9) 
where β0,	β1,	β2, are the variable coefficients [178]. The test set observations are 
classified using the hyperplane. If f(x)=0, the test set observation lies on the line. If 
f(x) <0, the observation is classified into class 0 and if f(x) > 0 the observation is 
classified into class 1. The magnitude of f(x) gives an estimate about how far the 
observation x lies from the hyperplane. 
 
Figure 5.5 Maximum margin classifier 
Adapted from James et al. [178]. Example of a maximum margin classifier 
identified hyperplane in two dimensions. The margin is the distance from the 
solid line to the dashed lines. The distance from the three points indicated by 
the arrows are the support vectors. 
−1 0 1 2 3
−1
0
1
2
3
x1
x 2
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The smallest perpendicular distance from an observation to the hyperplane is 
referred as the margin (Figure 5.5).  
Generalizing to p dimensions, with a given a set of observations X1, X2,…, Xn Î Rp and 
associated two class labels y1, y2,…,yn Î (-1,1), the maximum margin hyperplane 
solution is given by the values of b maximizing the margin, M, such that: 
 (VWS? + SQRVQ +⋯+ SYRVYZ ≥ \, ∀	% = 1,2,3, … , # (5.10) 
The maximum margin classifier has largest marginal distance on the training set 
observations but may not have the largest margin on the test set, which is an example 
of overfitting. The maximum margin classifiers are desirable when classes are 
clearly/linearly separable. However, the need to classify all observations accurately 
can often lead to overfitting on the training data. This makes the maximum margin 
hyperplane extremely sensitive to individual observations. The support vector 
classifier is an extension of this method which can tolerate some misclassifications 
while classifying the majority of the observations accurately [178].  
5.2.6.2 Support vector classifiers 
Support vector classifiers are also called soft-margin classifiers [178]. The soft-
margin concept does not strictly adhere to classifying all the observations on the right 
side of a hyperplane; it allows some misclassifications. The solution to optimizing a 
soft-margin classifier is choosing b such that: 
 (VWST + SQRVQ +⋯+ SYRVYZ ≥ \(1 − bV) (5.11) 
for all i = 1, . . . , n, subject to the constraint: 
 LbV ≤dVPQ e (5.12) 
where C is a non-negative hyperparameter, M is the width of the margin and 
e1,e2,…,en are the (non-negative) slack variables that allow misclassification of 
observations. The slack variables provide information about location of training 
observations with reference to the margin and the hyperplane. If ei =0, the observation 
is on the correct side of hyperplane. If ei >0, the observation is on the wrong side of 
the margin. If ei >1, the observation is on the wrong side of hyperplane.  
The hyperparameter C controls the misclassification rate allowed in the training set. 
At large values of C, a narrow margin is chosen and no misclassification is tolerated; 
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the SVM algorithm tries to classify all training observations correctly [172, 186, 187]. 
For small values of C, the SVM algorithm tries to identify a hyperplane with wider 
margin and tolerates some misclassification of training set observations. 
This hyperparameter also controls bias-variance trade-off: lower C values result in a 
model with higher bias and lower variance (underfitting), and higher C results in a 
model with high variance and low bias (overfitting). This hyperparameter C is tuned 
using a k-fold cross-validation approach. The observations that lie on margins are 
known as support vectors. When C is large, many support vectors are involved in 
determining the hyperplane, while smaller values of C correspond to fewer support 
vectors. 
Like maximum margin classifiers, support vector classifiers work well with classes 
that are linearly separable by tolerating some misclassification. In case of non-linearly 
separable classes, support vector classifiers extend to higher order feature space 
functions, e.g. quadratic, cubic etc. This would require a lot computation time which 
is not practically feasible [178].  
5.2.6.3 SVM using linear kernel function 
SVM are an extension of support vector classifiers which enlarge the features space 
using kernel functions [172, 178, 188]. The idea of this is to find linear boundaries in 
the enlarged space and transform it back to non-linear boundaries in the original 
space. The solution to the support vector machine problem with a linear kernel 
involves calculation of inner product of observations, given by 
 fWgV,ghZ = LRVMRhMYMPQ  (5.13) 
where K is the kernel function which quantifies similarity between two observations gi and gj, each having p predictor variables. The equation (5.5) is the linear kernel 
function that quantifies similarity between two observations using a Pearson’s 
correlation coefficient form. 
5.2.6.4 SVM using non-linear kernel function 
The SVM kernel function can be extended to a higher order polynomial function as, 
 fWgV,ghZ = i1 +LRVMRhMYMPQ j
k
 
(5.14) 
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where d is the degree of the polynomial [178]. Using a higher order polynomial 
function provides a flexible decision boundary since it tries to fit the classifier in a 
higher dimensional space than the original feature space (Figure 5.6 left).  
The features of observation X in higher dimensional space are calculated as: 
 3(g) = S? +	LlVf(g, gV)mVPQ  (5.15) 
where f(X) is the new feature vector of X. The feature vector can be input into equation 
5.11 to calculate the predicted class of observation X. The parameter a is a vector of 
coefficients, b0 is a constant parameter and S are the total number of training set 
observations. 
Another choice apart from polynomial kernels is the radial basis kernel (Figure 5.6 
right) which takes the form, 
 fWgV,ghZ = exp i−qLWRVM−RhMZNYMPQ j (5.16) 
where g is a positive constant. The radial basis kernel calculates the Euclidean 
distance between the observations, and if the distance is large then kernel term will 
be small.  
The hyperparameter g controls a trade-off between errors due to the bias and the 
variance in the model. If a test observation X* is far from a training observation Xi 
(based on Euclidian distance), then the kernel term will be small and Xi will play no 
role in predicting the class of X*. This suggests that radial kernels have a local 
behaviour, and training observations have a larger impact on predicting the class of 
test observations closest to them (Figure 5.6 right). A further advantage of using 
kernels in comparison to support vector classifiers is that it is computationally 
efficient.  
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Figure 5.6 Polynomial kernel SVM and radial kernel SVM 
 Adapted from James et al. [178]. The figure shows an example of polynomial 
kernel SVM, with degree=3 (left) and radial Kernel SVM (right). 
5.2.6.5 k-fold Cross-validation  
Resampling-based strategies have been applied to estimate the error rate of 
prediction models [178, 189]. The two widely used resampling strategies are 
bootstrapping and cross-validation [178]. Bootstrapping proceeds by randomly re-
sampling a subset of data multiple times, with replacement, to generate several 
prediction models. The performance of these models is assessed on observations 
that were not included in the bootstrapped subset [178]. (This is the approach taken 
in RF algorithm). The cross-validation approach, on the other hand, proceeds by re-
sampling data subsets multiple times without replacement to generate prediction 
models.  
The k-fold cross-validation approach divides training data into k equal subsets 
referred to as k-folds. The first fold is held out and referred to as the validation set. 
The prediction model is generated by training on the remaining k-1 folds. The 
performance of this prediction model is assessed on the validation set. This process 
is repeated k times and each time a different set of observations are assigned to the 
validation set. The overall performance estimate of the prediction model after k 
iterations is calculated as, 
 
e8 = 1rL+"63VMVPQ  (5.17) 
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where CV is the cross-validation performance estimate across k iterations and Perfi 
is the performance estimate on the validation set at the ith iteration. The advantage 
of using the k-fold cross-validation approach is that it is not prone to overfit and it 
gives a reliable estimate of performance of the model during training [178]. 
5.2.6.6 Application of SVM to LMC 
SVM algorithm was applied on the training set using linear and non-linear kernel 
(polynomial and radial basis) functions to generate prediction models. The 
hyperparameters of these kernel functions were tuned via grid-search using a 10-fold 
cross-validation approach. The cross-validation sets were generated using stratified 
sampling which maintained the proportion of classes across the training and 
validation sets. Kappa measure was used to estimate the performance of the model 
in 10-fold cross-validation. The hyperparameter values which showed the best 
performance on the cross-validation set were selected in the final model. The 
predictions made by the final model on the left-out observations were used to 
estimate model performance during training. The final model was applied on the test 
set observations and performance measures were calculated. The analyses were 
performed using R-packages Caret [180] and kernlab [190].   
5.2.6.7 Dealing with class imbalance using under sampling  
As for the RF, the SVM model was generated using the under-sampling scheme for 
the majority class. This was done at each cross-validation iteration using down-
sampling function in Caret R-package [180]. The model was generated using a linear 
kernel, and cross-validation performance was assessed using Kappa index. The 
performance measures on the training and test sets were calculated as described in 
the previous section. The analyses were performed using R-packages Caret [180] 
and kernlab [190] . 
5.2.7 Calculating agreement between RF and SVM models 
The agreement between the RF model and SVM model was calculated using the 
Cramer’s V statistic (refer to section 3.2.6). The predictions of these two models were 
compared on the test set and the model with higher performance was further 
explored.  
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5.2.8 Generating permutation-based baseline models 
Permutation-based classification models were developed using random datasets 
generated after shuffling of class labels in the training set over 100 iterations. The 
best performing algorithm among RF and SVM was used to generate prediction 
models using each of these random datasets and the model performance was 
assessed on the test set (non-shuffled). The aim of these analyses was to produce 
average classification performance metrics from 100 random models and use them 
as baseline to appraise the real value of similar metrics obtained from the unshuffled 
training dataset. 
 
5.3 Results 
5.3.1 Training and test sets in LMC 
The gene expression dataset was divided into training and test sets after selecting 
survival cut-off at 6 years. The training set contained 70% of the observations and 
test set contained 30% of the observations. As expected, the training and test sets 
showed no significant differences in clinico-histopathological characteristics of the 
observations (Table 5.2). 
5.3.2 RF applications to predict outcome 
5.3.2.1 RF with unbalanced class design 
The RF algorithm sampled 20,000 bootstrap datasets from the training set and 
generated 20,000 decision trees that predicted outcome. The performance was 
assessed on OOB samples for each bootstrap dataset. Initially, the overall OOB error 
decreased with the addition of more decision trees, however the error stabilised after 
generating approximately 2500 trees (Figure 5.7). The OOB error was much lower 
for majority class observations (class 0, survivors) in comparison to minority class 
observations (class 1, non-survivors). Since the training set was unbalanced, the 
prediction model based on this set will be referred to as the RF model with 
unbalanced class design. 
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Table 5.2 Comparing histopathological differences between the training and 
test set  
Characteristics n(%) 
LMC dataset 
P Training 
n=368(%) 
Test  
n=157(%) 
Sex: male, 226 (43) 159 (43) 67 (43) 0.98 
Site: limbs, 222 (58) 155 (42) 67 (43) 0.98 
Ulceration status: yes 176 (34) 127 (34) 49 (31) 0.53 
AJCC stage:               I 181 (35)  124 (34) 57 (37) 
0.33                                    II 266 (51) 194 (53) 72 (47) 
                                  III 74 (14) 48 (13) 26 (17) 
Breslow (mm)  
median =2.3 (range= (0.3,20)) 2.3 (0.3, 18) 2.1 (0.5, 20) 0.20 
Age (years)  
median=57.4 (range= (20,81)) 58 (20, 81) 57 (20, 76) 0.96 
TILS:  Absent 59 (15) 37 (15) 17 (15) 
0.83 Non-Brisk 260 (72) 181 (72) 79 (70) 
Brisk 49 (13) 32 (13) 17 (15) 
 
When the RF model with unbalanced class design was applied on test set 
observations, the model had similar prediction performance when compared with the 
training set (Table 5.3). The model performance parameters indicated that the RF 
model had high specificity (0.95) and low sensitivity (0.23) on test set (Table 5.3). 
There was no difference between the NPV (0.71) and PPV (0.71) of the RF model. 
The kappa index (0.22) for the model suggested low agreement between actual and 
predicted classes (Table 5.3). 
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Figure 5.7 RF model using unbalanced class design 
RF OOB error estimate as the number of decision trees were added to the 
forest. The red line is the overall OOB error, green line shows the error rate for 
class 0 observations, and blue line shows the error rate for class 1 
observations.  
  
0.00
0.25
0.50
0.75
1.00
0 5000 10000 15000 20000
Number of trees
O
O
B 
er
ro
r
Overall
Class 0
Class 1
138 
 
Table 5.3 Summary of the RF model performance on training and test set 
Sens. is the sensitivity, spec. is the specificity, PPV is the positive predictive 
value and NPV is the negative predictive value. 
Class 
design Set Sens. Spec. PPV NPV kappa 
Unbalanced 
Training 0.19 0.95 0.62 0.72 0.17 
Test 0.23 0.95 0.71 0.71 0.22 
Balanced 
Training 0.44 0.77 0.47 0.75 0.22 
Test 0.54 0.86 0.65 0.79 0.41 
 
5.3.2.2 RF with balanced class design 
As shown above, in the unbalanced class design, the RF model predicted majority 
class (class 0) observations more accurately than minority class (class 1) 
observations. To overcome this, RF model was re-run under-sampling the majority 
class at each iteration to achieve a balanced class design. The new model showed 
a much lower OOB error for class 1 observations in comparison to the previous model 
with unbalanced design (Figure 5.7 and Figure 5.8). However, this improvement 
came at the expense of an increased error rate for class 0; the overall error rates in 
the two designs were comparable (Figure 5.7, Figure 5.8). As a result of the shift in 
error rates corresponding to class 1 and class 0, the RF model in the balanced design 
had an higher sensitivity (0.54) and lower specificity (0.86) in comparison to the RF 
model with unbalanced design (sens.= 0.23, spec.= 0.95) (Table 5.3). Compared with 
the unbalanced design, the kappa index was much higher for the balanced design 
(kappa= 0.41), and this further indicated that the balanced design RF model had 
better agreement between predicted class labels and actual class labels on the test 
set (Table 5.3). 
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Figure 5.8 RF model using balanced class design 
RF OOB error estimate using balanced class design. The red line is the overall 
OOB error, green line is the error rate for class 0, and blue line shows the error 
rate for class 1 observations. 
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5.3.3 SVM applications to predict outcome 
The SVM prediction models were generated using linear and non-linear kernel 
functions. 
5.3.3.1 SVM application using linear kernel  
The SVM algorithm using a linear kernel generated a model that achieved similar 
classification performance on both the training and test sets. The kappa index 
increased with the hyperparameter C and stabilised after C reached 0.0005. The SVM 
model with the highest average kappa index across the 10-fold cross validation 
during training was selected and was applied to the test set.  
The SVM model had comparable performance measures on the training 
(sensitivity=0.43, specificity=0.83, kappa=0.27) and test sets (sensitivity=0.46, 
specificity=0.80, kappa=0.27) (Table 5.4). Like the RF model, the SVM model had a 
high specificity (0.80) and NPV (0.75), and a low sensitivity (0.46) and PPV (0.53) 
(Table 5.4).   
The initial grid search for hyperparameter C was done for a large range of values. It 
was hypothesized that fine-tuning the grid search around the above selected C value 
may further improve the model performance. Fine-tuning the hyperparameter C value 
did not improve the performance of SVM model as this model achieved comparatively 
similar performance to the previous SVM model (Table 5.4). As before, the fine-tuned 
SVM model had a higher specificity (0.90) and NPV (0.74), than the sensitivity (0.34) 
and PPV (0.60) on the test set. 
Table 5.4 Summary of SVM model performance on training and test set 
Sens. is the sensitivity, spec. is the specificity, PPV is the positive predictive 
value and NPV is the negative predictive value. 
SVM Set Sens. Spec. PPV NPV kappa 
Wide range C 
Training 0.43 0.83 0.53 0.76 0.27 
Test 0.46 0.80 0.53 0.75 0.27 
Fine-tuned C 
Training 0.38 0.86 0.56 0.75 0.26 
Test 0.34 0.90 0.60 0.74 0.27 
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5.3.3.2 SVM application using non-linear kernel  
Overall, the SVM algorithm with non-linear kernel functions (radial and polynomial) 
performed poorly in predicting outcome (Table 5.5). The SVM radial kernel function 
generated a majority class model with low sensitivity (0) and high specificity (1) and 
a kappa index of 0 in both training and test sets (Table 5.5). The SVM algorithm with 
a polynomial kernel function generated a model with low sensitivity (0.15) and high 
specificity (0.93) (Table 5.5) in the test set with a kappa index of 0.10, a PPV of 0.53 
and NPV of 0.69 (Table 5.5). 
Table 5.5 Summary of SVM non-linear kernel functions on training and test set 
Sens. is the sensitivity, spec. is the specificity, PPV is the positive predictive 
value and NPV is the negative predictive value. 
Kernel Set Sens. Spec. PPV NPV kappa 
SVM radial 
Training 0 1 NaN 0.66 0 
Test 0 1 NaN 0.69 0 
SVM poly 
Training 0.24 0.95 0.68 0.73 0.23 
Test 0.15 0.93 0.53 0.69 0.10 
5.3.4 SVM using balanced class design 
The SVM models described above were generated using unbalanced classes. Like 
RF, it was hypothesised that under-sampling the majority class to achieve a balanced 
class design may further improve the model performance.  
Unlike RF, using balanced class design did not generate a better performing SVM 
model. This newly generated SVM model had similar performance to the SVM model 
with unbalanced class design. The SVM model with balanced design had similar 
kappa index on the test set (kappa=0.26) when compared with SVM model with 
unbalanced design (kappa=0.27) (Table 5.4, Table 5.6). However, the new model 
had improved sensitivity (0.61) in comparison to the model with unbalanced design 
(sensitivity=0.46) on the test set (Table 5.4, Table 5.6), at the expense of a decreased 
specificity (0.67 in the balanced design, 0.80 in the unbalanced design) (Table 5.4, 
Table 5.6).  
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Table 5.6 Summary of SVM linear kernel model after under sampling the 
majority class 
Sens. is the sensitivity, spec. is the specificity, PPV is the positive predictive 
value and NPV is the negative predictive value. 
Set Sens. Spec. PPV NPV Kappa 
Training 0.63 0.66 0.47 0.80 0.28 
Test 0.61 0.67 0.48 0.78 0.26 
5.3.5 Comparing RF and SVM predictions 
The Cramer’s V statistic (0.71) indicated good agreement between predictions from 
the RF and SVM classification models (Table 5.7). The RF and SVM models were 
generated using the balanced class design approach (refer to 5.3.2.2 and 5.3.4). All 
the observations classified by RF in class 1 were also classified in same class by 
SVM model (Table 5.7). Seventy nine percent of observations classified in class 0 by 
RF were classified also in the same class by SVM and rest 21% of observation 
showed different class labels (Table 5.7). Overall both the methods made consistent 
predictions on test set but the RF model (kappa=0.41) had slightly better performance 
when compared with SVM model (kappa=0.27) (Table 5.6). 
The RF and SVM models classified 90 observations as class 0 (survivors, n=90) and 
78% of these observations had survival time greater than 6 years (Figure 5.9A). The 
observations that were classified as class 1 (non-survivors, n=43) by both the 
models, 65% experienced death from melanoma within 6 years (Figure 5.9B).  
Among 24 disagreeing observations, 20 had survived for more than 6 years (Figure 
5.9). The RF model predicted these 24 observations as survivors and the prediction 
was correct for 20 cases and incorrect for just 4 cases. SVM model on the other hand 
predicted these 24 observations as non-survivors and the prediction was correct only 
for 4 observations and was incorrect for 20 observations. Overall, these results 
highlight that RF model had higher classification performance than the SVM model 
on the test set.  
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Figure 5.9 Comparing RF and SVM predictions  
Survival time of the observations classified in the same classes by RF and SVM, 
i.e. (A) class 0, (B) class 1. (C) Survival time of the observations which had 
disagreement between their predictions by RF and SVM models. The red line 
indicates the survival cut-off at 6 years. 
Table 5.7 Comparing overlap between RF model and SVM model prediction on 
test set 
Test set 
RF 
Class 1 n(%) Class 0 n(%) 
SVM 
Class 1 43 (100) 24 (21) 
Class 0 0 90 (79) 
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5.3.6 Permutation-based RF model 
As shown in previous section, the RF algorithm had higher performance than the 
SVM algorithm. Therefore, RF algorithm was selected and applied to 100 random 
datasets generated by permuting class labels in the training set. As in the real data, 
the prediction in these random datasets showed a higher specificity than sensitivity 
(Figure 5.10). Over 100 iterations, the median specificity, sensitivity, and kappa index 
were respectively 0.89, 0.09 and -0.01 (Figure 5.10).  
The non-permuted RF model (refer to section 5.3.2.2) had higher sensitivity and 
kappa in comparison to the permuted models. Across the 100 permuted datasets, 
none of the models showed a kappa index and sensitivity value higher than 0.41 and 
0.54 respectively (Figure 5.10). However, the median specificity of the permuted 
model was sometimes higher than the non-permuted RF model. This analysis 
therefore shows that specificity is a poor performance metric for the analysis of our 
dataset; sensitivity and the kappa index are good metrics as they are close to 0 on 
average in random data.  
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Figure 5.10 Performance summary of the permuted model 
Permuted model performance parameters (A) sensitivity (B) specificity and (C) 
kappa on the test set over 100 iterations of permutation based RF model. The 
red line is the median value of performance measure for permuted models and 
blue line represents the observed performance measure for the non-permuted 
RF model.   
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5.4 Discussion 
Machine learning applications have shown great promise in improving diagnosis and 
predicting prognosis of cancer patients [109, 111, 112, 168, 191, 192]. Recently, it 
was shown that a machine learning approach achieved better diagnostic 
performance than a group of trained dermatologists in detecting melanoma from 
dermoscopic images [169].  
The main aim of this chapter was to test whether transcriptomic information from the 
tumours of patients from LMC can predict clinical outcome (death from melanoma 
within 6 years). To this end, the LMC data were partitioned into a training and test set 
to respectively develop and evaluate two machine learning classification methods, 
RF and SVM. The random data splitting meant that the two obtained subsets had no 
difference between them in terms of clinical characteristics. The prediction outcome 
was defined as surviving up to 6 years, as the majority of patients who have 
melanoma metastasis and die from it, normally do so very early after the initial 
diagnosis [193].  
One major advantage of using the RF is that the use of OOB samples to evaluate 
performance in the training step yields an unbiased estimate of the model 
performance [171]. The unbiasedness means that the results observed in the training 
dataset are reproduced in the test set. This was confirmed in the LMC as the RF 
model showed similar performance measures in both training and test sets (Table 
5.3). The RF model predicted the majority class observations better than the minority 
class observations, i.e. had a higher specificity than the sensitivity. This class-
imbalance is a well-recognized problem in supervised classification [173, 183, 194]. 
Several methods were proposed to overcome this issue and have shown some 
improvement in performance of machine learning algorithms [173, 182, 183, 194-
196]. Among the available methods, over-sampling the minority class and synthetic 
minority over-sampling technique are more prone to overfit the training data, and 
hence the majority class was under-sampled (less prone to overfitting) to achieve 
balanced class design. Applying an under-sampling approach resulted in improved 
sensitivity and kappa index of RF model. The new RF model with balanced design 
had a lower OOB error for the minority class in comparison to the unbalanced design. 
The SVM approach identifies a hyperplane using linear or non-linear kernel functions 
[184]. The hyperparameters in SVM were tuned using 10-fold cross validation and 
the selected parameter value was used in the final SVM model [186]. In LMC dataset, 
the SVM with linear kernel outperformed SVM with non-linear kernel functions. In 
particular, the SVM model with a radial kernel showed no utility at all as it classified 
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all observations in the majority class (maximum specificity, zero sensitivity), which is 
equivalent to the best guess without using the available transcriptomic data. The 
linear SVM outperformed the non-linear and its performance on the training set was 
comparable to the test set. The initial grid search for hyperparameter C of the linear 
kernel function was done on a large interval and its fine-tuning on the grid search 
around the previously selected C value did not improve prediction performance of the 
SVM model.  
Like the RF model with unbalanced design, the SVM model also had a much higher 
specificity than sensitivity. Undersampling the majority class to overcome class 
imbalance brought an improvement to the sensitivity of the SVM model but this 
improvement came at a greater cost to the specificity. The kappa value however 
remained unchanged, suggesting a similar level of agreement overall between actual 
and predicted class labels with and without undersampling.  
Shi et al. compared several machine learning methods by generating more than 
30,000 models using different microarray datasets and assessing their performances 
on independent test sets [170]. They found none of the methods to consistently 
outperform all the others. The prediction performance was observed to be mainly 
dependent on the quality of the microarray data (i.e. pre-processing) and prediction 
endpoint variable. Overall, in good quality microarray datasets, the majority of 
methods made similar predictions [170]. In our analysis of the LMC, the RF and SVM 
models made similar predictions on the test dataset. However, for the observations 
with conflicting predictions, the RF model showed higher classification accuracy and 
classified most of the observation into the actual classes. 
Transcriptomic information of a patient’s tumour has been demonstrated to be of 
prognostic significance [105, 106, 114, 116, 197]. To assess whether the generated 
RF model has captured truly prognostic information from the dataset, several null 
models were generated after randomly shuffling training set observations. As 
expected, the RF model had consistently a better performance (higher sensitivity and 
kappa index) than the permuted RF models. The permuted models had high 
specificity and low sensitivity and kappa, which suggests that these models are likely 
to misclassify non-survivors as survivors. It also hints that higher sensitivity and 
higher kappa are good measures to assess the performance of prediction models in 
LMC.  
Overall, these results provide evidence that machine learning methods can predict 
prognosis of a patient using transcriptomic information from the patient’s tumour. The 
limitation of these approaches is that although training and test sets were scaled 
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independently, some dependency still lies between the two sets as the samples were 
profiled using the same technique and were pre-processed together. In next chapter, 
these issues will be addressed by pursuing model validation on an independently 
generated dataset. 
In summary, RF and SVM algorithms generated models that predicted the patient 
prognosis in the LMC. Undersampling to achieve balanced class design further 
improved the performance of RF but not the SVM model. Overall, the RF and SVM 
made comparable predictions on the test dataset. In the next chapter, only the RF 
will be further explored, both because this method performed better as a classifier 
and because it provides an estimate of the importance of each gene in the model, 
while SVM works as “black box” in nature and generates very limited output. In what 
is presented so far, the RF model was based on gene expression data alone. The 
next step is to combine gene expression data and clinical information to see if an 
improvement is possible. The performance of the combined model will be validated 
on an independent dataset from Lund, Sweden. 
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Chapter 6 
Combining clinical information and gene expression 
for predicting outcome and independent validation 
The objectives of this chapter are: 
Objective 11: To generate a RF model after combining clinical information and gene 
expression data and compare its performance with a clinical information based RF 
model 
Objective 12: To generate a refined RF model by performing variable selection 
Hypothesis: The refined RF model using top predictor genes will predict prognosis 
similarly to the model using all genes 
Objective 13: To validate the prognostic value of the refined RF on an independent 
dataset of primary melanoma from Lund, Sweden  
Objective 14: Biological interpretation of the refined model using pathway 
enrichment analysis 
 
6.1 Introduction 
Machine learning approaches like Random Forest (RF) and Support Vector 
Machines (SVM) are black-box in nature; they allow the user a very limited control 
over the steps involved in making predictions. The RF algorithm partly overcomes 
this issue by calculating a Gini index for each predictor variable in the model (refer to 
5.2.5.2). This importance measure can be used to assess the contribution of each 
variable included in the model. The prediction models previously generated using RF 
with a balanced class design will be further explored in this chapter (refer to 5.3.2.2).  
In clinical settings, AJCC staging system is a widely used procedure for predicting 
prognosis and deciding treatment protocols [44]. However it predicts outcome 
accurately only for 68% of the population (AUC:0.68) [114]. Therefore, it is of interest 
to develop better prognostic biomarkers which can complement AJCC staging in 
clinical settings. Other clinical variables, such as age at diagnosis, sex and body site 
of tumour have been shown to be associated with melanoma prognosis [42]. These 
variables independently predicted melanoma-specific survival in the LMC (refer to 
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4.3.3.1). Hence, a baseline RF model was generated by jointly analysing the clinical 
variables described above.  
In this chapter, a RF model will be constructed after combining clinical variable 
information and gene expression data. The performance of this model will be 
compared with the baseline clinical variable based RF model. To maximise clinical 
utility, a refined model with a limited number of predictor variables will be generated. 
The refined model will be validated by comparing its performance with the baseline 
model in an independent cohort of primary melanoma from Lund, Sweden (refer to 
section 4.2.5.1). To get biological insights into the decision-making process of the 
refined RF model, the predictor genes included in this model will be tested for their 
overrepresentation in curated biological pathways. Finally, to compare the 
unsupervised clustering signature with the supervised classification signature, the six 
LMC classes defined in chapter 4 will be compared with the refined RF model 
classification. 
 
6.2 Methods 
6.2.1 Using clinical information to generate RF model 
The RF model was generated using clinical variable information of melanoma 
tumours in LMC. The clinical variables included in the model were AJCC stage, age 
at diagnosis, sex and body site of tumour. AJCC stage was treated as an ordered 
categorical variable, age at diagnosis was treated as a continuous variable, sex was 
coded as 0 for females and 1 for males, and body site of tumour (limbs, trunk, head 
and neck, rare) was converted into a series of dummy variables using model.matrix 
function in the R base package. The dummy variables form the main variable was 
generated by assigning its categorical levels a value of 1 if true and 0 if false. In this 
case, from site of tumour, four new variables were generated named as limbs, trunk, 
head and neck, and rare. These variables were initialised with a value of 1 if true for 
a patient or 0 if not. 
As described previously, the RF model was generated using a balanced class design 
approach (refer to 5.2.5.5), the number of trees was set to 500 and the number of 
variables selected for consideration at each node  (mTry) was 2. The RF analysis 
was performed using R-packages randomForest and Caret [180, 181]. The error for 
OOB samples was plotted using R-package ggplot2 [130]. The performance of this 
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model was assessed on the test set using previously described performance 
measures (refer to 5.2.4). 
Since clinical variables Breslow thickness and ulceration are included in the definition 
of AJCC stage [44], these variables were not included in the model. Four 
observations in the dataset had missing information on AJCC stage, and these 
samples were excluded. TILs and mitotic rate had more than 21% (n=115) and 14% 
(n=74) of missing values respectively. Hence, these variables were not included in 
the analysis.  
6.2.2 Removing clinical information from the gene expression 
To remove clinical variable information from gene expression data, a linear 
regression approach was used with the gene expression as the outcome variable 
(equation (6.1)). The regression approach assumes a linear relationship between the 
outcome variable and the predictors. The linear regression line is represented as: 
 K"#"V = SV? + SVQRQ + SVNRN +⋯+ SVYRY + sV (6.1) 
where Genei is a vector of expression values of ith gene (outcome variable) and x is a 
vector of p predictor variables (e.g. x1 for AJCC stage, x2 for age, x3 for sex ….). bs 
are the parameter coefficients for predictor variables and are different for different 
genes. bo is the intercept and sV	is the error term in the model or the residual, i.e. the 
difference between the actual outcomes and those predicted by the model. All 
parameters are estimated using a least squares approach which tries to minimise the 
sum of squared errors. Residuals are assumed to be normally distributed with mean 
zero and are independent of the predictor variables.  
The linear regression was performed using clinical variables as independent 
predictors and gene expression data as the outcome variable. The residual values 
for each gene from the linear regression were used as input data in the RF algorithm. 
A new RF analysis was conducted using the same parameters as described 
previously (refer to the 5.2.5.5), and the performance measures were calculated for 
both training and test sets (refer to 5.2.4). 
6.2.3 Combining clinical information and gene expression 
The RF model was generated after combining clinical variable information and gene 
expression residuals for LMC patients. The clinical variables used in the previous 
section were included in this analysis. During training, at each node the predictor 
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variables were selected such that the selected variable pool included all the clinical 
variables along with randomly selected genes. The variable from the selected pool 
that gave the best split at the node was chosen to make the split into two daughter 
nodes. The number of randomly selected genes was decided based on the value of 
mTry parameter which was set to 117 (square root of total number of gene). The 
number of trees was fixed at 20,000. 
 In keeping with previous analyses, the RF model was generated using a balanced 
class design by selecting an equal proportion of samples from both classes at each 
iteration (refer to 5.2.5.5). During training, the error rate of the RF model was 
calculated on OOB samples, and final performance was assessed on the test set. 
This analysis was done using R-packages Caret [180] and ranger [198]. The ranger 
R-package contains ranger function, which performs fast implementation of the RF 
algorithm and also forces selection of a desired set of variables at each node of the 
decision tree (clinical variables in this instance). 
6.2.4 Refining the RF model via variable selection 
The RF model developed in the previous chapter was generated using ~13,000 
genes (refer to 5.2.5.5). In clinical settings however, it may not be practical to use a 
biomarker/signature based on such a large number of genes. To mitigate this, smaller 
gene sets of varying size were selected based on Gini index (Figure 6.1). The top n 
(10, 50,100, 200, 400, 800, 1600 and all genes) ranked genes were selected and 
combined with the clinical variables to generate several RF models (Table 6.1). 
These RF models were built using the same training set, and the performances of 
these models were compared on the test set. The RF model with best performance 
was retained as the final refined model. The analysis was done using R-packages 
Caret [180] and ranger [198]. 
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Figure 6.1 Gini importance index  
Plot showing Gini importance measure for each gene in the RF model, x-axis 
is the gene index and y-axis is the Gini index for each gene. The red line shown 
the importance measure of the 1600th gene. 
Table 6.1 Refining the RF model by selecting variable number of genes, mTry, 
and number of trees 
Number of genes mTry Number of trees 
10 3 100 
50 7 700 
100 10 1000 
200 14 2000 
400 20 4000 
800 29 5000 
1600 40 5000 
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6.2.5 ROC analysis for the refined RF model 
The prognostic value of the refined RF model was compared with the baseline RF 
model (based on clinical variables alone) using ROC analysis. Previously, for each 
sample logistic regression was used for calculating probabilities of MSS up to 6 years 
(refer to 4.2.6). In this analysis, for each sample, the proportion of votes received that 
classified in class 0 in the refined RF and baseline RF models were used in place of 
probability of surviving up to six years. The comparison was drawn for four RF models 
described as follows:  
1) Baseline RF model using clinical variable alone; 
2) RF model based on gene expression alone (refer to 5.2.5.5); 
3) Combined RF model; 
4) The final refined RF model. 
ROC curves were plotted for each of these models and AUCs were calculated. The 
test of AUC improvement in nested models was performed using DeLong’s test (refer 
to 4.2.6). These analyses were performed using R-packages ROCR, plotROC, pROC 
and ggplot2 [130, 149, 150, 199]. 
6.2.6  Application of the refined RF model on independent dataset 
The prognostic value of the refined RF model was validated on an independent 
dataset of primary melanomas from Lund, Sweden (refer to 4.2.5.1). Clinical 
variables including AJCC stage, sex, age at diagnosis and tumour site were provided 
upon request by Prof. Göran Jonsson and Dr. Martin Lauss (collaborators at Lund 
University). Some of the tumour samples had missing AJCC stage value (n=76). For 
a subset of these (n=49), the AJCC stage was calculated manually based on the 
guidelines of the 7th edition of AJCC staging system [44], using the records of Breslow 
thickness and ulceration status of tumours. This AJCC edition had been used for all 
other samples in that dataset, as was the case also in the LMC. 
The tumour samples for which AJCC stage could not be calculated were excluded 
from the analysis (n=37). Finally, the dataset had gene expression values of 186 
tumours. Since cause of death was not recorded in the Lund cohort, death from any 
cause (deaths due to melanoma and other causes) and melanoma relapse before 6 
years were used as outcomes. The cut-off at six years was consistent with the LMC, 
and samples were classified as class 0 or class 1, henceforth referred to as actual 
class labels.
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In keeping with previous chapters, gene expression data from the Lund cohort was 
standardised to give each gene mean 0 and standard deviation 1. The refined RF 
model was applied to the Lund dataset similarly to how it was applied to the LMC test 
set. The refined RF model stored after previous analyses was re-loaded in the R 
environment for application to the Lund dataset, and Lund samples were classified 
into class 0 or class 1. The predicted class labels were compared to the actual class 
labels and performance measures were calculated (refer to 5.2.4). The baseline RF 
model (refer to 6.2.1) was also applied on the Lund dataset, and the performance 
was compared with the refined RF model (based on gene expression and clinical 
variables). As before, these analyses were done using R-package ranger [198]. 
The prognostic value of the refined RF model was compared with the baseline RF 
model using ROC analyses. Similar to section 6.2.5, the proportion of votes received 
classifying in class 0 was used as a probability measure. The outcome measures 
were death from any cause and melanoma relapse at 6 years. The ROC curves for 
both the RF models were plotted, and AUC was calculated for each ROC curve. The 
analysis was performed using R-packages ROCR, plotROC, pROC and ggplot2 [130, 
149, 150, 199]. The statistical comparison of AUC in ROC was performed using 
DeLong’s test (refer to 4.2.6). 
6.2.7 Pathway enrichment of predictor genes in the refined RF 
model 
Pathway enrichment analysis was performed for the selected predictor genes in the 
refined RF model. The genes were input into ReatcomeFIViz, a tool designed to 
identify associated biological pathways. The pathways were visualised using R-
packages wordcloud [200] and RColorBrewer [201]. 
6.2.8 Comparison between the LMC classes and the refined RF 
model predictions  
In this thesis, the two final gene signatures developed are: the refined LMC class 
signature from the unsupervised clustering (refer to 4.3.5.1) and the refined RF model 
signature after combining clinical variable information and gene expression data from 
the supervised classification model. To compare these signatures, their classification 
was tabulated against the actual outcome. During supervised classification, the 
training and test set samples were classified into the four categories, true positive 
(TP), true negative (TN), false positive (FP), and false negative (FN). The bar plot 
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comparing samples classified in the four categories with the LMC classes was 
generated using R-package ggplot2 [130]. 
 
6.3 Results 
6.3.1 Baseline RF model using clinical information alone 
To evaluate the combined prognostic value of the clinical variables, an RF model was 
generated using AJCC stage, sex, site of tumour and age at diagnosis. During the 
training stage, the RF model had a lower OOB error for class 0 observations in 
comparison to class 1 observations (Figure 6.2). The overall OOB error stabilised 
after generating 200 decision trees (Figure 6.2). 
The performance of the model was comparable on both training and test sets. The 
RF model had higher specificity in both training (0.68) and test (0.71) sets than the 
sensitivity (training:0.63, test:0.63) (Table 6.2). This also translated in a higher NPV 
than the PPV in both training and test sets (Table 6.2). The kappa value was slightly 
higher in the test set (0.32) in comparison to training set (0.28) indicating better 
agreement between actual and predicted class labels in the test set (Table 6.2). 
Table 6.2 Summary of clinical variable based RF model performance  
Set Sensitivity Specificity PPV NPV kappa 
Training 0.63 0.68 0.48 0.80 0.28 
Test 0.63 0.71 0.50 0.81 0.32 
 
6.3.2 Prediction after removing clinical information from gene 
expression  
Gene expression data has shown to be associated with prognostic clinical variables 
such as stage of tumour, sex and age of the patient. To test whether gene expression 
data can independently predict prognosis after removing clinical information from the 
expression data, a linear regression model was fitted for each gene using clinical 
variables as predictors in the multivariable model. A strong correlation was found 
between gene expression and clinical variables as illustrated in Figure 6.3. Among 
the 13,688 genes tested, the clinical variables were a significant predictor of gene 
expression for approximately 5500 genes (FDR adjusted p <0.05) in the multi-
158 
 
variable model (Figure 6.3A). From the linear regression model, residual values for 
each gene were extracted. Figure 6.3B shows an example of a gene that has different 
expression value across males and females but, as expected, the residuals were no 
longer associated with sex.  
 
 
 
Figure 6.2 Clinical variable based RF model. 
RF model OOB error estimates as the decision trees were added to the forest. 
The red line is the overall OOB error, the green line is the error rate for class 0, 
and the blue line is the error rate for class 1. 
0.00
0.25
0.50
0.75
1.00
0 100 200 300 400 500
Number of trees
O
O
B
 e
rr
or
Overall
Class 0
Class 1
159 
 
 
Figure 6.3 Gene expression association with clinical predictors of melanoma.  
(A) Histogram plot of FDR adjusted P values from the linear regression model 
predicting gene expression using clinical variables. Red line shows the adj. P 
value (FDR) cut off at <0.05. (B) Example boxplot showing expression values 
of a Y-linked gene USP9Y across males and females (left) and the same 
distribution when applied to the gene expression residuals values after 
adjusting for clinical variables in linear regression. P value was calculated using 
Mann-Whitney/Wilcoxon test. 
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6.3.2.1 RF model from using adjusted gene expression 
To test whether gene expression can predict outcome after adjusting for clinical 
information, a RF model was generated using residual values as described above. 
To be consistent with previous analyses (refer to 5.2.5.5), the RF model was 
generated using a balanced class design. Similar to previous results, the RF model 
had a higher OOB error rate in class 1 than in class 0 during training (Figure 6.4). 
The overall error rate of the RF model (combining the 2 classes) stabilised after 
adding 5000 trees to the model (Figure 6.4). 
The model had a higher specificity in both training (0.81) and test sets (0.78) than 
sensitivity (training: 0.32, test: 0.49), and consequently, a higher NPV than PPV in 
both the sets (Table 6.3). When comparing training and test sets, the RF model had 
higher performance on the test set (kappa=0.27 in the test set and 0.14 in the training 
set) (Table 6.3). 
 
Figure 6.4 RF model from adjusted gene expression 
RF model OOB error estimate as more decision trees were added to the forest. 
The red line is the overall OOB error, green line is the error rate for class 0 
observations, and blue line is the error rate for class 1 observations. 
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Table 6.3 Summary of residual based RF model performance  
Set Sensitivity Specificity PPV NPV kappa 
Training 0.32 0.81 0.43 0.72 0.14 
Test 0.49 0.78 0.50 0.77 0.27 
6.3.3 RF model from combining clinical information and gene 
expression 
As shown earlier, even after adjusting for clinical variable information, the gene 
expression demonstrated prognostic significance as the resultant RF model 
predicted outcome on the test set. Hence it was hypothesised that combining clinical 
variable information and gene expression data may lead to generation of a RF model 
with improved performance in comparison to clinical variables alone.  
As expected, the RF model from combining gene expression data and clinical 
variables (combined RF model) (kappa=0.37) had higher performance on the test set 
in comparison to the RF model from clinical variables alone (kappa=0.32). Overall 
the combined RF model had higher specificity in both training (0.82) and test sets 
(0.76) compared to the sensitivity (training:0.50, test:0.63) and a higher NPV than 
PPV; indicating that the model predicted class 0 observations more accurately than 
class 1 observations. The kappa values were similar in both training (0.33) and test 
sets (0.37) (Table 6.4). 
The combined RF model (sens.=0.50, spec=0.82, kappa=0.33) also had higher 
performance on the training set in comparison to the gene expression based model 
developed in chapter 5 (sens.=0.44, spec.=0.77, kappa=0.22) (Table 6.4, refer to 
5.2.5.5). However, performance of the combined RF model (sens.=0.63, spec.=0.76, 
kappa=0.37) was slightly lower than the gene expression based model (sens.=0.54, 
spec.=0.86, kappa=0.41) on the test set.  
Table 6.4 Summary of combined RF model performance  
Set Sensitivity Specificity PPV NPV kappa 
Training 0.50 0.82 0.53 0.78 0.33 
Test 0.63 0.76 0.54 0.82 0.37 
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6.3.4 Variable selection to generate the final refined RF model 
The combined RF model was based on ~13 thousand gene expression values and 
four clinical variables. To improve clinical utility of the RF model, variable selection 
was performed on the gene expression dataset. The top n genes (10, 50, 100, 200, 
400, 800, 1600) were selected based on Gini index and new RF models were 
generated for each of the gene sets (total 7 models). Clinical data was integrated into 
gene expression as described above (refer to 6.2.3).  
Interestingly, reducing the number of genes did not result in a reduced performance 
as the RF models with 10, 50, 100, 200, 400, 800 and 1600 genes along with clinical 
variables had a better kappa index than all genes- and clinical variable-based RF 
model (Table 6.5).  
The RF models with reduced gene sets had comparable kappa values on the test set 
indicating similar levels of agreement between actual and predicted class labels 
(Table 6.5). All the reduced signatures (gene sets) RF models maintained a higher 
specificity than sensitivity, as in all previous analyses, but the difference between 
these two metrics was much lower in these models in comparison to RF models 
based on all genes or referred to as the combined RF model previously. These 
reduced models maintained a higher NPV than PPV, consistent with previous results. 
The RF model with 200 genes had the highest kappa value in both training and test 
sets (Table 6.5) and was selected as the “final refined RF model” for further analyses. 
 
  
Table 6.5 Summary performance of RF models generated after selection of genes based on Gini index measure 
 ClinVar refers to the clinical variables.  
Set Gene set Sensitivity Specificity PPV NPV kappa 
Training 
10 genes + ClinVar 0.61 0.81 0.60 0.81 0.42 
50 genes + ClinVar 0.59 0.76 0.53 0.80 0.34 
100 genes + ClinVar 0.59 0.78 0.56 0.80 0.36 
200 genes + ClinVar 0.59 0.82 0.61 0.81 0.42 
400 genes + ClinVar 0.58 0.82 0.60 0.81 0.40 
800 genes + ClinVar 0.59 0.82 0.60 0.81 0.41 
1600 genes + ClinVar 0.58 0.81 0.58 0.80 0.39 
All genes 0.50 0.82 0.53 0.78 0.33 
Test 
10 genes + ClinVar 0.71 0.75 0.56 0.85 0.43 
50 genes + ClinVar 0.69 0.78 0.59 0.85 0.45 
100 genes + ClinVar 0.71 0.76 0.57 0.85 0.44 
200 genes + ClinVar 0.69 0.79 0.60 0.85 0.46 
400 genes + ClinVar 0.67 0.77 0.57 0.84 0.42 
800 genes + ClinVar 0.67 0.75 0.55 0.83 0.40 
1600 genes + ClinVar 0.67 0.75 0.55 0.83 0.40 
All genes 0.63 0.76 0.54 0.82 0.37 
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6.3.5 ROC analysis of the final refined RF model 
A ROC analysis was performed to compare the prognostic value of the final refined 
RF model with three other models on the training and test sets of LMC. Overall, the 
four RF models compared were: 
1) Baseline RF model using clinical variable alone (refer to 6.3.1) 
2) RF model based on gene expression alone (refer to 5.2.5.5)  
3) Combined RF model (refer to 6.3.3) 
4) The final refined RF model (refer to 6.3.4).   
 
On the training set, the final refined RF model (0.77) had the highest AUC in 
comparison to the other three models (baseline clinical variable based, gene 
expression based, and combined RF models) (Figure 6.5A). This observation was 
consistent on the test set as the final refined RF model (0.83) maintained the highest 
AUC value in comparison to the other three models (Figure 6.5B). Among the three 
other models, the combined RF model (0.71) had slightly better performance than 
the baseline clinical variable based RF model (0.70) and had much better 
performance than the gene expression based RF model (0.66) on the training set 
(Figure 6.5A). On the test set, the combined RF model and the gene expression RF 
model had same AUC (0.78) and AUC for the baseline clinical variable RF model 
(0.73) was much lower (Figure 6.5B). 
Overall, the final refined RF model consistently outperformed the other three models 
in both training and test sets (Figure 6.5). Moreover, the 7% (training) and 10% (test) 
increase in the AUC of the final refined model was statistically significant when 
compared with the baseline RF model using clinical variables alone (train: P=0.03 , 
test: P=0.02) (Figure 6.5).  
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Figure 6.5  Comparison of the refined RF model with baseline RF models 
ROC curves of the RF models on (A) training and (B) test sets. ClinVar refers 
to the clinical variables model, All genes refers to the genome-wide gene 
expression based model, ClinVar+ All genes is the model including clinical 
variables and genome-wide gene expression, and ClinVar + 200 genes is the 
final refined model.  
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6.3.6 Validating prognostic significance of the refined RF model 
on Lund dataset 
To validate the prognostic significance of the refined RF model, it was applied to the 
Lund primary melanoma dataset, using the same clinical variables as used in the 
LMC dataset. Among 200 predictor genes of the refined RF model, 96 genes were 
not present in the Lund dataset. The missing genes were initialised with 0 value in 
the Lund data. Since cause of death was not recorded in the Lund dataset, death 
from any cause and melanoma relapse at 6 years were used as alternative outcomes. 
For both these outcomes, the refined RF model predicted outcome in the Lund 
dataset (Table 6.6). Similarly to the LMC dataset, this model had higher specificity 
(0.86-0.88) than sensitivity (0.54-0.57) and higher NPV (0.81) than PPV (0.63-0.69) 
in the Lund dataset (Table 6.6). The kappa index was comparable to what was 
observed in the LMC test set (Table 6.6).  
The ROC analysis confirmed the model’s prognostic value in this new dataset (Figure 
6.6). For melanoma relapse before 6 years endpoint, the increase in the AUC for the 
refined RF model was 4% when compared with using clinical variables alone, 
although it failed to reach statistical significance (P=0.2). The AUC improvement was 
more modest for deaths from any cause before 6 years post diagnosis (1% increase, 
P=0.7, Figure 6.6B).  
Table 6.6 Summary of refined RF model performance on the Lund dataset 
Event at 6 years Sensitivity Specificity PPV NPV Kappa 
Relapse 0.57 0.88 0.69 0.81 0.47 
Death from any cause 0.54 0.86 0.63 0.81 0.42 
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Figure 6.6 ROC analysis of the RF models in the Lund dataset  
The outcome was (A) relapse and (B) deaths within 6 years post diagnosis. 
ClinVar refers to the baseline model and ClinVar + 200 genes is the final refined 
model.  
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6.3.7 Biological interpretation of the refined RF model  
To understand the biology behind the refined RF model predictions, a pathway 
enrichment analysis was performed on the 200 predictor genes of the refined RF 
model (Appendix I, Table 8.14). The enrichment analysis identified association with 
pathways linked to DNA damage repair (e.g. Fanconi anemia pathway),  cell cycle 
and cell proliferation (e.g. meiotic recombination, mitotic prometaphase, mitotic 
metaphase and anaphase, mitochondrial translation), PIK3-Akt signaling, and 
generic terms like pathways in cancer, small cell lung cancer, Parkinson’s disease 
and Alzheimer’s disease etc (Figure 6.7).  
 
Figure 6.7 Biological interpretation of the refined RF model. 
Summary of biological pathways enriched in the top 200 genes from the RF 
model. All the pathways with FDR <0.1 were selected. The text size in the figure 
is based on FDR value associated with each pathway i.e. more significant 
pathways are shown in a larger font. (K)- refers to entry from KEGG database, 
N- NCBI database and R- Reactome database. 
6.3.8 The LMC class association with the refined RF model 
predictions 
The LMC classes defined in Chapter 4 (refer to 4.3.1) were compared to the refined 
RF model prediction classes (class 0 and class 1) (Figure 6.8). The LMC classes 
showed significant association with RF model predictions in training (P< 2 C 10-16) 
and test sets (P= 7 C 10-9). The LMC class 1 and class 5 samples were almost 
exclusively predicted as survivors (class 0) by the RF forest model (i.e. true 
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Signaling by Rho GTPases(R)
Fc−epsilon receptor I signaling in mast cells(N)
LPA receptor mediated events(N)
PI3K−Akt signaling pathway(K)
Chemokine signaling pathway(K)
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negatives, with some false negatives) (Figure 6.8). The LMC class 2 samples were 
also mainly predicted as survivors but with a. few true and false positives (Figure 
6.8). The LMC class 3 samples were mainly predicted as non-survivors (class 1) by 
the RF model (Figure 6.8). The LMC class 4 and class 6 had a mixture of samples 
from each of the predictor categories; these classes had the highest proportion of 
wrongly classified samples (Figure 6.8).  
 
Figure 6.8 Comparing the LMC classes with refined RF model. 
The overlap between the RF model predictions and LMC classes in the (A) 
training and (B) test dataset. TP refers to true positive samples, FP are false 
positive samples, FN are false negative samples, TN are true negative 
samples. 
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6.4 Discussion 
In this chapter, the prognostic performance of gene expression-based RF models 
was compared with a clinical information-based RF model. Moreover, integration of 
these 2 data types demonstrated an improvement in the prediction performance. The 
performance further improved after refining the RF model using variable selection on 
gene expression. The refined RF model prediction performance was higher than the 
baseline clinical variable RF based model, although it showed only a little 
improvement in the Lund dataset.  
6.4.1 Prognostic value of clinical information and gene expression 
based RF models 
The baseline RF model using clinical variables alone predicted prognosis in training 
and test sets. The clinical variables included were AJCC stage, sex, body site of 
tumour and age at diagnosis; these variables are also most likely to be recorded 
during a clinical visit. The AJCC staging system is one of the most widely used clinical 
variable for predicting prognosis of melanoma patients and is built upon strong 
prognostic factors like Breslow thickness and ulceration status [44]. Other clinical 
variables like sex, age and tumour site have also shown an association with 
melanoma prognosis [42]. Therefore, as expected, the RF model generated using 
these clinical variables predicted prognosis in the LMC data. Previous studies have 
shown strong association between clinical variables and gene expression in 
melanoma [114, 202]. In keeping with these studies, in LMC it was observed that 
clinical variables significantly predicted gene expression for more than five thousand 
genes (Figure 6.3). Removing the clinical variable information from the gene 
expression data demonstrated that the resultant RF model based on gene expression 
residuals was still predictive of prognosis. This is interesting as it signifies that gene 
expression data has independent prognostic information of melanoma tumours. 
Hence it was hypothesised that combining clinical variables and gene expression 
data may improve prediction performance in comparison to using clinical variables 
alone. As expected, the combined RF model has improved performance in 
comparison to the baseline clinical variables based RF model. These results highlight 
the potential clinical relevance of performing gene expression profiling alongside 
assessing the clinical characteristics of tumours for predicting prognosis of 
melanoma patients. 
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6.4.2 Refining combination of clinical information and gene 
expression based RF model 
Application of the combined RF model would require profiling a large number of 
genes, and this would limit the clinical utility due to the associated higher economical 
cost or practicality. Variable selection is crucial in supervised classification as 
selecting irrelevant features can sometimes leads to low accuracy and overfitting 
[203-206]. Therefore, to mitigate this, the model was refined by performing variable 
selection using the Gini index measure for each gene in the RF model (refer to 
5.2.5.5). Multiple subsets were evaluated, and the final refined RF model with 200 
genes had a higher performance than the original model. The difference in 
performance of the final refined RF model and original RF model may well be due 
the difference in the number of predictor variables used for generating the RF model 
at each iteration. The RF randomly selects genes to be included in the model at each 
iteration and selecting them from the whole genome means there is a high likelihood 
of using uninformative genes (i.e. those not associated with the outcome) in a 
significant number of iterations. The selection of which genes to consider at each 
node is random, and does not use information on which variables are most relevant. 
Therefore, incorporating variable importance measures into the model building 
process is a two-staged approach, and our results indicate that this approach may 
be more efficient than a one-staged approach which does not use variable 
importance information. 
6.4.3 Prognostic value of refined RF model and validation  
The refined RF model showed an improved prognostic value when compared with 
the baseline RF model based on clinical variables. Interestingly, the increase in AUC 
from ROC analysis of the refined RF model increased by 10% in the test set when 
compared with the baseline model (p=0.02). This highlights the potential translational 
value of the refined RF model in clinical settings for predicting melanoma prognosis. 
However, in order to confirm this, an independent validation was required. 
The refined RF model was tested on an independently generated dataset of primaries 
from Lund. In keeping with the LMC test set, the refined RF model showed 
consistency in predicting prognosis and improved the AUC by 4% (relapsed) and by 
1% (death from any cause) when compared with the baseline model. The 
improvement in AUC was modest and did not reach the significance threshold of 
P<0.05. The AUC was higher for melanoma relapse than using death from any cause 
as an outcome because not all deaths were caused by melanoma in the Lund cohort 
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(median age 67), as the cohort had high morbidity given the advanced age of patients 
in comparison to LMC (median age 57). As described previously, Lund data was 
generated in a different population and using a different microarray platform and 
quality control steps [105]. It is noteworthy that among the 200 genes selected in our 
refined model, the Lund dataset only contained 104 genes. The others were excluded 
in quality control steps (in fact, only ~8900 probes, representing 7753 unique genes 
were in the Lund data, compared to ~29000 probes and 20807 genes in the LMC). 
Hence, a further validation on larger primary melanoma datasets is required to fully 
confirm the robustness of this model and demonstrate its superiority to one based on 
clinical variables alone. The current limitation is that only one primary melanoma 
dataset is so far publicly available. Therefore, the robustness of refined RF model 
could not be assessed on additional datasets.  
6.4.4 Biological interpretation of the refined RF model 
Biological pathway enrichment analysis of predictor genes in the refined model 
showed association with pathways such as the Fanconi anemia pathway, PI3K-AKT 
signalling pathway and cell cycle related pathways. These pathways have been 
implicated in various cancers. The Fanconi anemia pathway has been shown to play 
crucial role in DNA repair mechanisms [207-209]. Disruption of this pathway has been 
associated with acquiring tumour resistance in various cancers [210-214]. The PI3K-
AKT signalling pathway has been reported as one of the most frequently disrupted 
pathways in melanoma, which has now paved the way for therapeutic drug discovery 
[215-219]. The predictor genes were also associated with cell cycle related pathways. 
These pathways provide an overview of biological information being utilised by the 
RF model in the decision-making process. However, furthermore work is required to 
investigate the individual impact of the predictor genes on melanoma survival which 
is beyond the scope of this thesis. 
In summary, integrating clinical variables into the gene expression-based RF model 
improved the prediction performance. Applying variable selection further improved 
the performance and generated a refined model with better prognostic value in the 
LMC and the Lund datasets. The refined model was shown to be of biological 
significance. Overall, this model after further validation on larger cohorts could be 
useful in clinical settings for predicting prognosis of melanoma patients. 
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Chapter 7 
Final summary and discussion 
7.1 Summary of the two main aims of this study 
In this study, statistical and bioinformatic analysis were developed to classify primary 
melanoma tumours of the LMC. The analyses addressed the two main aims: 1) 
generating molecular classes of melanoma using unsupervised clustering and 2) 
developing a prognostic classification model using supervised classification. 
Chapters 3 and 4 reported the results of unsupervised clustering while chapters 5 
and 6 dealt with supervised classification. 
In the first aim, applying unsupervised clustering to gene expression data of LMC 
tumours led to discovery of the six LMC classes signature. This LMC class signature 
showed prognostic value in the whole dataset, including in the stage I tumours. A 
validation of this signature was conducted in primary melanomas from the Lund 
cohort, although the paucity of stage I samples in the Lund cohort did not allow 
replication in that particular subgroup. 
In the second aim, supervised classification models were generated to classify the 
LMC patients into two classes (survivors and non-survivors) based on survival up to 
6 years. The classification models were developed using Random Forest (RF) and 
Support Vector Machine (SVM) algorithms, after splitting the LMC dataset in a 
training and a test set. The training set was imbalanced (the majority being survivors), 
and an attempt to overcome the class imbalance problem still generated prediction 
models with higher accuracy in predicting the majority class (survivors) than the 
minority class (non-survivors). 
In a comparison, the supervised classification model (refined RF model) showed 
good agreement with some of the LMC classes. LMC classes 1 and 5, with strong 
upregulation of immune and stroma related genes, were consistently predicted as 
the survivors by the supervised classification model. Tumours of LMC class 3, with 
downregulation of immune genes and upregulation of cell cycle mechanisms, were 
consistently predicted as non-survivors by the supervised classification model. The 
strong overlap between some of the LMC classes and supervised classification 
model prediction is not surprising because the association between the immune and 
cell cycle related gene expression and survival is well-established in the field [103, 
117, 197, 220-224]. Interestingly, the LMC classes which showed intermediate levels 
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of immune and cell cycle related gene expression (LMC classes 2, 4, 6) were 
predicted to include both survivors and non-survivors by the supervised classification 
model. The LMC molecular classes are a good foundation for understanding the 
underlying biological pathways driving melanoma prognosis, and the LMC class 
signature, after successful validation on another dataset, could be of direct clinical 
relevance to AJCC stage I melanoma. The machine learning (refined RF model) 
model on the other hand would be more appealing in clinical practice because it is 
based on only two classes (survivors or non-survivors), and therefore has lower 
complexity in interpretation of the results generated from this model. 
 
7.2 Context and discussion of findings 
The AJCC staging system is one of the most powerful and widely used classification 
tools in clinical settings for predicting melanoma prognosis [44]. In keeping with 
previous reports, the AJCC staging system performed only  moderately well at 
predicting prognosis (AUC= 0.69) (refer to 4.3.5.4) [114]. Therefore, additional 
biomarkers are required to complement this tool for predicting prognosis in clinical 
settings.  
Gene expression profiling has allowed molecular classification of tumours in several 
cancers [85, 106, 158, 225-236]. Molecular classification has drastically improved the 
biological understanding of the disease and has led to development of new drug 
targets. Additionally, these molecular classes have also been shown to predict 
clinical outcome for a patient [81, 105, 106, 225, 228, 234, 235, 237-239]. In breast 
cancer, for example, previous retrospective studies of gene expression profiling have 
identified five molecular classes with prognostic significance, and  furthermore these 
classes predicted response to adjuvant treatments [237, 240-245]. Paik et al. 
surveyed 250 genes reported to be associated with clinical outcome for breast cancer 
patients and generated a refined 21 gene-based prognostic biomarker (Oncotype-
DX) which has been successfully validated in prospective clinical trials [231, 246-
251]. This test predicts recurrence of breast cancer, and recently its ability to stratify 
patients for adjuvant chemotherapy has been demonstrated [251]. Overall, these 
studies highlight the crucial role of gene expression profiling in developing 
biomarkers with prognostic and predictive value. 
Similarly, in melanoma, several studies have performed gene expression profiling of 
tumours from retrospective cohorts to generate prognostic gene signatures [81, 100, 
102, 104-106, 108, 113, 114, 144, 252-254]. Unlike breast cancer, the prognostic 
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significance of these gene signatures has not yet been tested in prospective clinical 
trials. Most of these studies have been based on small sample size, and the gene 
signatures were generated from cohorts predominantly of advanced stage tumours 
[81, 84, 100, 101, 104-106, 113]. 
Most of the biomarkers developed from retrospective studies fail to translate into 
clinical settings due to low prognostic and predictive value on other validation cohorts 
[255, 256]. Therefore, it is highly recommended that studies are conducted with low 
ascertainment bias, with appropriate sample size, and with validation on other 
independently generated datasets to avoid overfitting [255, 256]. It has also been 
suggested that a biomarker based on gene expression must be jointly analysed in a 
multivariate model with the histopathological factors of a disease [107]. 
7.2.1 Class discovery using unsupervised clustering 
Previously, the Lund and TCGA groups have developed molecular classes of 
melanoma using a similar unsupervised clustering algorithm [81, 105, 106]. These 
molecular classes (Lund and TCGA classes) were applied to the LMC dataset. As 
shown in Chapter 3, the Lund and TCGA classes were predictive of MSS in the whole 
LMC dataset. When the LMC patients were stratified on the basis of AJCC stage, the 
signatures predicted outcome in stage II & III tumours but showed no association with 
MSS in stage I tumours. This was confirmed as a significant statistical interaction, 
illustrating the fact that the lack of association in stage I was not merely due to a 
power issue. 
The Lund and TCGA class signatures were derived from cohorts predominantly of 
metastatic tumours (i.e. AJCC stages III and IV) [81, 106], but subsequent replication 
studies have validated their prognostic value in primary tumours with only few AJCC 
stage I cases (n=61 in Lund, n=58 in Leeds subset) [105, 114]. The lack of 
association of these signatures with prognosis in stage I tumours in this larger dataset 
was disappointing, since currently the majority of melanomas (91%) are diagnosed 
at AJCC stages I and II [257]. Although these patients have a good prognosis overall, 
there is a significant number of deaths among these patients [257, 258]. Therefore, 
there is an urgent need to develop both prognostic and predictive biomarkers for 
those early stage melanoma patients.  
The LMC dataset has a large number of stage 1 cases, and its make-up in terms of 
disease stages offered the potential to generate a prognostic signature across all 
AJCC stages in a new unsupervised analysis. As shown in Chapter 3, the LMC 
tumours were clustered using robust consensus based HC, KM and PAM clustering 
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algorithms. Previous comparisons of clustering algorithms spanning over multiple 
gene expression and protein sequence information datasets suggested that none of 
the algorithms clearly outperformed the others [142, 143, 259]. In keeping with that, 
although different clustering algorithms (HC, KM and PAM) identified a different 
number of tumour classes in the LMC, i.e. HC algorithm identified 5 classes, KM 
identified 6 classes, and PAM identified 7 classes, the algorithms showed agreement 
with each other and with the existing Lund and TCGA classes. Since the PAM classes 
had higher stability in comparison to HC and KM classes, the 7 PAM classes were 
further explored.  
It has been reported that some noise may remain in the dataset even after adjusting 
for technical variation in gene expression quality control [260]. However, over-
normalisation can remove some biological variation, thereby reducing the utility of 
these experiments. Although batch correction was applied during normalisation, the 
PAM algorithm still identified one small class whose mRNA samples were processed 
in the same batch [117]. On further investigation, these samples were identified to be 
in similar positions on the plates, i.e. in first or last rows of the plates. Previously, the 
LMC samples were plated and sent to a gene expression profiling company in Leiden 
(Netherlands). The plate edges may have been impacted (for example by 
evaporation) during transport or other manipulations for one particular batch. 
Investigating different clustering algorithms allowed identification of these samples. 
Taking a cautious approach, it was concluded that this class may represent technical 
noise, and hence samples from this class were excluded. 
Re-clustering the remaining samples using the same consensus PAM algorithm 
confirmed the previously observed six classes (LMC classes). As shown in Chapter 
4, the LMC classes were significantly associated with clinical prognostic factors of 
melanoma, such as sex, body site of tumour, ulceration status, age at diagnosis, 
Breslow thickness and TILs. Most of these factors were also associated with the Lund 
and TCGA classes when applied to the LMC data. However, the LMC classes further 
showed a strong association with tumour mutation status in BRAF and NRAS 
oncogenes, while the Lund and TCGA classes did not.  
Interestingly, the LMC classes were prognostic in the whole dataset, including within 
the AJCC stage I group. To our knowledge this is the first and only clustering based 
prognostic molecular signature in stage I melanoma. This study used a much larger 
number of genes (~13,000) in comparison to the Lund (~7000) and TCGA  (1500) 
studies [81, 106]. Using a larger number of genes may have allowed more biological 
variation in the data to be captured. Secondly, the LMC data is based on the HT12-
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version 4 array, whereas the Lund study used a previous version of array and the 
TCGA study used an altogether different platform (RNA-seq). However, high overlap 
for some of the classes (LMC classes, 1, 3 and 5) with the Lund and TCGA classes 
may reflect the conservation of gene expression profiles in primary and metastatic 
melanoma. 
In clinical settings, performing expression profiling with a large number of genes is 
associated with higher economical cost. Hence, a prognostic test with few genes is 
preferred over a test based on large number of genes. To make the LMC classes 
signature clinically feasible, the signature was refined from 13,688 genes to 150 
genes. Since gene reduction was done by selecting the top genes which characterise 
the LMC classes, this may have also removed relevant biological information. As 
expected, application of the reduced LMC signature (150 genes) to the LMC dataset 
resulted in some misclassification (especially for LMC class 2) in comparison to using 
the original classification. 
The biological characterisation of the LMC classes using pathway enrichment 
analysis and Lund biological modules gave consistent results [81, 106]. High immune 
gene expression has been reported to be predictive of good prognosis in melanoma 
and other cancers [103, 117, 197, 206, 220-223, 226, 261-267]. In keeping with this, 
the LMC classes with good prognosis had higher immune gene expression and lower 
cell cycle related gene expression; LMC classes with poor prognosis had higher cell 
cycle related gene expression and lower immune gene expression. A similar 
observation has also been made by a fellow PhD student in the group (Joanna 
Pozniak personal communication) by clustering the LMC tumours based on immune 
response related genes and observing an inverse correlation between the genes in 
proliferation pathways and the genes in immune response pathways. However, this 
dichotomy did not apply to all the classes: LMC class 6 showed evidence of increased 
expression of both immune and cell cycle genes and the corresponding prognosis 
was very poor, especially in stage I tumours. This class is therefore unusual and was 
poorly captured with the existing Lund and TCGA classification systems (refer to 
4.3.4). Although it was not among the aims of this thesis, a preliminary biological 
investigation found significant increase in JUN expression and copy number in LMC 
class 6 tumours along with evidence for activation of the epithelial to mesenchymal 
transition pathway. Overall these results suggests that the LMC class 6 may be a 
biologically different class with strong clinical relevance for AJCC stage I melanoma. 
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7.2.2 Class prediction using machine learning  
Several studies have performed comparisons between patients with various clinical 
endpoints of melanoma and have generated biomarkers based on clinico-
histopathological and genomic characteristics [104, 109, 252, 254, 268-271]. A gene 
expression based prognostic test for melanoma, Decision-Dx by Castle Biosciences, 
identifies patients who are likely to metastasize in 5 years and is available 
commercially [109]. It contains 28 prognostic genes and 3 control genes and 
produces an accurate prediction of high and low risk of metastasis. Another 12-gene 
based biomarker from Liu et al. achieved higher diagnostic performance in 
distinguishing metastatic melanomas from normal skin and benign naevi. The 11 
gene-based signature from Brunner et al. when combined with the AJCC staging 
system for predicting MSS showed 4-6% increase in performance in comparison to 
the AJCC staging system alone [108]. Overall, these signatures have been 
developed on comparatively small retrospective cohorts of primary melanoma, and 
the robustness of these gene signatures is yet to be determined on larger melanoma 
cohorts and especially in prospective cohorts. Recently, it was showed that a 
machine learning based algorithm achieved higher classification accuracy in 
detecting melanoma in comparison to several trained dermatologists [169]. This 
study suggested that dermatologists may benefit from using this machine learning 
model in clinical settings for detecting melanoma at early stages.  
Previously, several other studies have developed gene signatures predicting various 
melanoma outcomes, but none of the studies were done using a large number of 
early stage patients and using machine learning algorithms [84, 100-102, 104, 108, 
109, 113, 272]. The LMC dataset so far is the largest dataset available for early stage 
melanoma with good follow-up data. In Chapter 5, two machine learning approaches, 
Random Forest (RF) and Support Vector Machine (SVM), were applied to predict 
outcome. Although these methods have been used in different applications, they 
have not been widely used for class prediction based on gene expression data.  
To avoid sample losses to censoring, a survival time cut-off was chosen at 6 years, 
but the LMC dataset still had a higher proportion of survivors than non-survivors. This 
is inevitable given that the majority of patients with primary melanoma survive for 
more than 5 years but the unbalanced dataset caused a challenge in machine 
learning. Consistent with the literature [182], in RF, under-sampling the majority class 
in the training set to achieve a balanced class design showed an improvement in 
prediction performance in comparison to using an unbalanced class design. Unlike 
RF, the SVM model performance did not change with or without balanced class 
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design approaches. Overall both the RF and SVM algorithms were influenced by 
class imbalance and generated prediction models which predicted the majority class 
(survivors) better than minority class (non-survivors), i.e. these models had higher 
specificity than sensitivity. In future, more investigations will be required to overcome 
the class imbalance problem. 
Several studies have compared the performance of RF and SVM algorithms and 
have found contradictory results. The study by Diaz-Uriarte et al. showed that the RF 
algorithm achieved comparable performance to that of SVM on simulated and real 
microarray datasets [273]. However, Statnikov et al. performed comparisons across 
22 diagnostic and prognostic datasets and reported that the SVM algorithm 
outperformed the RF algorithm [274]. In LMC, the RF model was identified to have a 
higher performance overall in comparison to the SVM model. A grid search to select 
the parameters of SVM initially improved the performance of the model, but further 
fine-tuning of the hyperparameter search brought no further improvement. Further 
comparisons indicated that the RF and SVM models made consistent predictions on 
test set observations which was reflected in higher Carmer’s V agreement. However, 
when comparing the inconsistent predictions between the models, the RF model 
showed higher accuracy than the SVM model.  
Previous studies have shown that although gene expression data has prognostic 
significance, when jointly analysed with other clinico-histopathological variables of 
melanoma it does not show much improvement in predicting outcome in comparison 
to clinical variable variables alone [52, 100, 107, 113, 114]. Therefore, in Chapter 6, 
the prediction of outcome using gene expression (analyses performed in Chapter 5) 
was compared to that of the known prognostic clinico-histopathological variables of 
primary melanoma. As expected, the RF model generated using clinical variables 
alone predicted outcome in the LMC test set. When clinical variables were combined 
with the gene expression data, the performance of the resulting model improved 
slightly in comparison to using clinical variables alone. A feature selection was 
conducted (based on their importance in the RF) which generated a reduced RF 
model with 200 genes and clinical variables. The predictor genes in the refined RF 
model had biological relevance, as many of them are implicated in pathways, e.g. 
fanconi anemia pathway, PI3-AKT signalling and cell cycle related mechanisms, that 
have previously been reported to play a role in melanoma and other cancers [207-
210, 212-219]. 
Ferris et al. reported that combining Decision-DX test and AJCC stage information 
further improved prediction of overall deaths and risk of metastasis in comparison to 
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using the AJCC stage alone [253]. They found that the model based on the Decision-
DX test + AJCC stage had 82% sensitivity and 62% specificity while the model based 
on the AJCC stage alone had 60% sensitivity and 74% specificity [253]. Brunner et 
al. reported that the combining the gene signature and the AJCC staging system 
(AUC=0.66) had comparable AUC to the AJCC staging system alone (AUC=0.60). In 
keeping with these studies, the refined RF model had 69% sensitivity and 79% 
specificity, while the clinical variables model had 63% sensitivity and 71% specificity. 
The AUC for the combined model (AUC=0.83) was 10% higher than the clinical 
variables alone (AUC=0.73). It is worth noting that previous studies [108, 253] used 
the AJCC stage as the only clinical variable, whereas in this study sex, age at 
diagnosis and site of primary melanoma were also included in addition to the AJCC 
stage.  
The prognostic value of the refined RF model was validated on the dataset from Lund. 
Since the Lund dataset did not have MSS information, melanoma relapse and death 
from any cause in 6 years was used as the outcome measures. In keeping with the 
LMC dataset, this model predicted outcome in the Lund cohort. The AUC for the 
refined RF model increased by 4% (melanoma relapse as outcome) and 1% (death 
from any cause as outcome) when compared to clinical variables alone in the Lund 
cohort. The improvement in AUC reached statistical significance in the LMC, but not 
in the Lund dataset, probably due to the smaller sample size, exacerbated by a 
considerable amount of missing data. Therefore, in future, validation of the refined 
RF model is required on another independent dataset to fully confirm the prognostic 
value of this model. 
 
7.3 Strengths and limitations 
The major strengths of this study are: 
1. Cohort size: This study is one of the largest studies conducted on 
understanding the influence of tumour transcriptomics on primary melanoma 
survival. The largest cohort used in previous studies (Lund cohort) was about 
one third of the size of the LMC. 
2. Extensive genomic and phenotypic data: Detailed clinico-histopathological 
and survival information has been recorded for the participants of the LMC. 
The gene expression data were generated from the tumour samples using a 
genome-wide array. Altogether these data are complementary to each other 
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and their integration can bring additional insights in melanoma biology, patient 
survival and a potential basis for a stratified care. 
3. Melanoma-specific survival: Unlike previous studies, this study utilised 
melanoma-specific survival for testing the association of signatures with 
survival. This was made possible by the attention to detail in the  data 
collection, which includes records of the cause of death, rarely recorded in 
most other studies. This information is continually retrieved from reliable 
sources (Public Health England) as the cohort follow-up continues. 
4. AJCC stage subsets: The LMC participants have been recruited in hospitals 
as they were diagnosed, so they represent more closely the population as a 
whole (North of England). Although population ascertained but due to 
difficulties in sampling thin tumours, the tumour cores were sampled 
predominantly from thick tumours. However, sufficient thin tumours were also 
sampled to ensure that the conclusions drawn are more likely to be applicable 
to the wider population. This is in contrast with many other transcriptomic 
studies which often use highly selected samples (e.g. most advanced 
disease), which may result in a deeper biological understanding and even 
drug development but may be less applicable to the whole patient group. 
Having a good representation of AJCC stage I patients (the most common 
diagnosis in the population) allowed development of a signature of relevance 
in this group. 
5. Validation dataset: The LMC classes and supervised classification signatures 
developed in this thesis were validated on an independent dataset published 
in 2012 [105] by Prof Göran Jönsson and Dr Martin Lauss (Lund University, 
Sweden). My work has therefore benefitted from the long-held collaboration 
between the two universities. 
 
The main limitations of this study are: 
1. Availability of data at one time point: The gene expression data used in this 
study represent the tumour’s characteristics at only one time point. 
Longitudinal data were not available to evaluate the consistency of tumour 
gene expression patterns with time. However, it was noted that previously 
reported survival associations with gene expression were validated in this 
dataset (Chapter 3), indicating the robustness of the approaches used. 
Moreover, there is a need to identify a prognostic biomarker relevant to 
patients at presentation with primary disease. 
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2. AJCC stage I validation set: The LMC 6 class signature was shown to be of 
prognostic value in AJCC stage I melanoma. Unfortunately, this finding could 
not be validated in an independent dataset because none of the studies have 
generated gene expression dataset from sufficient stage I melanomas. As 
shown in Chapter 4, the replication of the refined LMC signature on the Lund 
dataset regenerated the LMC classes in this dataset. However, this cohort 
had only few AJCC stage I tumours and the prognostic value of the signature 
could not be validated in stage I melanoma. Most of melanoma research is 
conducted in advanced stage melanoma because of the challenges 
associated with sampling thin early stage melanomas, hence our efforts to 
find a validation dataset comprising of AJCC stage I tumours was not 
successful. 
3. Missing information in the Lund dataset: Half of the predictor genes of the 
refined RF model were missing in the Lund data. The missing genes were 
filtered out in quality control steps due to the poor quality of the array platform 
that was used, the Illumina HT8.3 (only ~7,200 genes passed the QC filters). 
Hence, the Lund dataset was not an ideal replication dataset but it was the 
only one available. 
4. Clinical utility: The prognostic signatures generated in this study have been 
demonstrated to be of prognostic value in LMC data and on an additional 
cohort. However, validation in additional cohorts is required to further confirm 
the robustness of the signatures, especially for stage I tumours.  
 
7.4 Future perspectives 
There are several recommendations for future work following the analyses conducted 
in this thesis: 
1. Biological characterisation of the LMC classes: In chapter 4, differentially 
expressed genes and an overview of biological pathways associated with 
LMC classes were presented. For future analysis it would be interesting to 
explore the key regulatory genes governing the outcome in each of the 
classes. 
2. Predictive value of LMC classes: The LMC signature had shown to be of 
prognostic importance but its association with response to adjuvant therapies, 
especially immunotherapy, was not tested. Immunotherapy response 
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datasets are currently being collected to test the value of these signatures in 
predicting response to immunotherapy. 
3. Additional validation cohorts: There are currently no large enough AJCC 
stage I gene expression datasets available. It would be a step forward to 
generate data from stage I melanoma and validate the prognostic value of the 
signature. 
4. Comparison with other signatures: Several molecular signatures have been 
proposed to predict risk of metastasis in melanoma. It would be interesting to 
compare these signatures and those presented in this thesis for their 
performance and their composition and possibly to pool them into one 
signature if the comparison reveals a limited overlap. 
5. Combining gene expressions with Copy Number Variation (CNV) data: This 
thesis was focused on gene expression and clinical data. Next-generation 
sequencing derived copy number variation data have been generated in a 
subset of the same tumours (N=266) and are being analysed by another PhD 
student in the group. Despite the limited number of tumours profiled, it would 
be interesting to investigate the additional power of combining the two 
datasets, although this would certainly not be of relevance for stage I disease 
where the overlap would be even smaller.
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Chapter 8 
Appendix I 
Table 8.1 The 150-gene based LMC 6 class signature 
Gene 
LMC class 
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 
RASAL3 1.619 0.016 -0.996 -0.401 -0.019 0.111 
SH2D1A 1.549 0.128 -1.047 -0.327 0.053 -0.068 
SMAP2 1.548 0.127 -0.84 -0.584 0.073 0.067 
TRAT1 1.542 0.139 -0.845 -0.33 -0.026 -0.099 
BTLA 1.541 0.078 -0.801 -0.384 -0.059 0.018 
ZNF831 1.504 0.048 -0.598 -0.408 -0.172 0.09 
RHOF 1.498 -0.04 -0.944 -0.381 0.151 0.01 
NLRC3 1.495 0.053 -1.04 -0.249 0.101 -0.104 
TIGIT 1.491 0.059 -0.994 -0.349 0.017 0.05 
WAS 1.488 0.016 -1.207 -0.359 0.003 0.222 
SPN 1.487 -0.137 -0.866 -0.28 0.171 -0.063 
SPOCK2 1.478 0.118 -1.273 -0.369 0.06 0.129 
FCRL3 1.47 0.069 -0.752 -0.348 -0.045 -0.015 
STAP1 1.47 0.113 -0.702 -0.361 -0.068 -0.042 
P2RY8 1.468 0.084 -0.732 -0.436 -0.086 0.092 
CD3G 1.466 0.134 -1.178 -0.366 0.116 0.015 
VAV1 1.464 -0.082 -0.944 -0.268 0.086 0.011 
CD2 1.463 0.109 -1.009 -0.518 0.146 0.075 
SLAMF6 1.46 0.024 -1.003 -0.333 -0.027 0.126 
NOD3 1.46 0.064 -0.84 -0.314 -0.021 -0.016 
RAB37 1.459 -0.019 -0.63 -0.208 -0.187 0 
ELMO1 1.458 0.074 -1.074 -0.383 0.106 0.043 
LCK 1.453 0.161 -1.044 -0.492 0.061 0.109 
IKZF1 1.449 0.109 -1.268 -0.435 0.115 0.162 
FAM113B 1.448 0.01 -1.371 -0.325 0.106 0.198 
NCRNA00219 -0.275 0.643 0.676 -0.132 -0.476 -0.175 
TIGA1 -0.279 0.631 0.66 -0.096 -0.492 -0.174 
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Gene 
LMC class 
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 
ARID5B 0.165 0.615 0.301 -0.234 -0.413 -0.135 
HNRNPA2B1 -0.133 0.607 0.666 -0.499 -0.479 0.164 
C20orf199 -0.435 0.603 0.746 -0.003 -0.1 -0.585 
RPL15 -0.072 0.601 0.698 -0.009 -0.334 -0.51 
CCNI 0.085 0.594 0.628 -0.771 -0.272 0.161 
RPS13 -0.134 0.593 0.481 -0.273 0.004 -0.418 
EPS15 -0.183 0.591 0.556 -0.375 -0.51 0.164 
ANKRD36B 0.179 0.587 0.276 -0.193 -0.205 -0.346 
C5orf53 -0.005 0.58 0.491 -0.383 -0.467 0.085 
RPS3A -0.162 0.558 0.708 -0.188 -0.119 -0.459 
APEX1 -0.349 0.547 0.836 -0.351 -0.252 -0.131 
ENOSF1 -0.416 0.547 0.237 0.196 -0.169 -0.419 
ARGLU1 0.113 0.544 0.47 -0.534 -0.479 0.231 
C9orf61 -0.368 0.534 0.531 -0.083 -0.392 -0.089 
SUPV3L1 0.032 0.53 0.327 -0.481 -0.081 -0.077 
CCNH 0.169 0.526 0.427 -0.332 -0.281 -0.152 
PPP3CB 0.502 0.525 -0.039 -0.554 -0.331 0.193 
KIAA0141 0.066 0.523 0.564 -0.485 -0.36 0.062 
RPS15A 0.2 0.523 0.566 -0.418 -0.091 -0.331 
UNC84A -0.048 0.522 0.389 -0.235 -0.257 -0.141 
PAN2 -0.081 0.521 0.531 -0.44 -0.356 0.104 
ABCA10 0.042 0.518 0.292 0.108 -0.452 -0.293 
HNRPA1L.2 -0.267 0.516 0.568 -0.267 -0.116 -0.221 
CCT7 -0.734 -0.402 0.101 0.765 0.114 -0.219 
SOCS6 -0.71 -0.273 0.391 0.72 -0.159 -0.184 
BAHCC1 -0.578 -0.249 0.384 0.709 -0.073 -0.339 
CLN6 -0.513 -0.307 0.108 0.705 0.194 -0.432 
RBM8A -0.365 -0.198 0.079 0.692 0.122 -0.503 
POLR2K -0.514 -0.435 0.032 0.68 0.074 -0.142 
AGPAT1 -0.397 -0.395 0.032 0.672 0.052 -0.205 
C17orf41 -0.345 -0.356 0.357 0.666 -0.048 -0.329 
NDNL2 -0.17 -0.443 0.193 0.659 -0.11 -0.191 
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Gene 
LMC class 
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 
C4orf23 -0.385 -0.315 0.132 0.655 0.048 -0.31 
ISYNA1 -0.803 -0.36 0.58 0.652 -0.353 0.094 
SCARNA11 -0.002 -0.183 -0.212 0.65 0.063 -0.447 
PRPF39 -0.4 -0.006 0.315 0.645 -0.243 -0.375 
ANKRD40 -0.304 -0.28 0.167 0.643 0.075 -0.412 
PTPN9 -0.506 -0.411 0.067 0.638 0.009 -0.079 
LOC100128164 -0.305 -0.344 0.162 0.635 -0.275 -0.012 
HRH4 -0.35 -0.089 0.5 0.633 -0.356 -0.302 
EPM2A -0.343 -0.212 0.425 0.629 -0.329 -0.183 
CLEC17A 0.109 -0.317 0.072 0.628 -0.187 -0.273 
ZBTB6 -0.165 -0.36 0.287 0.627 -0.183 -0.211 
FIZ1 -0.174 -0.526 -0.043 0.624 -0.184 0.109 
NUTF2 -0.557 -0.539 0.178 0.623 0.229 -0.197 
LOC100125556 -0.737 -0.062 0.366 0.622 -0.064 -0.332 
CXorf64 -0.552 -0.425 0.25 0.619 -0.072 -0.041 
C19orf12 -0.181 -0.192 0.166 0.615 -0.175 -0.281 
MPZL2 -0.1 -0.264 -1 0.14 1.048 -0.355 
IL20RB -0.071 -0.007 -0.849 -0.002 1.036 -0.513 
FAM83A -0.195 -0.274 -0.751 0.186 1.029 -0.454 
AQP3 -0.062 -0.136 -0.976 0.146 1.027 -0.481 
PPL 0.005 0.001 -0.783 -0.025 1.026 -0.559 
PVRL1 -0.183 -0.143 -0.692 0.066 1.026 -0.478 
S100A9 0.032 -0.193 -1.237 0.141 1.019 -0.332 
SERPINB3 -0.309 -0.183 -0.752 0.183 1.008 -0.451 
TRIM16 -0.057 -0.18 -0.539 0.067 1.003 -0.568 
TMEM45A -0.128 -0.134 -0.898 0.153 1.002 -0.474 
GRHL1 0.033 -0.031 -1.091 0.16 1.002 -0.55 
FAM83C -0.133 -0.096 -0.796 0.181 1 -0.582 
GJA1 0.087 -0.041 -1.17 0.067 1 -0.432 
GSDMC -0.114 -0.087 -0.772 0.016 0.997 -0.442 
RHOV -0.099 -0.14 -0.803 0.168 0.997 -0.541 
PPP1R13L 0.093 -0.131 -1.095 0.208 0.995 -0.533 
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Gene 
LMC class 
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 
KLC3 -0.286 -0.104 -0.847 0.208 0.993 -0.492 
ABCA12 -0.187 -0.063 -0.829 0.167 0.992 -0.545 
PLEKHN1 -0.016 -0.222 -0.903 0.204 0.989 -0.49 
GLTP -0.202 -0.112 -0.619 -0.084 0.989 -0.347 
FABP5 -0.379 -0.196 -0.566 0.049 0.987 -0.346 
CD24 -0.057 -0.116 -0.682 0.061 0.985 -0.526 
PGLYRP3 -0.155 -0.064 -0.808 0.152 0.981 -0.545 
FAM110C 0.011 -0.16 -0.837 0.112 0.98 -0.49 
PKP1 -0.132 -0.094 -0.831 0.193 0.977 -0.556 
HSPA13 -0.239 0.067 0.492 -0.469 -0.491 0.752 
PRAF2 -0.14 0.022 0.353 -0.351 -0.526 0.727 
GNS -0.054 0.04 -0.008 -0.464 -0.27 0.723 
SDSL -0.241 -0.243 0.222 -0.348 -0.16 0.719 
C3AR1 0.447 -0.052 -0.382 -0.473 -0.206 0.69 
VKORC1 -0.494 -0.025 0.527 -0.35 -0.353 0.688 
CYTSA -0.162 0.156 0.296 -0.341 -0.571 0.686 
RNGTT -0.139 -0.138 0.196 -0.262 -0.332 0.669 
SNAPIN -0.582 -0.193 0.535 -0.099 -0.397 0.662 
GAL3ST4 -0.605 -0.11 0.322 -0.188 -0.25 0.66 
CDR2 0.302 0.123 0.216 -0.592 -0.45 0.659 
MUL1 -0.35 -0.054 0.292 -0.363 -0.229 0.657 
YIPF5 -0.382 0.182 0.578 -0.503 -0.429 0.655 
RAB23 -0.167 -0.206 0.036 0.031 -0.462 0.652 
ATP6V0B -0.035 -0.178 -0.05 -0.519 0.072 0.65 
TOMM34 -0.419 0.083 0.32 -0.308 -0.382 0.649 
CHPF -0.683 -0.103 0.448 -0.311 -0.136 0.643 
C11orf17 -0.222 0.096 0.375 -0.348 -0.475 0.641 
ATP2B1 0.224 -0.08 0.347 -0.294 -0.591 0.641 
SNX11 0.156 -0.13 0.033 -0.345 -0.287 0.639 
SACM1L 0.008 0.067 0.436 -0.368 -0.578 0.639 
BIRC2 0.31 0.178 0.007 -0.487 -0.478 0.637 
RAB8B 0.619 0.192 0.134 -0.597 -0.601 0.634 
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Gene 
LMC class 
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 
CNN3 -0.098 0.184 0.251 -0.475 -0.412 0.634 
UBLCP1 -0.063 0.109 0.304 -0.504 -0.352 0.627 
CDC73 -0.361 0.071 1.03 0.113 -0.583 0.035 
MKI67IP -0.686 0.135 1.027 0.013 -0.392 0.061 
KLHL12 -0.725 0.172 1.022 -0.064 -0.429 0.165 
FAM172A -0.242 0.282 1.014 -0.082 -0.52 -0.062 
ZFAND1 -0.611 0.401 1.008 -0.043 -0.522 -0.014 
LYSMD1 -0.665 0.149 1.006 -0.005 -0.493 0.165 
TMEM55A -0.632 0.324 0.983 0.003 -0.578 0.083 
SNRPE -0.398 0.277 0.972 -0.18 -0.688 0.302 
PHF20 -0.5 0.047 0.967 0.212 -0.444 -0.075 
TMEM133 -0.654 0.166 0.966 0.225 -0.565 0.002 
C12orf23 -0.547 -0.013 0.96 -0.165 -0.622 0.553 
PLA2G12A -0.508 0.291 0.95 0.061 -0.37 -0.191 
ZBTB41 -0.595 -0.059 0.948 0.263 -0.414 -0.008 
ZFP106 -0.883 0.226 0.948 0.316 -0.384 -0.19 
WDR3 -0.615 0.386 0.947 -0.091 -0.551 0.108 
SSR1 -0.389 -0.014 0.945 -0.142 -0.373 0.222 
BEND5 -0.237 0.167 0.935 0.123 -0.409 -0.238 
BTBD3 -1.073 0.076 0.931 0.325 -0.306 -0.041 
SLC9A5 -0.675 0.259 0.923 0.294 -0.444 -0.23 
DENND5B -0.423 0.387 0.92 -0.324 -0.356 0.073 
TTPA -0.537 0.298 0.914 0.135 -0.526 -0.089 
OSBPL9 -0.699 0.36 0.908 0.049 -0.321 -0.169 
KANK2 -0.518 0.067 0.908 0.01 -0.29 0.002 
LOC441743 -0.402 0.411 0.903 -0.294 -0.211 -0.119 
LASS2 -0.703 -0.026 0.899 0.073 -0.351 0.174 
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Table 8.2 Summary of upregulated biological pathways in LMC class 1, FDR is 
the false discovery rate 
Pathway P value FDR 
NF-kappa B signaling pathway(K) 1.11 x 10-16 1.10 x 10-14 
Chemokine signaling pathway(K) 1.11 x 10-16 1.10 x 10-14 
Natural killer cell mediated cytotoxicity(K) 1.11 x 10-16 1.10 x 10-14 
TCR signaling in na&#xef;ve CD4+ T cells(N) 1.11 x 10-16 1.10 x 10-14 
TCR signaling in na&#xef;ve CD8+ T cells(N) 1.11 x 10-16 1.10 x 10-14 
Cytokine-cytokine receptor interaction(K) 1.11 x 10-16 1.10 x 10-14 
Osteoclast differentiation(K) 1.11 x 10-16 1.10 x 10-14 
Hematopoietic cell lineage(K) 1.11 x 10-16 1.10 x 10-14 
IL12-mediated signaling events(N) 4.44 x 10-16 3.91 x 10-14 
GPVI-mediated activation cascade(R) 6.66 x 10-16 5.26 x 10-14 
T cell receptor signaling pathway(K) 1.33 x 10-15 9.59 x 10-14 
Measles(K) 2.11 x 10-15 1.39 x 10-13 
Primary immunodeficiency(K) 2.89 x 10-15 1.76 x 10-13 
Interferon gamma signaling(R) 1.13 x 10-14 6.45 x 10-13 
Signaling by Interleukins(R) 6.89 x 10-14 3.65 x 10-12 
Tuberculosis(K) 1.21 x 10-13 5.92 x 10-12 
TNF signaling pathway(K) 1.82 x 10-13 8.38 x 10-12 
Pathways in cancer(K) 5.21 x 10-13 2.29 x 10-11 
B cell receptor signaling pathway(K) 6.05 x 10-12 2.54 x 10-10 
Jak-STAT signaling pathway(K) 7.84 x 10-12 3.06 x 10-10 
DAP12 interactions(R) 6.75 x 10-11 2.57 x 10-9 
T cell activation(P) 8.65 x 10-11 3.11 x 10-9 
Transcriptional misregulation in cancer(K) 1.01 x 10-10 3.43 x 10-9 
Toll-like receptor signaling pathway(K) 1.16 x 10-10 3.60 x 10-9 
Staphylococcus aureus infection(K) 1.16 x 10-10 3.60 x 10-9 
Interferon alpha/beta signaling(R) 1.39 x 10-10 4.18 x 10-9 
Gastrin-CREB signalling pathway via PKC and 
MAPK(R) 1.45 x 10
-10 4.19 x 10-9 
Costimulation by the CD28 family(R) 2.90 x 10-10 8.12 x 10-9 
Chagas disease (American trypanosomiasis)(K) 3.05 x 10-10 8.13 x 10-9 
CXCR4-mediated signaling events(N) 3.13 x 10-10 8.13 x 10-9 
Cell adhesion molecules (CAMs)(K) 8.53 x 10-10 2.13 x 10-8 
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Pathway P value FDR 
Fc-epsilon receptor I signaling in mast cells(N) 1.11 x 10-9 2.67 x 10-8 
Leukocyte transendothelial migration(K) 1.53 x 10-9 3.67 x 10-8 
Toll-Like Receptors Cascades(R) 1.70 x 10-9 3.91 x 10-8 
Cell surface interactions at the vascular wall(R) 2.08 x 10-9 4.57 x 10-8 
BCR signaling pathway(N) 2.67 x 10-9 5.88 x 10-8 
Interleukin signaling pathway(P) 3.57 x 10-9 7.50 x 10-8 
Leishmaniasis(K) 3.79 x 10-9 7.95 x 10-8 
IL12 signaling mediated by STAT4(N) 4.37 x 10-9 8.73 x 10-8 
Pertussis(K) 8.16 x 10-9 1.55 x 10-7 
Signaling by SCF-KIT(R) 9.21 x 10-9 1.75 x 10-7 
IL4-mediated signaling events(N) 9.79 x 10-9 1.76 x 10-7 
Downstream signaling in na&#xef;ve CD8+ T 
cells(N) 9.79 x 10
-9 1.76 x 10-7 
HTLV-I infection(K) 1.06 x 10-9 1.91 x 10-7 
Inflammatory bowel disease (IBD)(K) 1.28 x 10-8 2.18 x 10-7 
Antigen processing and presentation(K) 1.33 x 10-8 2.27 x 10-7 
Signalling by NGF(R) 1.50 x 10-8 2.40 x 10-7 
Malaria(K) 1.54 x 10-8 2.47 x 10-7 
 
  
191 
 
Table 8.3 Summary of upregulated biological pathways in LMC class 2, FDR is 
the false discovery rate 
Pathway P value FDR 
Eukaryotic Translation Initiation(R) 1.49 x 10-14 8.48 x 10-12 
Eukaryotic Translation Elongation(R) 2.85 x 10-13 8.11 x 10-11 
Eukaryotic Translation Termination(R) 2.13 x 10-12 4.06 x 10-10 
SRP-dependent cotranslational protein targeting 
to membrane(R) 5.35 x 10
-12 7.60 x 10-10 
Nonsense-Mediated Decay (NMD)(R) 6.40 x 10-11 6.08 x 10-9 
Selenoamino acid metabolism(R) 6.40 x 10-11 6.08 x 10-9 
Ribosome(K) 3.09 x 10-10 2.50 x 10-8 
Processing of Capped Intron-Containing Pre-
mRNA(R) 7.98 x 10
-6 5.30 x 10-4 
Regulation of nuclear SMAD2/3 signaling(N) 8.41 x 10-6 5.30 x 10-4 
SUMOylation(R) 6.34 x 10-5 3.61 x 10-3 
Regulation of cytoplasmic and nuclear SMAD2/3 
signaling(N) 2.80 x 10
-4 0.0143 
Internalization of ErbB1(N) 3.67 x 10-4 0.0172 
Signaling events mediated by focal adhesion 
kinase(N) 6.83 x 10
-4 0.0294 
BMP receptor signaling(N) 7.46 x 10-4 0.0298 
Nongenotropic Androgen signaling(N) 9.51 x 10-4 0.0362 
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Table 8.4 Summary of upregulated biological pathways in LMC class 3, FDR is 
the false discovery rate 
Pathway P value FDR 
Mitotic Metaphase and Anaphase(R) 5.42 x 10-12 3.76 x 10-9 
Assembly of the primary cilium(R) 8.95 x 10-12 3.76 x 10-9 
Mitotic Prometaphase(R) 1.50 x 10-10 4.21 x 10-8 
Mitochondrial translation(R) 2.14 x 10-10 4.48 x 10-8 
The citric acid (TCA) cycle and respiratory 
electron transport(R) 1.15 x 10
-9 1.93 x 10-7 
RNA Polymerase I, RNA Polymerase III, and 
Mitochondrial Transcription(R) 1.47 x 10
-8 2.06 x 10-6 
Ribosome(K) 2.78 x 10-8 3.34 x 10-6 
Fanconi anemia pathway(K) 3.60 x 10-8 3.78 x 10-6 
S Phase(R) 1.55 x 10-7 1.44 x 10-5 
Cell cycle(K) 3.05 x 10-7 2.56 x 10-5 
Processing of Capped Intron-Containing Pre-
mRNA(R) 4.24 x 10
-7 3.22 x 10-5 
HDR through Homologous Recombination (HR) 
or Single Strand Annealing (SSA)(R) 1.17 x 10
-6 7.12 x 10-5 
Mitotic G1-G1/S phases(R) 1.27 x 10-6 7.12 x 10-5 
Signaling by Rho GTPases(R) 1.28 x 10-6 7.12 x 10-5 
Huntington's disease(K) 1.32 x 10-6 7.12 x 10-5 
Nucleosome assembly(R) 1.37 x 10-6 7.12 x 10-5 
SUMOylation(R) 1.64 x 10-6 8.04 x 10-5 
Resolution of Abasic Sites (AP sites)(R) 2.81 x 10-6 1.29 x 10-4 
Eukaryotic Translation Initiation(R) 5.19 x 10-6 2.28 x 10-4 
Nucleotide Excision Repair(R) 7.14 x 10-6 3.00 x 10-4 
Fanconi anemia pathway(N) 7.73 x 10-6 3.09 x 10-4 
Mitotic G2-G2/M phases(R) 9.63 x 10-6 3.53 x 10-4 
Oxidative phosphorylation(K) 9.82 x 10-6 3.53 x 10-4 
SRP-dependent cotranslational protein targeting 
to membrane(R) 1.14 x 10
-5 3.99 x 10-4 
Base excision repair(K) 2.68 x 10-5 8.86 x 10-4 
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Table 8.5 Summary of upregulated biological pathways in LMC class 4, FDR is 
the false discovery rate 
Pathways P-value FDR 
Assembly of the primary cilium(R) 5.50 x 10-7 4.10 x 10-4 
Processing of Capped Intron-Containing Pre-
mRNA(R) 1.82 x 10
-6 6.79 x 10-4 
RNA Polymerase II Transcription(R) 2.93 x 10-6 7.26 x 10-4 
p75(NTR)-mediated signaling(N) 5.12 x 10-6 9.53 x 10-4 
Intrinsic Pathway for Apoptosis(R) 8.11 x 10-5 0.0105 
NoRC negatively regulates rRNA expression(R) 8.48 x 10-5 0.0105 
Syndecan-3-mediated signaling events(N) 1.31 x 10-4 0.0139 
Nonsense-Mediated Decay (NMD)(R) 2.34 x 10-4 0.0218 
 
Table 8.6 Summary of upregulated biological pathways in LMC class 5, FDR is 
the false discovery rate 
Pathway P value FDR 
Cell junction organization(R) 2.01 x 10-7 1.58 x 10-5 
Validated transcriptional targets of AP1 family 
members Fra1 and Fra2(N) 1.22 x 10
-7 3.81 x 10-5 
Pathways in cancer(K) 1.46 x 10-7 3.81 x 10-5 
EPH-Ephrin signaling(R) 5.67 x 10-7 1.11 x 10-4 
Beta1 integrin cell surface interactions(N) 1.71 x 10-6 2.24 x 10-4 
ECM-receptor interaction(K) 1.97 x 10-6 2.24 x 10-4 
Extracellular matrix organization(R) 2.02 x 10-6 2.24 x 10-4 
Validated transcriptional targets of TAp63 
isoforms(N) 2.73 x 10
-6 2.65 x 10-4 
AP-1 transcription factor network(N) 3.34 x 10-6 2.91 x 10-4 
Proteoglycans in cancer(K) 4.31 x 10-6 3.36 x 10-4 
Axon guidance(K) 1.58 x 10-5 1.12 x 10-3 
Hippo signaling pathway(K) 1.87 x 10-5 1.21 x 10-3 
Ras signaling pathway(K) 2.74 x 10-5 1.55 x 10-3 
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Table 8.7 Summary of upregulated biological pathways in LMC class 6, FDR is 
the false discovery rate 
Pathway P value FDR 
Signaling by Rho GTPases(R) 3.90 x 10-8 3.45 x 10-5 
Mitotic Metaphase and Anaphase(R) 7.98 x 10-8 3.52 x 10-5 
Mitotic G1-G1/S phases(R) 5.27 x 10-7 1.43 x 10-4 
Phagosome(K) 6.48 x 10-7 1.43 x 10-4 
APC/C-mediated degradation of cell cycle 
proteins(R) 9.15 x 10
-7 1.61 x 10-4 
Regulation of retinoblastoma protein(N) 1.58 x 10-6 2.33 x 10-4 
Iron uptake and transport(R) 2.88 x 10-6 3.62 x 10-4 
Signaling by Insulin receptor(R) 8.82 x 10-6 8.64 x 10-4 
Rheumatoid arthritis(K) 1.10 x 10-5 8.64 x 10-4 
Mitochondrial translation(R) 1.10 x 10-5 8.64 x 10-4 
Toll-Like Receptors Cascades(R) 1.15 x 10-5 8.64 x 10-4 
Beta1 integrin cell surface interactions(N) 1.18 x 10-5 8.64 x 10-4 
Oxidative phosphorylation(K) 1.30 x 10-5 8.72 x 10-4 
Mitotic Prometaphase(R) 1.42 x 10-5 8.97 x 10-4 
ROS, RNS production in response to bacteria(R) 2.15 x 10-5 1.25 x 10-3 
Mitotic G2-G2/M phases(R) 2.27 x 10-5 1.25 x 10-3 
Cell Cycle Checkpoints(R) 2.83 x 10-5 1.36 x 10-3 
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Table 8.8 Summary of downregulated biological pathways in LMC class 1, FDR 
is the false discovery rate 
Pathway P value FDR 
Mitotic G1-G1/S phases(R) 1.16 x 10-11 5.62 x 10-9 
Mitochondrial translation(R) 1.44 x 10-11 5.62 x 10-9 
Cell Cycle Checkpoints(R) 6.52 x 10-10 1.70 x 10-7 
Cell cycle(K) 1.35 x 10-8 2.63 x 10-6 
Mitotic Metaphase and Anaphase(R) 1.88 x 10-8 2.93 x 10-6 
APC/C-mediated degradation of cell cycle 
proteins(R) 6.04 x 10
-8 7.51 x 10-6 
Signaling by Rho GTPases(R) 6.77 x 10-8 7.51 x 10-6 
Validated targets of C-MYC transcriptional 
activation(N) 3.46 x 10
-8 3.35 x 10-5 
S Phase(R) 4.33 x 10-8 3.72 x 10-5 
FOXM1 transcription factor network(N) 7.42 x 10-7 5.79 x 10-5 
Nucleosome assembly(R) 9.63 x 10-7 6.83 x 10-5 
The citric acid (TCA) cycle and respiratory 
electron transport(R) 1.47 x 10
-6 9.55 x 10-5 
Mitotic G2-G2/M phases(R) 1.67 x 10-6 1.00 x 10-5 
Aurora B signaling(N) 3.44 x 10-6 1.89 x 10-5 
Mitotic Prometaphase(R) 4.22 x 10-6 2.20 x 10-5 
M/G1 Transition(R) 5.00 x 10-6 2.40 x 10-5 
E2F transcription factor network(N) 1.22 x 10-5 5.60 x 10-5 
Hedgehog 'off' state(R) 1.42 x 10-5 6.10 x 10-5 
Regulation of DNA replication(R) 1.97 x 10-5 8.07 x 10-4 
Parkinson's disease(K) 2.10 x 10-5 8.18 x 10-4 
Nucleotide Excision Repair(R) 2.25 x 10-5 8.34 x 10-4 
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Table 8.9 Summary of downregulated biological pathways in LMC class 2, FDR 
is the false discovery rate 
Pathway P value FDR 
PLK1 signaling events(N) 2.12 x 10-8 3.63 x 10-6 
Systemic lupus erythematosus(K) 2.20 x 10-8 3.63 x 10-6 
Alcoholism(K) 2.93 x 10-8 3.63 x 10-6 
ATR signaling pathway(N) 2.04 x 10-7 1.90 x 10-5 
FOXM1 transcription factor network(N) 3.70 x 10-7 2.74 x 10-5 
APC/C-mediated degradation of cell cycle 
proteins(R) 1.36 x 10
-6 8.42 x 10-5 
Signaling by Rho GTPases(R) 9.17 x 10-6 4.47 x 10-4 
Mitotic G2-G2/M phases(R) 9.72 x 10-6 4.47 x 10-4 
Mitotic Metaphase and Anaphase(R) 1.33 x 10-6 5.44 x 10-4 
Progesterone-mediated oocyte maturation(K) 2.66 x 10-5 9.85 x 10-4 
Mitotic Prometaphase(R) 5.43 x 10-5 1.85 x 10-3 
Cell Cycle Checkpoints(R) 6.26 x 10-5 1.94 x 10-3 
Oxidative Stress Induced Senescence(R) 7.25 x 10-5 2.03 x 10-3 
Assembly of the primary cilium(R) 1.52 x 10-4 3.87 x 10-3 
p73 transcription factor network(N) 1.61 x 10-4 3.87 x 10-3 
Cell cycle(K) 1.84 x 10-4 4.23 x 10-3 
NoRC negatively regulates rRNA expression(R) 3.38 x 10-4 7.43 x 10-3 
Oocyte meiosis(K) 9.32 x 10-4 0.0186 
General transcription by RNA polymerase I(P) 1.04 x 10-3 0.0197 
Meiotic recombination(R) 1.32 x 10-3 0.0238 
Validated targets of C-MYC transcriptional 
activation(N) 1.63 x 10
-3 0.0277 
regulators of bone mineralization(B) 2.52 x 10-3 0.0409 
HDR through Homologous Recombination (HR) 
or Single Strand Annealing (SSA)(R) 2.56 x 10
-3 0.0409 
Mechanism of protein import into the nucleus(B) 2.99 x 10-3 0.0422 
RNA Polymerase I, RNA Polymerase III, and 
Mitochondrial Transcription(R) 3.01 x 10
-3 0.0422 
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Table 8.10 Summary of downregulated biological pathways in LMC class 3, 
FDR is the false discovery rate 
Pathway P value FDR 
IL12-mediated signaling events(N) 1.11 x 10-16 2.22 x 10-14 
Cytokine-cytokine receptor interaction(K) 1.11 x 10-16 2.22 x 10-14 
Osteoclast differentiation(K) 1.11 x 10-16 2.22 x 10-14 
Hematopoietic cell lineage(K) 1.11 x 10-16 2.22 x 10-14 
TNF signaling pathway(K) 2.22 x 10-16 3.55 x 10-14 
NF-kappa B signaling pathway(K) 3.33 x 10-16 4.43 x 10-14 
Extracellular matrix organization(R) 1.59 x 10-14 1.81 x 10-14 
Chemokine signaling pathway(K) 2.02 x 10-13 2.02 x 10-14 
Pathways in cancer(K) 9.33 x 10-13 8.31 x 10-11 
Natural killer cell mediated cytotoxicity(K) 2.05 x 10-12 1.64 x 10-10 
GPVI-mediated activation cascade(R) 3.61 x 10-12 2.60 x 10-10 
Primary immunodeficiency(K) 2.56 x 10-11 1.57 x 10-9 
TCR signaling in na&#xef;ve CD8+ T cells(N) 2.58 x 10-11 1.57 x 10-9 
T cell receptor signaling pathway(K) 3.79 x 10-11 2.16 x 10-9 
Beta1 integrin cell surface interactions(N) 5.14 x 10-11 2.72 x 10-9 
TCR signaling in na&#xef;ve CD4+ T cells(N) 7.06 x 10-11 3.53 x 10-9 
Interferon gamma signaling(R) 1.17 x 10-10 5.48 x 10-9 
Signaling by Interleukins(R) 1.70 x 10-10 7.47 x 10-9 
DAP12 interactions(R) 2.28 x 10-10 9.57 x 10-9 
Interferon alpha/beta signaling(R) 2.66 x 10-10 1.07 x 10-8 
Downstream signaling in na&#xef;ve CD8+ T 
cells(N) 7.34 x 10
-10 2.79 x 10-8 
IL12 signaling mediated by STAT4(N) 9.47 x 10-10 3.41 x 10-8 
Cell adhesion molecules (CAMs)(K) 1.95 x 10-9 6.64 x 10-8 
Focal adhesion(K) 2.15 x 10-9 7.11 x 10-8 
Cell surface interactions at the vascular wall(R) 4.18 x 10-9 1.34 x 10-7 
Staphylococcus aureus infection(K) 6.16 x 10-9 1.85 x 10-7 
Signaling by PDGF(R) 6.42 x 10-9 1.86 x 10-7 
Signaling by SCF-KIT(R) 9.69 x 10-9 2.71 x 10-7 
Fc gamma R-mediated phagocytosis(K) 1.12 x 10-8 3.02 x 10-7 
Complement and coagulation cascades(K) 1.42 x 10-8 3.64 x 10-7 
ECM-receptor interaction(K) 1.46 x 10-8 3.64 x 10-7 
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Pathway P value FDR 
PI3K-Akt signaling pathway(K) 1.78 x 10-8 4.33 x 10-7 
Measles(K) 1.81 x 10-8 4.33 x 10-7 
IL23-mediated signaling events(N) 5.17 x 10-8 1.19 x 10-6 
Costimulation by the CD28 family(R) 5.96 x 10-8 1.31 x 10-6 
T cell activation(P) 6.06 x 10-8 1.33 x 10-6 
Validated transcriptional targets of AP1 family 
members Fra1 and Fra2(N) 7.46 x 10
-8 1.57 x 10-6 
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Table 8.11 Summary of downregulated biological pathways in LMC class 4, FDR is 
the false discovery rate 
Pathway P value FDR 
T cell receptor signaling pathway(K) 1.98 x 10-11 1.75 x 10-8 
Osteoclast differentiation(K) 3.82 x 10-10 1.69 x 10-7 
Natural killer cell mediated cytotoxicity(K) 6.75 x 10-10 1.98 x 10-7 
Toll-Like Receptors Cascades(R) 1.72 x 10-9 3.11 x 10-7 
TCR signaling in na&#xef;ve CD4+ T cells(N) 1.79 x 10-9 3.11 x 10-7 
Interferon gamma signaling(R) 2.37 x 10-9 3.11 x 10-7 
Measles(K) 2.47 x 10-9 3.11 x 10-7 
Signalling by NGF(R) 5.11 x 10-9 5.62 x 10-7 
IL12-mediated signaling events(N) 8.59 x 10-9 8.42 x 10-7 
Primary immunodeficiency(K) 1.67 x 10-8 1.47 x 10-6 
TCR signaling in na&#xef;ve CD8+ T cells(N) 3.11 x 10-8 2.49 x 10-6 
T cell activation(P) 5.51 x 10-8 4.02 x 10-6 
Chemokine signaling pathway(K) 7.40 x 10-8 4.96 x 10-6 
TCR signaling(R) 1.18 x 10-7 7.37 x 10-6 
B cell receptor signaling pathway(K) 1.34 x 10-7 7.37 x 10-6 
Leishmaniasis(K) 1.34 x 10-7 7.37 x 10-6 
Interferon alpha/beta signaling(R) 1.46 x 10-7 7.46 x 10-6 
DAP12 interactions(R) 1.64 x 10-7 7.76 x 10-6 
Tuberculosis(K) 1.69 x 10-7 7.76 x 10-6 
Signaling by SCF-KIT(R) 2.22 x 10-7 9.78 x 10-6 
Costimulation by the CD28 family(R) 3.20 x 10-7 1.34 x 10-6 
Signaling by Interleukins(R) 4.04 x 10-7 1.56 x 10-6 
NF-kappa B signaling pathway(K) 4.11 x 10-7 1.56 x 10-6 
BCR signaling pathway(N) 5.07 x 10-7 1.82 x 10-6 
Cell surface interactions at the vascular wall(R) 5.72 x 10-7 2.00 x 10-5 
Signaling by Rho GTPases(R) 7.02 x 10-7 2.32 x 10-5 
MAPK signaling pathway(K) 1.21 x 10-6 3.88 x 10-5 
Cytokine-cytokine receptor interaction(K) 1.32 x 10-6 4.10 x 10-5 
Downstream signaling in na&#xef;ve CD8+ T 
cells(N) 1.71 x 10
-6 5.14 x 10-5 
Fc gamma R-mediated phagocytosis(K) 1.77 x 10-6 5.14 x 10-5 
CXCR4-mediated signaling events(N) 2.70 x 10-6 7.56 x 10-5 
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Pathway P value FDR 
HTLV-I infection(K) 3.83 x 10-6 1.00 x 10-4 
Pertussis(K) 3.96 x 10-6 1.00 x 10-4 
Signaling by EGFR(R) 4.01 x 10-6 1.00 x 10-4 
IL12 signaling mediated by STAT4(N) 4.08 x 10-6 1.02 x 10-4 
Phagosome(K) 4.25 x 10-6 1.02 x 10-4 
GPVI-mediated activation cascade(R) 4.57 x 10-6 1.05 x 10-4 
Fc-epsilon receptor I signaling in mast cells(N) 4.58 x 10-6 1.05 x 10-4 
Signaling by PDGF(R) 6.60 x 10-6 1.45 x 10-4 
TNF signaling pathway(K) 9.06 x 10-6 1.91 x 10-4 
Hematopoietic cell lineage(K) 9.08 x 10-6 1.91 x 10-4 
Leukocyte transendothelial migration(K) 9.13 x 10-6 1.92 x 10-4 
Chagas disease (American trypanosomiasis)(K) 1.18 x 10-5 2.36 x 10-4 
Beta2 integrin cell surface interactions(N) 1.23 x 10-5 2.46 x 10-4 
Signaling by VEGF(R) 1.54 x 10-5 2.92 x 10-4 
Signaling by FGFR3(R) 1.67 x 10-5 3.01 x 10-4 
Signaling by FGFR4(R) 1.67 x 10-5 3.01 x 10-4 
Signaling by FGFR1(R) 1.81 x 10-5 3.26 x 10-4 
Signaling by FGFR2(R) 1.81 x 10-5 3.26 x 10-4 
amb2 Integrin signaling(N) 2.25 x 10-5 3.82 x 10-4 
Class I PI3K signaling events(N) 2.98 x 10-5 5.07 x 10-4 
Signaling by Insulin receptor(R) 3.25 x 10-5 5.20 x 10-4 
EPO signaling pathway(N) 3.93 x 10-5 6.29 x 10-4 
Pathways in cancer(K) 4.07 x 10-5 6.52 x 10-4 
Fc epsilon RI signaling pathway(K) 4.47 x 10-5 6.83 x 10-4 
Signaling by ERBB2(R) 4.56 x 10-5 6.83 x 10-4 
Toll-like receptor signaling pathway(K) 4.70 x 10-5 7.04 x 10-4 
Class I MHC mediated antigen processing & 
presentation(R) 5.40 x 10
-5 8.10 x 10-4 
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Table 8.12 Summary of downregulated biological pathways in LMC class 5, 
FDR is the false discovery rate 
Pathway P value FDR 
Wnt signaling pathway(P) 1.99 x 10-10 1.56 x 10-7 
Assembly of the primary cilium(R) 6.85 x 10-8 2.69 x 10-5 
Cadherin signaling pathway(P) 1.42 x 10-7 3.20 x 10-5 
Processing of Capped Intron-Containing Pre-
mRNA(R) 1.63 x 10
-7 3.20 x 10-5 
RNA Polymerase I, RNA Polymerase III, and 
Mitochondrial Transcription(R) 1.00 x 10
-4 0.0126 
SUMOylation(R) 1.08 x 10-4 0.0126 
E2F transcription factor network(N) 1.13 x 10-4 0.0126 
Ubiquitin mediated proteolysis(K) 1.60 x 10-4 0.0142 
Regulation of retinoblastoma protein(N) 1.63 x 10-4 0.0142 
tRNA processing in the nucleus(R) 2.33 x 10-4 0.0182 
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Table 8.13 Summary of downregulated biological pathways in LMC class 6, 
FDR is the false discovery rate 
Pathway P value FDR 
Eukaryotic Translation Termination(R) 1.11 x 10-16 1.35 x 10-14 
Eukaryotic Translation Initiation(R) 1.11 x 10-16 1.35 x 10-14 
Nonsense-Mediated Decay (NMD)(R) 1.11 x 10-16 1.35 x 10-14 
SRP-dependent cotranslational protein targeting 
to membrane(R) 1.11 x 10
-16 1.35 x 10-14 
Eukaryotic Translation Elongation(R) 1.11 x 10-16 1.35 x 10-14 
Selenoamino acid metabolism(R) 1.11 x 10-16 1.35 x 10-14 
Ribosome(K) 8.88  x 10-16 9.24 x 10-14 
Cell junction organization(R) 2.06 x 10-8 1.87 x 10-6 
Phosphatidylinositol signaling system(K) 1.13 x 10-6 9.18 x 10-5 
Rap1 signaling pathway(K) 4.19 x 10-5 3.06 x 10-3 
Regulation of actin cytoskeleton(K) 5.01 x 10-5 3.30 x 10-3 
Oxytocin signaling pathway(K) 5.71 x 10-5 3.48 x 10-3 
Focal adhesion(K) 1.07 x 10-4 6.00 x 10-3 
Direct p53 effectors(N) 1.15 x 10-4 6.00 x 10-3 
Regulation of Telomerase(N) 1.66 x 10-4 7.96 x 10-3 
Tight junction(K) 1.91 x 10-4 8.26 x 10-3 
Sphingolipid signaling pathway(K) 1.96 x 10-4 8.26 x 10-3 
Stabilization and expansion of the E-cadherin 
adherens junction(N) 2.25 x 10
-4 8.26 x 10-3 
Inositol phosphate metabolism(K) 2.27 x 10-4 8.26 x 10-3 
Generic Transcription Pathway(R) 2.30 x 10-4 8.26 x 10-3 
Nectin adhesion pathway(N) 2.43 x 10-4 8.26 x 10-3 
Adherens junction(K) 2.78 x 10-4 8.96 x 10-3 
EPHA forward signaling(N) 2.89 x 10-4 8.96 x 10-3 
Ras signaling pathway(K) 3.12 x 10-4 9.36 x 10-3 
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Table 8.14 Gini index value for 200 predictor genes of the refined RF model 
Gene Gini  Gene Gini 
RNF31 0.11 
 
FOXD1 0.06 
SEC11C 0.1 IMPA1 0.06 
LMAN2L 0.1 MLL3 0.06 
SNORA12 0.09 C21orf63 0.05 
ATP5A1 0.09 CACNB1 0.05 
PPP1R3B 0.09 CENPQ 0.05 
C1orf43 0.09 USP50 0.05 
CBLN1 0.08 HDGFRP3 0.05 
MS4A1 0.08 FAM65C 0.05 
CCL19 0.08 GMIP 0.05 
CUGBP2 0.08 ELP4 0.05 
RCN2 0.08 ZNF281 0.05 
NDUFAB1 0.08 ABCB6 0.05 
RMI1 0.07 CHKB 0.05 
HSPA13 0.07 MRPL13 0.05 
DNAJA3 0.07 RASA4 0.05 
MOV10 0.07 DOK2 0.05 
BTBD3 0.07 TNFRSF18 0.05 
PHF20 0.07 KLHL12 0.05 
DLL3 0.07 RPIA 0.05 
PRICKLE4 0.07 GBAS 0.05 
IFI44 0.07 C8orf33 0.05 
YTHDF3 0.07 CD1A 0.05 
WDSOF1 0.07 H19 0.05 
UBL5 0.06 GPR19 0.05 
UBA2 0.06 DDX28 0.05 
LAMP3 0.06 ZC3H12D 0.05 
NDUFB2 0.06 PECI 0.05 
COPA 0.06 SLC35E3 0.05 
FCRLB 0.06 PLEKHG1 0.05 
ZNF322A 0.06 PBK 0.05 
ST13 0.06 ATP6V1G1 0.05 
NOL11 0.06 C12orf23 0.05 
BOC 0.06 PARP12 0.05 
STMN1 0.06 PRRC1 0.05 
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Gene Gini  Gene Gini 
ZCRB1 0.05 
 
LAMA2 0.04 
TYMS 0.05 LASS2 0.04 
P2RY4 0.05 CLIC2 0.04 
CYBRD1 0.05 PTTG1IP 0.04 
PDE1B 0.05 HOXC5 0.04 
ATHL1 0.05 MANEAL 0.04 
LPAR1 0.05 VCPIP1 0.04 
ACBD3 0.05 FH 0.04 
TATDN1 0.05 PGCP 0.04 
FLJ42986 0.05 EPRS 0.04 
C11orf46 0.05 UTP14C 0.04 
CCDC17 0.05 RNASE2 0.04 
MRPS28 0.05 ZNF512 0.04 
PRDX4 0.05 GGH 0.04 
PMP22 0.05 ERI2 0.04 
ST14 0.05 TMEM178 0.04 
RAB27B 0.05 FANCC 0.04 
TUBB4 0.05 CCR7 0.04 
HERC6 0.05 SEC24A 0.04 
CDK4 0.05 ZNF146 0.04 
C5orf20 0.05 N6AMT2 0.04 
RPA3 0.05 ZUFSP 0.04 
DHX58 0.05 MED20 0.04 
DDX60 0.05 MRPL30 0.04 
NFKB2 0.04 NDUFS2 0.04 
NAB1 0.04 PROK2 0.04 
ZNF385A 0.04 DCI 0.04 
COL29A1 0.04 PIGM 0.04 
ZNF318 0.04 PTK2 0.04 
NLRP1 0.04 CBX4 0.04 
KIAA1683 0.04 PLAT 0.04 
IL28RA 0.04 C6orf125 0.04 
CD37 0.04 GATA4 0.04 
CCDC7 0.04 NKD2 0.04 
RAD54B 0.04 CENPF 0.04 
ITPR2 0.04 BLM 0.04 
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Gene Gini  Gene Gini 
TMEM117 0.04 
 
CYTH1 0.03 
BRPF3 0.04 ETV6 0.03 
C11orf21 0.04 C16orf59 0.03 
SLC25A28 0.04 PCDH21 0.03 
FCER1A 0.04 OR2W3 0.03 
FKBP4 0.04 FAM78B 0.03 
PTAR1 0.04 COX5A 0.03 
PPM1D 0.04 KIF4B 0.03 
SNORD112 0.04 PCDHB10 0.03 
USP37 0.04 HLA.DQB1 0.03 
CBFA2T3 0.04 ERCC6L 0.03 
IFI44L 0.04 LARP6 0.03 
MVP 0.04 HOXB8 0.03 
C6orf111 0.04 SFRP2 0.03 
C1orf53 0.04 SNRPA1 0.03 
DHX15 0.04 KCNH4 0.03 
IL16 0.04 PCGF1 0.03 
F11R 0.04 SLC25A45 0.03 
EPHA4 0.04 DKK1 0.03 
MKI67IP 0.04 CCDC48 0.03 
KIFC1 0.04 PUS7 0.03 
JMJD2C 0.04 MIR24.1 0.03 
DNAJC25 0.04 OTUD6B 0.03 
DCTPP1 0.04 FOSL2 0.03 
KITLG 0.04 MRPL50 0.03 
ANXA11 0.04 TMEM203 0.03 
TMEM64 0.04 RSPO1 0.03 
GFRA3 0.04 HBB 0.03 
HOXB13 0.03 POMP 0.03 
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